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ABSTRACT 
 
AN ENHANCED MODEL FOR PARENTAL  
DECISION MAKING FOR PEDIATRIC CARE 
 
 
 
By 
Jillian Walsh 
May 2015 
 
Dissertation supervised by Henk ten Have, PhD, MD 
 Pediatric medicine, the branch of medicine dedicated to taking care of children, is a 
relatively new medical specialty, developing in the mid-19th century.  Pediatrics emerged as 
society began to believe that children were different from adults and in need of specialized care.  
Soon after the development of specialty medicine for children it became evident that many 
challenging ethical issues were present with children that did not exist, or at least not to the same 
extent with adults.  In some cases, issues are similar, however they become much more complex 
or challenging when applied to children.  The field of pediatrics is constantly changing and 
developing, with tremendous advancements within the fields of genetics, neuroscience, and 
clinical research. Developments in these fields have led to the emergence of many new 
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diagnostic and therapeutic interventions for children, but with these new technologies come 
enhanced ethical issues and challenging decisions. Currently within pediatric medicine, decision-
making processes are primarily guided by the models of adult surrogate decision making, in 
particular substituted judgment and best interests models. The substituted judgment model 
focuses on executing the wishes of the patient, while best interests asks the surrogate to select the 
course of action that will most benefit the patient overall. These models are ethically contested 
within adult medicine, the field in which they originated, and are even more problematic when 
applied to children, specifically mature minors with varying developmental levels.  In pediatrics, 
the best interests standard is the typical model advocated for because children, as children, 
cannot legally make their own decisions, however that does not mean they should be 
automatically excluded from decision making processes or assumed to lack decision making 
capacity. These issues become larger when dealing with mature minors due to issues of agency, 
consent and assent, stewardship, and the vulnerable status of the child.   Children are not only 
viewed as vulnerable by society, but many times parents as well.  Many parents feel it is their 
obligation and duty to not only take care of their children but also advocate for and protect them.  
Additionally, because they are so emotionally invested and connected to the child, it is difficult 
to comprehend situations where the child is at risk or they are told something they never 
imagined or thought about, such as that their child is very sick and in need of advanced medical 
care. There are heightened emotions present due to the parent-child relationship. Despite parents 
wanting to protect their children, in most medical instances they are unable to do so, leaving 
parents vulnerable and full of emotion. Making decisions for another is very challenging in all 
instances throughout medicine, complicated even more so when the person for whom decisions 
are being made is a relative and a person that one strives to protect and take care of on a day to 
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day basis.  Additionally in pediatrics many decisions have higher stakes and longer impacts, due 
to the age, status, and development of the child.  Parents are in very challenging positions when 
making decisions for their children in light of the tremendous amounts of uncertainty that 
accompany new and emerging technologies, including obstacles that make determining the 
child’s best interests and inevitably make a decision challenging.  The addition of complicated 
medical information from presented by the new technologies within the fields of genetics, 
neuroscience, and clinical research, combined with the and heightened emotions only 
complicates this process, necessitating an enhanced decision making model. 
As in areas of adult medicine, decisions are challenging and difficult to work through, 
complicated more by the lacking of explicit goals of pediatric medicine and an overarching 
framework to use to structure all decision making processes, which exists in adult medicine. The 
current decision-making models do not accommodate the fact that within pediatrics there is a 
long term relationship and partnership that must be created and nurtured by all those involved; 
decisions are therefore not isolated decisions but components of a continuum.  Additionally, they 
do not ensure that parents receive support and guidance, identify the level of involvement of an 
older child, or facilitate and assist with decisions when parents and physicians disagree.  Along 
with some of the objective elements of medicine, pediatric decision making has many subjective 
components, and emerging technologies create even more. On the basis of these considerations, 
it is argued that there is a need for an enhanced decision making model developed out of the field 
of pediatrics, centered around the goals of pediatric medicine. Current models need to be 
reconsidered in order to outline a model that enables parents to make the optimal decision for 
their child in light of the possibilities of emerging technologies.  
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 This dissertation will look at the question “Why should an enhanced model for parental 
decision making be advocated for within pediatric care, and how can such a model be developed 
and applied?”  In Chapter 2 the history and development of the field of pediatrics will be looked 
at, followed by an analysis of the current decision making models of adult medicine in Chapter 3, 
demonstrating that they do not apply well to mature minors and are not sufficient for pediatric 
medicine.  In Chapter 4 the changing field of pediatric medicine will be explained, the new 
technologies will be introduced, and the ethical issues that the current models of decision making 
do not accommodate will be presented.  In Chapter 5, an enhanced model of shared decision 
making related to the goals of pediatric medicine will be developed followed by an analysis of 
the roles of parties involved and how they should work together to achieve the best results for the 
child who is the patient.  In chapter 6 the enhanced decision making model will be applied to 
areas of genetic screening, neuroscience, and clinical research to show how it will better 
facilitate decisions within these areas and address the concerns that the new technologies and 
developments create throughout present-day pediatrics.  Pediatric medicine is in great need of an 
enhanced parental decision-making model that addresses the goals of pediatric medicine to 
ensure that the best decisions are made in the face of new technologies and the continuous 
advancement of care for children. 
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Chapter 1 – Introduction 
Pediatric medicine, the branch of medicine dedicated to taking care of children, is a 
relatively new medical specialty, developing in the mid-19th century.  Pediatrics emerged as 
society began to believe that children were different from adults and in need of specialized care.  
Today, children receive a great deal of attention from the government, their families, and society 
in general, including the medical world, however this was not always the case.  In the Middle 
Ages children were thought of as miniature adults and it was thought that society and the medical 
world could care for them and treat them in similar ways. The concepts of “childhood” or a 
“child” were not present at that time and these “miniature adults” had an ambiguous place in 
society.  At this time children were viewed as important purely for their economic value and 
benefits, specifically being the property of their parents.  Over time children were acknowledged 
as being unique and different from adults in many ways, including being in need for education 
and protection, however these ideas were not immediately applied to medicine and the medical 
care of children. For a long time adult medical practices were applied to children directly without 
consideration given to how they might need to be modified or adjusted to accommodate the 
unique elements of children.  Children and adults were in the same wards or floors of hospitals, 
treated by the same staff in very similar fashions, including the enforcement of the rule of no 
visitors, including parents, after a certain time. Over time, the uniqueness and differences of 
children from adults were more fully developed and elaborated, leading to the specialty of 
pediatric medicine with its own guiding principles and an emphasis on children as children, not 
simply miniature adults.  Societies slowly changed from being completely ignorant about and 
uninterested in children and childhood, in many instances wanting to segregate them from the 
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rest of the population and society, to seeing children as a central component of the family with an 
actual role in society and in need of protection.  
The evolution of healthcare for children has been greatly impacted by society’s lack of 
differentiation of the needs of children from those of adults, however once these differences were 
realized and understood, the lives of children were greatly improved.  Children were no longer 
excluded from the medical world and received specialized attention and care developed 
specifically for them.  Children went from being viewed as property of their parents and of 
economic value to individuals with rights and privileges, of significance to society.  The field of 
pediatric medicine emerged as the conceptions and ideas about children changed but also 
because it came to be understood that they need their own specialized care.  Preventative 
measures for children soon became a focus of advancement and development, emphasizing their 
central component to society and the strong desire to protect children.  It was not only 
acknowledged that children are different from adults but that they are of importance and value 
and overall, vulnerable necessitating additional protections and measures to ensure their 
successful growth into contributing adults in society.  These changes were the beginning of the 
development into the current state of society, with children as a central component with many 
focused efforts on protecting them from harm and best facilitating the development and growth.  
The creation and development of the field of pediatric medicine did not come without 
challenges though.  Soon after the development of specialty medicine for children it became 
evident that many challenging ethical issues were present with children that did not exist, or at 
least not to the same extent with adults.  In some cases, issues are similar, however they become 
much more complex or challenging when applied to children. Children are not only viewed as 
vulnerable by society, but parents as well.  Many parents feel it is their obligation and duty to not 
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only take care of their children but also advocate for and protect them.  Additionally, because 
they are so emotionally invested and connected to the child, it is difficult to comprehend 
situations where the child is at risk or they are told something they never imagined or thought 
about, such as that their child is very sick and in need of advanced medical care. There are 
heightened emotions present due to the parent-child relationship. Despite parents wanting to 
protect their children, in most medical instances they are unable to do so, leaving parents 
vulnerable and full of emotion. Making decisions for another is very challenging in all instances 
throughout medicine, complicated even more so when the person for whom decisions are being 
made is a relative and a person that one strives to protect and take care of on a day to day basis.  
Additionally in pediatrics many decisions have higher stakes and longer impacts, due to the age, 
status, and development of the child.  Parents are in very challenging positions when making 
decisions for their children every day, ranging from where they should send them to school, what 
they should feed them, as well as the core values they should teach them.  The addition of 
complicated medical information and heightened emotions only complicates this process, 
necessitating a model of some kind to facilitate decision making processes.  
Throughout medicine there are many challenging decisions to be made ranging from the 
development of overall goals of care down to the selection of a specific treatment, therapy, or 
medication.1  Overall, it is well accepted that adult patients make their own medical decisions, 
but this was not always the case and at one time, patients relied on their physician to diagnose 
and select a proper course of action.  Eventually, western societies gained an appreciation for 
personal autonomy, and believed individuals with decision making capacity should be able to 
make decisions for themselves in light of their personal beliefs and values through a process of 
informed consent.  Decision making in adult medicine is based on the concept of personal 
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autonomy, enabling adult patients to make choices and select therapies that align with their own 
personal values and beliefs.  On the other hand, when a patient is found to lack the capacity to 
make his or her own decisions that does not eliminate the need for a decision, so someone is 
appointed to make decisions for the patient.  This appointment can occur in several ways, either 
by a legal document created by the patient before the loss of capacity or by legal standards of the 
area or jurisdiction.  In these cases the individual who makes medical decisions for the patient is 
known as his or her surrogate.  Surrogate decision makers are held to higher standards and 
required to act in a manner that is consistent with how the patient would have acted if capable.  
In most cases, surrogates may not choose to withhold or withdraw treatment when it is in the 
objective best interests of the patient, unless the patient has made an advance directive before 
losing decision making capacity.  Surrogates are argued by many to be able to exercise the 
“autonomy” of the patient lacking capacity.2  Despite this, it is not clear that a surrogate, or 
anyone, can exercise the autonomy of another individual.  Ethical obligations of respect for 
autonomy do not extend to persons who cannot act in a sufficiently autonomous manner, so it is 
not necessarily and unlikely possible that the surrogate is executing the autonomous wishes of a 
non-autonomous patient.3  Making decisions for another is not an easy task, as it is seemingly 
impossible to know what the patient would do in every instance, but surrogates are asked to do 
just that.  In response to this, ethical standards, specifically the substituted judgment and best 
interests models, have been developed to guide the decision making process of surrogate 
decision makers so the best possible decision is made for the patient in given circumstances.   
As in areas of adult medicine, decisions are challenging and difficult to work through, 
complicated more by the lacking of explicit goals of pediatric medicine and an overarching 
framework to use to structure all decision making processes, which exists in adult medicine. The 
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goals and guiding principles of adult medicine do not directly apply or fully capture the goals 
and dynamic attributes of pediatric medicine and care. The goals of pediatrics should include 
beneficence and non-maleficence, however autonomy cannot be directly applied or used as a 
guiding principal for the reasons just elaborated.  Even though autonomy cannot directly be 
applied, that does not mean it is not important, if not crucial, to decision making in pediatrics.  
Some argue that parents can exercise the autonomy of the non-autonomous patient, as a 
surrogate would in adult medicine, however it is first, not clear that that is where the authority of 
a surrogate is based, and additionally, unlikely that parents could exercise the not yet developed 
autonomy of their child.4 The principle is that of “respect for autonomy” rather than the exercise 
of autonomy, so it is possible that parents are selected as the most appropriate individuals to 
make decisions that would respect the child’s future autonomy.  These fundamental 
characteristics should be thought of as goals and should be incorporated into the specialty of 
pediatric ethics, a field that developed just as most pieces of pediatrics, out of the adult model as 
it was recognized that issues of pediatric medicine could not be handled in the same way as adult 
issues.  In response to these unique challenges and considerations, a special area of ethics was 
developed.  Pediatric ethics emerged out of the realization that issues within a pediatric ward or 
hospital are not only different but must be handled in a way that is not similar to adult medicine.  
The field of pediatric ethics emerged to handle the ethical issues of pediatric medicine created by 
scientific breakthroughs, research, and an increasing interest in and the awareness of children 
and their individual needs.5 The ethical issues that children and their families face are different 
from those in adult cases and cannot be handled in the same manner, inevitably leading to the 
specialty and emergence of pediatric ethics and the use of pediatric ethics committees (PECs).   
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Throughout pediatric medicine a shared model of decision making is recommended, 
however due to the heightened ethical issues and dilemmas that arise within pediatrics, it 
becomes even more crucial that parents and physicians not only work together, but that they do 
so in a way that upholds both of their obligations and responsibility to the child that is the 
patient.  Pediatric decision making involves both protection of the vulnerable child and the 
weighing of all of the factors in the child’s life appropriately.6 In order to do made the best 
decision for the child patient, all essential roles and stakeholders, specifically parents and 
physicians must be involved.  Decisions that are made for children are not simple and carry a lot 
of weight.  Many individuals have large responsibilities, specifically the parents or guardians and 
physicians, however the child and society as a whole also have impacts, although the boundaries 
of these impacts are not definite. Children do not have autonomy or the legal right to make their 
own decisions, but they are at a stage in life where they are approaching the necessary capacities 
that they would need for making medical decisions.7  Because they do not have autonomy or 
decision making capacity children cannot make their own medical decisions however they 
should be involved at an adequate and appropriate level based on several factors including age 
and development, but most importantly the specific child him or her self.  By including the child, 
as the patient, in decision making they are validated as individuals, they can have confidence and 
trust in the staff, and additionally will cooperate and comply better with their therapies, which all 
lead to better medical results.8  Pediatricians, like all physicians, are supposed to place their 
patient at the center of their medical care and do what is both right and good for the patient. 
However, when dealing with children, it is not only the child and his or her interests involved. 
The parents and family are closely tied to that of the child, and this adds a different dimension to 
pediatric care.9 In cases with minors it is unclear who the doctor should involve and whether his 
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formal obligations and responsibilities lie the child, parents, family, or a combination.  There are 
many stakeholders in pediatric medicine and the opinions and conceptions of all parties must be 
listened to and properly balanced.10  Although the parents legally have the final say and authority 
to make the child’s medical decisions, ethically this is not sufficient for the best decision to be 
made and there is a need that all who have a role be acknowledged in the decision making 
process for the sick child.   
In the past, physicians made most of the treatment decisions, however over time adults 
slowly started to argue for personal autonomy and the right to make their own decisions, 
inevitably based on the argument that they have a right to decide what would be done to their 
own body.  This shift however is not one that is clear and directly applicable to pediatrics since 
the patient is and never has been decisionally capable or autonomous, and normally is in the 
process of acquiring and developing such capacity.  Many parents believe that they have the right 
to make decisions for their children as they do for themselves, however children do not have 
autonomy or decision making capacity.  When parents act for their children it is not clear if they 
are executing the autonomy of their child or potentially some kind of autonomy for the family 
unit.11 Parents are not the only individuals with a stake or role in the decision making process for 
children.  Pediatricians have a responsibility to not only give the child good medical care, and 
ensure that the parents have enough information to give informed consent, but also be an 
advocate for the child if necessary.  However he or she must balance this responsibility with the 
additional duty to not be paternalistic and influence the decisions of parents.  With the new 
emphasis on patient autonomy, physicians have concerns of acting paternalistic and influencing 
parental decisions more than they should.   There seems to be a fine balance physicians must 
hold of telling parents enough to make the decision and not tell them so much as to sway their 
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decisions. Physicians and parents must be partners in pediatric medicine to ensure the best 
decisions are made and the highest level of care is provided for the child, however their 
individual roles are not well defined, and the two parties sometimes appear to be conflicting or at 
odds with one another.  Beyond parents and the physician, the exact role of the child, who is the 
patient, in this decision making process is unclear.  Parents, physicians, and children do not 
always agree or think of things in the same way, however they are all asked to work together to 
make treatment decisions.  Additionally, it is not clear when the state, which also has interests in 
protecting the life of the child, can and should step in. Despite the recognition that children are 
unique and different, the models of adult decision making are still applied, as best they can be, to 
pediatrics.  Specifically, parental decision-making is guided by the models of adult surrogate 
decision making, substituted judgment and best interests models. The substituted judgment 
model focuses on executing the wishes of the patient, while best interests asks the surrogate to 
select the course of action that will most benefit the patient overall. The substituted judgment 
model requires that the surrogate substitute the patient’s goals and opinions for his or her own, 
inevitably making a decision that would emulate that of the patient. This requires a great deal of 
intimate knowledge of the patient and what he or she would want in a myriad of situations. The 
best interests model on the other hand requires the surrogate to make the best decision for the 
patient, with the highest potential benefit and lowest net harms.  These assessments are 
challenging because determining benefit and burden, as well as what is “best” is challenging and 
has very subjective components.  Additionally, it does not necessarily take into account what the 
patient would want or select.  These models are ethically contested and challenging to 
incorporate within adult medicine, the field in which they originated, and are even more 
problematic when applied to children, specifically mature minors with varying developmental 
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levels.  In pediatrics, the best interests standard is the typical model advocated for because 
children, as children, have never had autonomy or the ability to make decisions, therefore it is 
challenging if not impossible to emulate their decisions.  Children cannot legally make their own 
decisions, however that does not mean they should be automatically excluded from decision 
making processes or assumed to lack decision making capacity. These issues become larger 
when dealing with mature minors due to issues of agency, consent or assent, and stewardship. 
There is a great need for a new decision making model for children not only because the 
models of adult medicine do not apply or are insufficient but also because, first and foremost, 
pediatric decision making is more complex than adult decision making due to the vulnerable 
position of the child who is additionally incapable of making medical decisions due to the fact 
that many individuals are involved in the process with relevant opinions and responsibilities, but 
also due to enhanced emotional dimensions, and the enhanced potential and possibilities 
associated with working with such a young patient with ideally a long life ahead.  Pediatric 
decision making involves both protection of the vulnerable child and the weighing of all of the 
factors in the child’s life appropriately.12  Children are considered to be a vulnerable population 
therefore parents, as their guardians, have the task of looking out for their interests and doing 
what is best for them in all areas of their lives including medicine.  Parents are charged by 
society with responsibility for the welfare and upbringing of children, and responsibility for 
children requires having the rights for decision-making for them.13 Parents know their children in 
ways that others cannot. Personal gut feelings and observations over time are valuable in ways 
that go beyond medical “test” in many ways.14 Overall, parents and their children have a special 
relationship and bond that is distinct from the relationship that the child will have with others.15  
This bond is one of the main reasons that parents are argued to be the best decision makers for 
 
10 
 
their children, specifically that they know them better than anyone else. In most cases, that is 
arguably true, however parents cannot do anything that they want and they additionally have 
obligations to their children that they must uphold.  While making medical decisions for their 
children many parents have noted feeling isolated, ostracized, misunderstood, overwhelmed. 
Parents making medical decisions for their children are already in an extremely difficult and 
undesirable position, and by adding all of the ethical dimensions of pediatric medicine including 
the new array of technologies available and the additional levels of uncertainty, it becomes more 
challenging and burdensome.   
 The delicate balance of the involvement of relevant parties in the decision making 
process becomes even more challenging in light of the many advances within pediatrics and 
modern medicine including the use of new technologies and additional therapies.  Pediatrics has 
always been a field full of innovation and advancement, however within the past decade 
tremendous progress has been made in several crucial areas, saving and improving the lives of 
many children, but additionally presenting enhanced ethical challenges.  The fields of genetics, 
neurology, and research all are expanding at an exponential rate, with promises of enhanced 
therapies, earlier or more accurate diagnoses, better care, and inevitably improved quality of 
life.16 Within the field of genetics common practices such as newborn screening, which have 
ethical issues in and of themselves, now have the potential to be coupled with the increasingly 
more affordable practice of whole genome sequencing (WGS), which could be additionally 
utilized at later points throughout the child’s life.  Genetic screenings bring new prediction tools 
to the table, many times for conditions without therapies, clear medical significance, or a 
complete understanding of future implications for the life of the child in society. Children began 
to be screened at birth after the development of a simple test to identify PKU, and the panel has 
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steadily increased to include anywhere from 20-54 conditions, some of which have no therapies, 
despite recommendations from many groups to only test for disorders with available and 
accessible treatments. Other groups argue additional benefits other than therapy, such as 
planning for the future or identifying subjects for research, making it unclear if it is in the child’s 
interests to be screened or not.  With the addition of WGS the therapeutic gap will be increased 
drastically, identifying children with disorders lacking therapies, those that do not develop until 
adulthood, or those with misunderstood clinical significance, including the fact that even when a 
mutation is found it is uncertain whether the child will develop the disorder, it is just a 
possibility.  The space between what tests can identify or diagnose and those that have valuable 
and available treatment options to mitigate or even eliminate the disorder has grown 
exponentially in recent years, and only will continue to do so as science progresses.17  Deciding 
what should and should not be screened for becomes a much bigger issue with the decreasing 
costs of whole genomic sequencing (WGS), and the possible detection of a multitude of diseases, 
and can be utilized at birth or later in life.  Genetic testing is becoming an important diagnostic 
tool in medicine, making discussions of determining benefit and burden crucial, as well as the 
creation of regulations and a decision making model to guide their utilization.  
Another field that has seen tremendous growth is that of neurology.  Neuroscience is the 
study of the brain and nervous system, encompassing many aspects, from molecular and cellular 
biology, to psychology and behavior.18  Neuroethics is a recently developed field that focuses on 
the ethical and legal issues and societal implications associated with neuroscience and the rapidly 
developing technologies of the field.19   The creation of its own subset of ethics emphasizes the 
critical decisions and challenging issues that arise in the field, made only more complex when 
applied to children. Neuroscience has led to many innovations in clinical medicine that have not 
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only therapeutic but also non-therapeutic dimensions, all with ethical implications.20  Some of 
the controversial developments of neuroscience are functional neuroimaging, brain mapping, 
psychopharmacology, and enhancement opportunities with the potential to impact behavior, 
personality, and consciousness.  Current researchers are beginning to identify brain processes 
that are related to experiences and concepts such as free will, agency, moral judgment, self and 
personality.21  New techniques for monitoring and manipulating brain functions are developing 
rapidly but it is not clear how these tools and interventions should be used together.22  It is 
currently not known how all of the different systems of the brain interact, or what a particular 
brain abnormality can predict about an individual, and it is further unknown how intervening in 
these systems can affect the beliefs, desires, intentions and emotions that constitute the human 
mind.23  Other issues of neuroethics arise when dealing with individuals with disorders of the 
brain including developmental and neurological disorders and new ways to assess, diagnose, and 
potentially treat them.24 New technologies have increased the burden on the physician  to obtain 
informed consent in theses scenarios and additionally challenges them  to refuse treatment when 
inappropriately demanded or when there is unclear benefit to the patient..25  Due to these 
uncertainties careful consideration must be given and precautions must be taken, but this does 
not mean that the field should stop expanding or developing new technologies.  When dealing 
with the brain, there are many issues that arise immediately, even before the introduction of 
technologies and therapies.  Many people have personal ideologies and conceptions of the brain, 
including those of the self, free will, personal choice, and even personality and consciousness, 
and when something challenges that or even presents new information, it raises concern and the 
need for extra considerations.26 Technological advancements of neuroscience, just as those of 
other fields of medicine, bring with them both new possibilities and new problems to address. 
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The field of neuroethics looks specifically at resolving these issues so the positive outcomes of 
the technology can be utilized.27  Neuroethics has emerged to address the theoretical and 
practical issues of neuroscience that have moral and social consequences in the laboratory, health 
care, and society.28 Neurotechnologies such as brain scans, fMRIs, transcranial magnetic 
stimulation, or the placement of brain chips all carry with them questions of personhood and 
identity of the child, and issues of how to handle incidental findings.29  Currently genetic 
screening is being used to identify many neurodevelopmental disorders, however in addition the 
findings of neurotechnologies such as brain scans and functional MRIs are associated with 
psychological and social disorders, labeling children with conditions such as autism, ADHD, 
schizophrenia, and bi-polar disorder.   
The final area, pediatric research, is additionally expanding at a tremendous rate. 
Pediatrics is drastically changing because of clinical research trials in many areas, including the 
areas of genetics and neuroscience.  Research with children has always raised ethical issues, and 
much has been published on how research with children must be conducted. A great deal of 
regulations and oversight exist to improve understanding and guide research, however current 
studies still show great misunderstandings of parents about the basic elements of research and the 
specifics of the trial. Ethical issues only increase as more and more research trials are being 
developed to include children who are healthy or without a terminal illness. Typically research of 
the past has focused on children with irreversible or terminal conditions, and research trials were 
in some ways a last resort for parents.   However when the research extends to include seemingly 
healthy children, it is unclear if parents should or even can enroll their child.  Studies have 
shown that parents have a hard time comprehending many aspects of research trials.  Greenly 
and colleagues found that parents did not understand the concept of randomization or random 
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selection, specifically that their children may not receive a specific drug or intervention, being 
part of the control group.30  Parents also did not fully comprehend the different phases of the 
trial, overall putting into question their actual consent for the child to participate in the study.31  
This emphasizes the other issue of clinical research in that many assume there is a medical 
benefit purely because it was offered to them by a provider who, in most cases, has the goal and 
intention of treating illnesses.  A key component of informed consent in medical research is the 
understanding that the research trial is not the same as treatment, however this was not what 
most studies found in practice with parents consenting for their children.32 Research with 
children is possibly the most troubling area of development for the current decision making 
models as it encompasses the issues of both genetics and neuroscience, highlights the vulnerable 
status of children, makes it possible that they will be exploited, and makes issues of therapeutic 
and non-therapeutic interventions immediately more troubling.  There are many legal and ethical 
issues associated with vulnerable populations such as children, especially those with genetic, 
neurological, or developmental abnormalities making conducting pediatric research 
challenging.33 
The areas of genetics, neuroscience, and clinical research are associated with uncertainty 
(medically, ethically, and socially), placing parents in difficult positions, and necessitating a new 
model to facilitate interactions between all involved to assess and determine the best interests of 
the child while acknowledging the ethical dilemmas and issues that arise every day. Parents are 
in a unique emotional position when making decisions for their children, however the addition of 
new technologies make these issues even larger, with potentially greater implications and levels 
of uncertainty.34 As science and technology progress, increasing numbers of options are added to 
the range of therapies or treatments that can be provided for children. It is up to physicians to 
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give parents adequate information to make decisions, and then the parents will be able to decide, 
however there are not many guidelines for either of those tasks. With the addition of new 
uncertainties and possibilities, and sometimes unrealized impacts, these decisions begin to carry 
even more weight than the already challenging and complex decisions throughout pediatric 
medicine.  New therapies bring more challenging decisions, leaving parents in difficult positions 
and physicians unsure of how to help or guide decision making processes.  There is not a 
sufficient decision making model to help parents to make decisions. In most cases, the models of 
adult medicine are applied to children, specifically the best interest standard, and parents are 
asked to make decisions that are in the best interests of their child.  However these models do not 
provide much structure or guidance or even inform the parents of who should be involved in the 
process and at what levels they should be involved, making these models insufficient for 
pediatric medicine.  Decision making is a significant concern in healthcare, especially when the 
patient is unable to make his or her own decisions, and this becomes even more challenging 
when making decisions for children. Best interests determinations are very difficult to make in 
any area of medicine, even more so in pediatrics where the decision maker is not the patient him 
or herself, and additionally the patient never had decision making capacity or a life to judge 
things upon to make decisions. In these instances it is unclear what parents should consider or 
take into account when making these determinations.  
  These issues of pediatric decision making not only need more attention, but they require 
a model developed specifically within the field of pediatrics, rather than introduced and applied 
from adult medicine.  A new model must identify the roles of all relevant parties to the decision 
making process and specifically outline how they should work together to achieve optimal care 
results for the child in light of the enhanced ethical dimensions of new technologies.  There are 
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many studies that examine how parents made decisions and worked with the physician, however 
none of them specifically look at emerging technologies, whereas many deal with end of life, or 
life threatening conditions.  The ethical issues become enlarged when the child is not in a life or 
death position, and parents are making decisions that carry with them a lifetime full of potential 
burdens and possibilities.  As technology grows at an exponential rate, a new model is required 
that facilitates and guides parents, physicians, and children together through uncertainty and 
challenges that were not present twenty, ten, or even just a few years ago.  The issues of modern 
pediatrics are not going away, quite the contrary, they appear to be developing at a rate much 
faster than ever before, making it necessary to have a model to adequately handle and facilitate 
the ethical decisions in regard to new technologies.  
  Overall, parents are placed in an incredibly difficult position when asked to make 
treatment decisions for their children, especially when there is not an adequate model that 
provides sufficient support or guidance to facilitate decisions.  With an unclear basis for 
decisional authority, and an insufficient way to manage the ideal “shared” roles of all involved in 
pediatric care and to determine the child’s “best” interests, parents are left many times feeling 
unsupported or lost when presented with uncertainty and a multitude of options, or even 
overshadowed and insignificant by a potentially overbearing physician. This is not even to 
acknowledge the undefined role of the opinions and feelings of the child, and how it is taken into 
account throughout the process.  There are not clear roles for all involved in decision making in 
pediatrics, especially with regard to decisions surrounding the utilization of new technologies. It 
is not clear if parents have a right to know everything about children, when they need to ask for 
more information or another opinion, or what to consider and weigh in the decision making 
process.  It is additionally unclear how much physicians should tell parents and how to involve 
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the child in the decision making process.  To address these questions, a new model and 
conception of shared decision making will be necessary to support the complexities and 
uncertainties of technology, accommodate the many stakeholders, and ensure overall 
understanding. Decision making is challenging in all areas of medicine, but it becomes even 
more complex with new and emerging technologies in the field of pediatrics.  
 It is argued that neither model of adult medicine addresses the conflicting roles and 
dimensions of pediatric medicine, especially with the enhanced complications and issues of 
emerging technologies with tremendous possibility but also uncertainty and unclear benefits and 
burdens. With these new and emerging technologies there are additional considerations, 
uncertainties, and obstacles that make determining the child’s best interests challenging. The 
current decision-making models do not, for example, accommodate the fact that within pediatrics 
there is a long term relationship and partnership that must be created and nurtured by all those 
involved; decisions are therefore not isolated decisions but components of a continuum.35  
Additionally, these models do not ensure that parents receive support and guidance, identify the 
level of involvement of an older child, or facilitate and assist with decisions when parents and 
physicians disagree.  Along with some of the objective elements of medicine, pediatric decision 
making has many subjective components, and emerging technologies create even more. On the 
basis of these considerations, it is argued that there is a need for an enhanced decision making 
model developed out of the field of pediatrics, centered around the goals of pediatric medicine. 
Current models need to be reconsidered in order to outline an enhanced model that enables 
parents to make the optimal decision for their child in light of the possibilities of emerging 
technologies.  
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This dissertation will look specifically at the question “Why should a new model for 
parental decision making be advocated in pediatric care, and how can such a model be developed 
and applied?” In chapter 2, it will be explained how pediatrics emerged out of the field of adult 
medicine, looking at the changes in the conception of a child leading to the inevitable creation of 
pediatric medicine as its own field of medicine.  Following that development it will be looked at 
how the field expanded with an emphasis on protecting children, with the development of 
preventative measures.  Once the field had emerged, it led to the need and creation of the sub 
discipline of pediatric ethics and the articulation of the goals of pediatrics as distinct from those 
of adult medicine. All of these components show how pediatrics developed and emerged, leading 
to the field as it is today.  Then, in chapter 3, the current decision making models of adult 
medicine will be analyzed and critically examined, demonstrating that they are not sufficient for 
pediatric medicine because they do not adequately support all roles involved in decision making 
processes or accommodate the child patient, especially adolescents into the process.  Pediatric 
medicine requires its own decision making model, addressing the unique elements of pediatrics.  
In the fourth chapter, the changing field of pediatrics will be elaborated, focusing on the changes 
and developments of the field, with great promise to enhance the lives of many children, but also 
with many more ethical issues that the current decision making models of pediatrics cannot 
handle, making a new model necessary. These ethical issues will be expanded here including 
those surrounding informed consent and assent, the therapeutic gap, uncertainty, privacy, future 
implications, and enhancements.  Emerging technologies within pediatrics have added more 
complexities and challenging decisions to the field, placing parents in even more difficult 
situations that current models of decision making do not address.  In Chapter 5, an enhanced 
model for parental decision making, related to the goals of pediatric medicine will be developed. 
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This will be followed by an analysis of the roles of parties involved.  The enhanced model looks 
at the roles of parties involved and how they should cooperate to achieve the best results for the 
child who is the patient when making decisions and best interests determinations with regard to 
the use of technologies.  In Chapter 6 the new model is applied to areas of neuroscience, 
genetics, and clinical research to show how it will better facilitate decisions within these areas 
and better address the concerns that the new technologies and developments create throughout 
present-day pediatrics.  This chapter will review the importance of the model to accommodate 
the ethical issues in those fields and overall facilitate decision making processes.  Pediatric 
medicine, as a field of continuous growth and advancement, is in great need of an enhanced 
decision-making model to ensure that the best decisions are made in the face of new and 
emerging technologies and the continuous advancements in care for children. 
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Chapter 2 - Background and History  
2.1. Introduction  
Children make up a large part of society throughout the world, although their specific 
role and significance has only been realized over the past few centuries, giving them a more 
central and defined place in society.  Pediatric medicine, the branch of medicine that specifically 
takes care of children, emerged over time in response to this realization and the slowly developed 
conception that children are different from adults.  Children in modern society receive a great 
deal of attention from the government, their families, and society in general, including the 
medical world, however this was not always the case.  Children were not ignored or 
unacknowledged in previous societies; they were simply not seen as children or different than 
adults.  Societies went from being completely ignorant about concepts and ideas of children and 
childhood to seeing them as a central feature of the family and in many cases, even society.1  
This development led to the realization that children have unique needs and require specialized 
care, thereby leading to the emergence and development of the specialty of pediatric medicine. 
Once specialized care developed for children, it quickly became evident that there were many 
issues, problems, and scenarios that are uniquely present within pediatrics, requiring new 
regulations, medical standards, and eventually, ethical standards.  These new regulations and 
standards, created from adult medicine rather than the field of pediatrics, do not directly address 
the specific elements of pediatric medicine, including the relationship between or responsibilities 
of parents, physicians, and the child him or herself.  The unique situations present in pediatric 
medicine, however, combined with the tremendous focus on and utilization of emerging 
technologies and interventions, necessitate special attention and new ways to determine courses 
of action and to make decisions. 
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Children are not simply miniature adults, and are no longer treated as such in society, 
however the models of adult decision making are still utilized by parents to make decisions for 
their children in many instances.  In order to argue against this, it will first be pointed out that 
pediatric medicine developed directly from the field of adult medicine, creating problems for the 
field and inevitably parents, physicians, children, and even society.  This chapter will first look at 
this development and the inevitable creation of a place in society for children by looking at the 
changes throughout history and the emergence of concepts of “child” and “children.”  The place 
of children in society, though arguably still somewhat ambiguous and ill defined, directly led to 
the emergence of pediatric medicine as it was recognized that adults and children needed and 
deserved distinct medical care.  These ideas encouraged the development of measures to protect 
children, such as child labor laws, education mandates, and a shift in focus within pediatric 
medicine to preventative measures.  These preventative measures will be looked at in the next 
section to elaborate the initial focus and direction of medicine, emphasizing the importance of 
children and the inevitable focus throughout pediatrics of doing everything possible for children.  
Before looking at the preventative measures it will be discussed how the field expanded, 
specifically with the utilization of research with children.  The final section will briefly introduce 
the ethical issues unique to pediatric medicine, the overall goals of pediatrics, and the inevitable 
creation of pediatric ethics.  These goals will be used to reframe the way decisions should be 
made for children to explicitly address the unique needs of children as well as the sometimes 
conflicting relationships and responsibilities of all involved. This argument will be fully 
developed in a later chapter, but will be briefly presented here to emphasize differences from the 
goals of adult medicine.  Pediatric medicine has slowly distanced itself from adult medicine 
making tremendous progress and advancements in the specialized care of children, however this 
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needs to expand to the decision making process. Making decisions should not be done in the 
same way as in adult medicine.   
 
2.2. Development of Pediatric Medicine  
Pediatric medicine developed in response to the recognition that children were different 
than adults, and should be treated as such.  Prior to this realization, children were viewed as 
miniature adults, and not seen as valuable members of society or families. However, over time, 
these views changed and it was recognized that children were in fact unique and different than 
adults.  This change in perception is clear by looking at the historical trends of art, literature, 
clothing, as well as the education practices of children. This first section will look at these 
developments, and explain how the views of children changed, concepts of childhood and 
adolescence emerged, and inevitably, the specialty of pediatric medicine was born. The next 
section will look at the emergence of the field of pediatric medicine and discuss how it 
developed out of adult medicine.  In the final section, some of the unique elements of pediatric 
medicine, as well as the emergence of pediatric ethics, will be introduced and it will be argued 
that the goals of adult medicine do not directly apply, and specific goals and principles are 
needed within pediatric medicine.  The changing views of children led to the creation of a 
specialty of medicine for children with adult medicine as a base.  This was not wrong and has 
inevitably saved the lives of millions of children, and slowly led to the development of therapies 
and practices specifically for children, however that was not initially how it was.  Most concepts 
of adult medicine were initially applied to pediatrics and then modified to accommodate the 
child. Therefore, it will be argued in this chapter that the same is true for the goals and guiding 
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principles, leaving room for enhancements and goals that specifically address the unique 
elements of pediatric medicine.    
  
2.2.1. Changes in Views of Children  
Throughout history the concept of childhood has not always been present and it was not 
until the past few centuries that it was acknowledged that children are different than adults.2 
Over time, the views surrounding children changed and there was an increased desire to study 
and realize these differences.3 It was not until the previous two centuries that emphasis was 
placed on the period of childhood and defining concepts of child and adolescent.  During the 
Middle Ages a period of “childhood” did not exist and it was thought that infancy was followed 
immediately by adulthood. Words for “child,” “childhood,” or “youth” did not exist, and 
children were considered to be miniature adults, dressing in a similar fashion and expected to 
work for money at a young age.4 It was hard to classify or define these concepts since childhood 
is different for each child and it is a changing and temporary state.5  Even though children were 
present in almost every period of history in some way, which is evident by looking at art and 
literature, they were not labeled as children or thought of as different.6  During the Middle Ages, 
some laws were created which prohibited infanticide and the selling of children into slavery, 
however they were not strictly enforced.7 At that time, children were more akin to property than 
actual persons, valued primarily for their economic benefits and the potential of what they could 
grow in to, specifically a “normal” adult.8  During the Middle Ages, children were not mentioned 
in literature and were almost completely absent from art.9 Children appear at the end of the 
Middle Ages during the 13th century, but evidence of emerging and changing ideas surrounding 
children became much more noticeable by the end of the 16th and throughout the 17th century.10  
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The increasing prevalence of children in art and literature, combined with the changing and 
emerging patterns of dress and education for children show the transition of ideas surrounding 
children, inevitably leading to them being recognized as different than adults.11 During the 16th 
and 17th centuries ideas of children needing additional attention and protections arose, however 
only among the upper class.12   The lower class, still needing children as sources of income, still 
viewed children as little adults.  This change is apparent by looking at art and distinct changes in 
the dress of upper class children.13  Children of lower classes continued wearing the clothes as 
adults and depicted as such in art, however children of upper classes began to wear robes and 
false sleeves, drawing attention to them as being different from adults. The uniqueness of 
children was first prevalent among the upper classes, however in the late 19th and early 20th 
century, the idea began to spread to the lower classes, and slowly, the concept of childhood 
emerged.  
Once a concept of childhood emerged, the situation of young persons in society began to 
change and concepts of their innocence and vulnerability led to a desire to protect and shelter 
them from the adult world. Scarre noted that men should be treated as men, and children should 
be treated as children.14  In 1836, the first versions of child labor laws passed in the US, 
requiring that all children under the age of 15 working outside of the home attend at least three 
months of school.15 Slowly, societies and families began the separation of children from the rest 
of the adult world, starting with identifying them as children, and then by sending them away to 
school, to their own “world.”  During previous centuries, children were educated in the home, 
however as it was acknowledged that they needed protections and assistance in their 
development to adulthood, parents began sending their children to day schools or in some cases, 
boarding schools far away.16 Beginning at the end of the 18th century and continuing throughout 
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the 19th century, boarding schools were a common choice by parents, as an increased desire to 
separate children from society developed in order to facilitate their proper development and 
transition into adulthood.17 A wide array of social institutions for children including schools, 
reformatories, orphanages, foundling homes, and asylums, and hospitals arose and in a way, 
replaced general society for children.18 This idea of a substituted society slowly disappeared as 
boarding schools became less popular and there was a shift to day schools for children by the end 
of the 19th century and children started to find a place in society, specifically within the family.  
Towards the end of the 19th century, children were not only viewed as vulnerable and in need of 
protections and proper preparations for adulthood, but as an integral part of the family.19 This 
transition in place in the family is evident by looking at the changes in the portrayal of the child 
in family portraits and art.  Prior to the 19th century, children were either absent from family 
portraits or portrayed as an infant in their mother’s arms, regardless of their age.20  However 
during the 19th century, a much more accurate family portrait developed and in many cases, 
planned around the child. At this time, the idea of children being an important part of the family 
emerged, an idea that continues in many modern societies. Societies came to believe that 
children were not only unique and different from adults, but also a central piece of the family, 
vulnerable, innocent, and in need of protections.  Societal changes greatly impacted the 
advancement of views of children creating enhanced social protections.21 Social movements and 
legislation brought attention to the special needs of children, leading to the implementation of 
stricter child labor laws to protect children and prevent them from entering the workforce too 
young and better facilitate the transition to adulthood.22  These laws attempted to implement the 
fundamental rights and obligations societies have towards children, highlighted by the 1989 UN 
Convention on the Rights of the Child and the Children Act of 1989, which gave children more 
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of a voice and additional protections within society.23  In addition, in England and Wales the 
Children Act of 2004 and the Children Act of 1989 have seen increasing amendments and 
changes giving children more of a voice and creating additional protections for them within 
society.  In response to all of the changes, the European Academy of Pediatrics (EAP) was 
created to promote the health of children as well as to alleviate suffering from diseases in 
infancy, childhood and adolescence up to the completion of growth and development, both 
within and outside the confines of Europe.24  Other protections were put in place outlining an age 
of responsibility, ensuring that children take some kind of responsibility for their actions, but 
also acknowledging that children are vulnerable, still learning and growing, and in need of 
protections from minor wrongdoings, giving them the chance to change.25  Many argue that 
children have a right to an open future, a right that must not be violated to ensure their 
development and ability to make choices to shape his or her own life.  The idea of an open future 
closely relates to ideas that children have a right to self-determination, specifically that they can 
develop into autonomous adults.26  Despite these claims, it is not argued that they should be 
given autonomy in their decisions or that they can guide all aspects of their lives, but rather that 
their futures are important and that they should be empowered to work to a successful future and 
not make decisions now that would negatively impact their future self-determination or 
autonomy.  Throughout the world there has been an increasing amount of attention given to 
children and legislation passed to ensure that children are protected and advocated for and have a 
place within society unique from adults.   
Central to their reasoning for the new legislation and protections is an acknowledgment 
of the child as a human being, as an individual greatly influenced by his or her environment and 
deserving of respect.27 In deserving respect, children should not be treated as a means, but rather, 
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as developing persons and individuals who have actualized some of the characteristics associated 
with adulthood.28 Throughout the world, attention has been given to children to ensure that they 
are protected, advocated for, and have a defined place within society unique from adults.  
Although it was acknowledged that children were different from adults and society created 
protections and opportunities for them, it was not entirely clear what a child was, or what exactly 
was meant by “child” or the period of “childhood.” Throughout the world different definitions of 
childhood exist, for instance, in some places individuals can participate in government and vote 
as young as 16, while in others not until 21 or 25.  Despite these differences in practices, there is 
some general agreement that the transition from child to adult occurs at 18 years of age.29  The 
age of consent for medical treatment or therapies however, like voting, is different in different 
countries, and even in different places within some countries, such as in the United States where 
such decisions are made by state not federal regulations.30  Within the UK, there is not a single 
law that defines the age of a child, however the United Nations Convention on the Rights of the 
Child, ratified by the UK but not the USA, states that a child is “every human being below the 
age of eighteen years unless, under the law applicable to the child, majority is attained 
earlier.”31 32   In the UK, specific age limits are set out in relevant laws such as voting or issues 
of consent, but there is not one age where childhood stops across the board.  There are also 
differences between the UK nations, for instances, England, Wales, Northern Ireland and 
Scotland each have their own guidance setting out the duties and responsibilities of organizations 
to keep children safe, but they generally agree that a child is anyone who has not yet reached 
their 18th birthday.  Despite the agreement over 18, in all countries there are exceptions, 
different ages for voting, military service, consenting to medical treatment, research, and even 
sex.  Even if at age 18 a child transitions to adulthood, it is not a clear if this change occurs the 
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day he or she turns 18, approaches it, or hits a certain threshold, placing children approaching the 
age of adulthood in an even more vulnerable and ambiguous place.  There is not agreement about 
how to define the stages or development process of the child, specifically the transitions from 
infant, to child, to adolescent in relation to being under the control of their parents.33 Children 
between the ages of 12-18 are still considered minors, and subject to their parents decisions, 
however they are in a transition period, often referred to as adolescence, with very unclear 
implications on the parent-child relationship and the role of each in the process.34  
Legally in most places parents are thought to be guardians of their children, empowered 
to make choices and decisions for them until they reach adulthood.35  Further, due to the 
ambiguity of the exact transition to adulthood, society, in need of a legal decision maker, 
typically defers to parents. Societal deference to parents as decision makers for their children 
rests on the respect for the integrity of the family, and the assumption that parents act in their 
child’s best interests,  however many decisions made by parents fall into gray areas, and it is not 
clear what will or will not benefit the child.36 The idea that parents have total control over their 
children as they had in previous centuries is no longer as prevalent however the explicit role of 
parents is not well defined.37  Society typically gives parents a great deal of autonomy to make 
decisions for their children, although there are regulations that prevent parents from causing 
harm to their children and allowing the government to step in in these instances.38 This then 
leads to the other large issue of when the parent’s actions have crossed a threshold that warrants 
a societal intervention.  There is much disagreement surrounding this threshold and a delicate 
balance of state and parental rights, both arguably working to protect and advocate for the “best” 
overall health and wellness of children and promote their wellbeing and transition into 
autonomous adults.39  It can be argued that the goal of the state interventions should be to respect 
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reasonable decisions made by parents for their children, leaving significant legal space for 
reasonable differences of opinion, beliefs and values.40  Brock and Buchanan argue for state 
intervention when parents abuse or neglect their children making them unacceptable parents, 
further arguing that the focus of parental choices and decisions should be on the current and 
future interests of the child only. Parents may not be the best decision makers for their children 
due to potentially large conflicts of interest that can exist, therefore parents should legally only 
be able to make decisions that will benefit the current and future interests of the child, without 
taking other factors into account.41  Ross however, disagrees with this, arguing that parents 
should have more authority to make choices for their children and families, raising them in the 
way that they see most fit with minimal interventions from outside sources.42 Ross argues for 
parental autonomy based on the intimate relationship between parents and their children, and the 
natural desire to do what is best for the child.  She believes that parents must provide for the 
basic needs of the child and uphold a threshold of “primary goods” for their children, but beyond 
that, parents should be allowed to do what they want.43  Further, Ross makes a distinction 
between the autonomy of the parents and that of the family, arguing that parents should be able 
to take into account and pursue goals of the family, based on family autonomy, provided they do 
not require the sacrifice of any member’s basic needs.44  It is hard to separate the goals of the 
child immediately from the goals of the parents, and additionally, there are things other than the 
immediate and future interests of the child that impact the lives of the parents.45   There is much 
debate surrounding what both the state and parents can and cannot do, when parents should be 
left alone, and when the state should step in.46   
 Much discrepancy exists about what rights children should have from both a humanistic 
and legal perspective, and further, if any of those rights should be guaranteed by society.47  
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Vardin and Brody believe that society has a duty to work as the child’s advocate in some 
instances. Children should be respected and treated as whole and complete individuals, in and of 
themselves. Children deserve the same respect as adults, however it is unclear how this translates 
into rights.  Some believe that they should be treated fairly and given the same respect and 
potential rights as adults, including the right to information, self-determination, alternate home 
environments, education, freedom from physical punishment, sexual freedom, economic power, 
and the right to justice.48 To not allow them these freedoms and show them the same level of 
respect as adults could arguably further their dependence, incompetence, and vulnerability.49 
Even more extreme arguments have been made that children should be freed from their parents' 
legal authority and limitations, and in turn, parents be freed from the burden of complete 
responsibility for their children's behavior.50 Although this is extreme and not argued for here, it 
emphasizes that disagreement exists about the exact roles of parents and society in the lives of 
children.  Children are not property, however they are not fully autonomous individuals allowed 
to make life decisions, so their place in both society and the family is slightly ambiguous and 
unclear.51  There further may be situations when the child, specifically during the period of 
adolescence, should have the ability to make decisions, and parental authority should be 
limited.52 It is further argued that because all children develop at different paces, capacity or the 
ability to be involved in decision making processes should not be dependent upon chronological 
age, but rather capacities.53 These ideas will be developed further in later chapters, looking at 
what capacities should be evaluated and the developmental stages children go through. However 
it will be emphasized that although children were given a place in society, that place has not been 
explicitly spelled out, nor the roles of society or parents.  
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2.2.2. Emergence of Pediatric Medicine 
  Pediatric medicine emerged as a specialty of medicine as the views of children developed 
and society realized that children need specialized medical care. The previous section explained 
how children were initially thought of as miniature adults and only as valuable for what they 
could become, not what they are. Over time, this view slowly disappeared and children received 
increasing attention throughout society, leading to the inevitable creation of the specialty of 
pediatric medicine, a specialty that is less than 200 years old.54 Prior to the creation of the 
specialty field of pediatrics, children and adults were cared for in the same way, and specialized 
medical training for physicians or caretakers did not exist.  However, as children became a focal 
point of attention within society, the medical world realized that the differences between adults 
and children were significant and eventually developed specialized care for children distinct 
from the care of adults.  Children were not only different, but they were an underserved 
population in need of social institutions including orphanages, infant asylums, dispensaries, and 
hospitals, launching the initial phases of the field of pediatric medicine.55  
 The history of medicine and children began with references to specific childhood 
illnesses and conditions in texts dating back to the ancient Egyptian, Greek, and Roman 
physicians, however, these references were more observational in nature rather than addressing 
the unique natures of children or ways to take care of them.56 Discussion of children and their 
illnesses became larger in the 1400s after the invention of the printing press when books were 
published discussing medicine and children for both physicians and the general public.57  These 
publications however, did not address the ways in which children were different than adults or 
unique, or the ways in which physicians or medical professionals should care for them, but rather 
the specifics of their illnesses and the overall course of diseases.58 The development of the field 
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of pediatrics was international however it did not begin in North America until the 17th 
century.59 At that time, medicine in general was a mixture of religion, folklore, and scientific 
principal, and there was little if any understanding that children were a special group with 
distinct medical needs, let alone how to care for them in a meaningful way.  
 Over time, as children developed a place in society and were studied as a unique 
population, they slowly began to receive more medical attention, but not right away.  In 1840, 
30% of the population was under the age of 10, but only 50% of them survived to adulthood due 
to infectious diseases and epidemics. In addition, infant mortality rates were sometimes as high 
as 99%.60 Although it was recognized that children were a special population, they did not 
receive a great deal of medical attention as less than 0.1% of hospitalized patients were children, 
and when they were, it was within adult wards in the same manner as adult patients. This lack of 
distinguishment of children from adults and a general concern over the lack of medical services 
for children, led several physicians in Dublin to start the first English-speaking hospital, the 
National Children’s Hospital, in 1821 devoted exclusively to the care and treatment of sick 
children.61  One of the founders of the National Children’s Hospital in Dublin moved to London 
thirty years later and helped launch the Great Ormond Street Hospital in 1852. Then in 1855 the 
first children’s hospital opened in the United States in Philadelphia, PA.  Soon, pediatric 
hospitals began showing up in all of the big cities and the field of pediatric medicine became a 
specialty with its own training programs launching around the world.   Then slowly pediatric 
medical schools and nursing programs began to develop.  The first school of pediatric nursing 
began at the Children’s Hospital of Philadelphia in 1895 and by 1900 more than half of the US 
medical schools had dedicated chairmen of pediatrics.62 Additionally, pediatric medical societies 
such as the American Pediatric Society (APS) developed in the United States and Europe, and 
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children received more attention in academic medical writings, including journals and 
textbooks.63 Soon after, the American Medical Association acknowledged pediatrics by adding a 
section on diseases of children in 1880, further giving credibility to the specialty.64 The APS 
pursued many strategies to improve the care of children and standards of pediatric medicine and 
attempted to link the APS to the Association of American Physicians, connecting pediatrics to 
the upper strata of American medicine, deserving elite status within medicine.65 With its initial 
start in Dublin, pediatric hospitals began opening around the world in response to a growing 
interest in children, solidifying the emergence of pediatrics as a distinct and arguable elite 
specialty of medicine.66  
 The launch of specialized hospitals and education were among the first big steps in the 
development of pediatric care and medicine.  It was the beginning of a period of history in which 
children were not thought of as property of their parents and incomplete organisms. They further 
had a bit more status and warranted their own specialized medical care.  The creation of 
pediatrics established children as beings in and of themselves with unique needs, no longer 
ignored, however it did not solve all problems.  Despite the creation of children’s hospitals and 
specialized pediatric wards separating children from adults, there were still many issues related 
to not fully comprehending and understanding the ways in which children were different than 
adults.   During the initial phases of pediatric medicine, physicians cared for children in the same 
manner as adults, applying many of the same regulations, practices, and delivery methods from 
adult healthcare directly to the care of children.67 One of the biggest problems was the 
enforcement of adult visitation hours, limiting the time parents could spend with their children 
and in many instances keeping children from parents all together.68  Before the development of 
antibiotics, visitation was limited in adult wards to prevent the spread of diseases, however even 
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after antibiotics were developed, parental visits were kept at a minimum because, as in adult 
medicine, visitors were thought to upset the patient and disrupt the routines of the ward. Then in 
the early to middle 1900s researchers became aware of the emotional effects of isolation of 
children from their families on medical outcomes and new policies and practices emerged.69 In 
1986 the American Academy of Pediatrics said that the design of pediatric environments may 
need to be changed to accommodate the emerging philosophies of care-by-parent and family-
centered care.70 Over time, parents became a “necessary nuisance,“ and an important component 
in the smooth hospitalization and best care of a child. In the 1960s Pediatric Intensive Care Units 
(PICUs) began to flourish, initially with restrictive visitations as well, but that too changed 
eventually as it was realized how much family centered care impacted children and their 
results.71 By including the family in every phase of a child’s care involved benefit, including the 
patient, family members, hospital staff, and the overall community.  In light of these realizations 
and new research studies, family centered care became a major piece of pediatric medicine.72 
 The family is not the only crucial component of pediatric care that emerged over time.  
Pediatricians, specifically physicians focusing solely on the treatment of children, soon emerged 
and became central to the care of children.  During the initial phases of pediatrics, physicians 
received little financial gain from working with children and most of the initial children’s 
hospitals were run by charities and dependent on philanthropy. However many physicians went 
into the field out of a desire to help children.73 Pediatrics developed to bring medical care to the 
underserved population of children, and there were many practitioners who wanted to do this, 
regardless of the financial incentives.  Money was not the only major difference between 
physicians and pediatricians; pediatricians have a very unique role that physicians of adult 
medicine do not always share, not only caring for sick children but also maintaining support for 
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and communication with parents and potentially an entire family.74 Pediatricians not only had to 
know how to medically care for the child, but also understand the social and developmental 
stages of childhood.  Additionally, they have to present all medically reasonable alternatives to 
parents, including what is not only possible but reliable.75 Pediatricians became a source of 
advice and guidance on not only the medical care of the child, but also the observation of healthy 
children, and the overall management and rearing of the child, taking on the role of a child and 
family advisor in the 1930-1940s.76 By 2000, 216 pediatric training programs with more than 15 
subspecialties emerged and there were more than 7500 residents and 60,000 fellows in the 
American Academy of Pediatrics.77  Although the role of the pediatrician is necessary in modern 
society, with parents scheduling appointments with pediatricians before they even have the baby, 
there are still many issues faced by pediatricians including their undefined role in the relationship 
with parents and the child, elaborated in a later chapter.    
 Despite some of the initial challenges, the field of pediatrics has led to tremendous 
improvements in the health of children.78  For example, when pediatric medicine first emerged, 
newborns were not part of the spectrum of “children” cared for and both children’s and regular 
hospitals were refusing the admittance of children under the age of 2 because they did not know 
what to do with them or how to help them.79  Then with the invention of the incubator, newborns 
became part of the realm of pediatrics, and the infant mortality rate significantly improved, 
although there was still a great need for more research and specialized care for newborns.80  This 
shows one of the many ways in which the development of a field that uniquely recognized the 
differences of children has improved the status of children.  Additionally, with new technologies 
and the study of the ways in which children were different than adults, medical subspecialties 
within pediatrics developed, including pediatric surgery, cardiology, neurology, urology, and 
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orthopedics.  Without the creation of pediatrics and the realization that children needed 
specialized care, there would never have been the chance for the development of subspecialties 
within pediatrics.  Specialties within pediatric medicine have led to the improved care and lives 
of thousands of children, of all ages.   
 The evolution of healthcare and medicine for children significantly impacted by society’s 
lack of differentiation of the needs of children from adults, has accomplished a great deal in the 
past two centuries.81  Soon after children were identified as individuals with a unique place in 
both the family and society, they were no longer excluded from the medical world and the lives 
of children were greatly improved. Children went from being property of their parents and of 
economic value only to individuals with rights and privileges who were valued in themselves.82  
Despite the changes and improvements, continued development is essential for the health and 
welfare of children throughout the world, making scientific research crucial. There are however, 
many ethical issues that come with scientific advances, specifically the creation of new therapies 
with ethical dimensions and potential problems.  This is true in all medicine, but especially 
within pediatrics due to the heightened risks, an increased desire for innovative technologies, the 
extreme vulnerability of children, and their lack of decision making capacity.83  Although the 
creation of the field of pediatric medicine has positively influenced children and their families, 
along with the enhanced care of children additional considerations have emerged, some of which 
will be looked at in the remainder of this chapter.  Medical advances do not come easily and in 
order for advances to actually impact children and be safe for them, physicians must do research 
and continue to develop new therapies and interventions.  
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2.2.3. Central Components of Pediatrics  
Research has served as a central component to the advancements made for children.84 
Specifically without clinical research, children would not be able to benefit from the many 
therapies and treatments, nor would pediatricians understand how the body of a child works and 
is different than that of an adult. On the other hand though, research is one of the most 
contentious aspects of adult medicine, bringing up issues of exploitation and vulnerable 
populations. Children belong to a vulnerable population, so this section will look at how the field 
expanded as children were allowed to participate in research and additionally it will focus on 
prevention for children that quickly emerged as a concern when advancements for children were 
made. As the care of children developed into its own field and new technologies emerged also 
came an immense need for research and the development of therapies and drugs specifically for 
children.  Children are both vulnerable subjects who need protection from research risks and 
“therapeutic orphans” who have been denied access to the benefits of research.85  The long term 
tradition of protecting children, extending to include medical research was recently shifted when 
the US created mandates promoting the inclusion of children in clinical research.86 The 
development of lifesaving cures for terminal childhood diseases depends on advances in 
pediatric research, but good intentions do not eliminate risks, -- risks that are even greater for 
child subjects.87 Despite the fact that children are vulnerable subjects and the population is 
smaller, the need for more pediatric studies is compelling.88 Scientific advances and therapies 
cannot be denied to children as a class based on these concerns. Translating knowledge gained 
from scientific advances in biology, genetics, and neuroscience into treatments for children is 
possible only through research.89  But pediatric research is not like adult research and it must be 
treated that way.  The overall needs of children differ from those of adults, but both are entitled 
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to a healthcare system that supports a healthy and productive life, making further research with 
children necessary.90  Children cannot be excluded from research, as they have been before, 
because they themselves need treatments, therapies, and inevitably drugs. But because they are 
children more things must be considered. If new advances are not tested or studied with or on 
children, then they will be blindly used on them without knowing exactly how these will work in 
a child. 91  Children are developing and changing at a much more complex rates than adults, and 
things that would not be issues for adults may be for children, and vice versa - adults and 
children cannot be lumped together and treated the same.   
 Children are not just “little adults” as they were once thought and they cannot be treated 
as such.  In addition because of their exceptional vulnerability, the structure of research methods 
is even more important because children must not be exploited or abused.  During the Nazi 
regime children were used as guinea pigs for research and because of this horrible experience, 
the Nuremberg code addresses children and appears to suggest an absolute prohibition against 
pediatric research:  “the voluntary consent of the human subject is absolutely essential. This 
means that the person involved should have the legal capacity to give consent.”92   In the 1970s 
the United States developed regulations that allow advances and the participation of children in 
research while protecting them from unnecessary and uncompensated risks and discomfort.93 
Current US regulations are there to provide additional protections to children participating in 
pediatric research. However despite regulations, bad outcomes are inevitable in all situations 
when dealing with an unknown.94   A harmed child does not immediately mean that the study 
was unethical, this add too high of a standard to research.  There is always risk and it cannot be 
eliminated from research, the mistakes must however be learned from to prevent future 
occurrences. 
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 Children have been exploited for research in the past, but this cannot be held as a reason 
not to continue, it merely argues that more things must be taken into consideration and extra 
precautions taken.  Without clinical research on pediatric illnesses and medical interventions, 
children might receive dangerous or ineffective treatments.95 In light of the need for research, 
society is obligated to protect them from excessive risk to foster their development that could 
potentially be threatened by involvement in research studies.  This is the ethical dilemma that 
most societies are facing.  The United Nations and the US have both commented on pediatric 
research and offer some ways to potentially enhance the process so it is ethical. The UN 
Convention on the Rights of the Child adopted in 1989 stipulated several things that pediatric 
research can to do improve results and limit the exploitation of children.96 The Convention stated 
that children’s views should be given attention and should be taken into consideration in 
medicine, including new treatments and therapies.  However, the Convention did acknowledge 
that research with children raises additional ethical questions.  Children and parents must be 
given details about the purpose and nature of the research, the methods and timing, in addition to 
the possible harms, benefits, and outcomes.97  Beyond the basics, doctors must also work with 
patients and their families to explain the concepts, such as consent, and give as much information 
as possible.98  Children should be given a leaflet to explain the research in their native language 
as well as given the opportunity to talk directly to the researcher. The child should be encouraged 
to ask questions because they themselves must be informed.  
 Research impacts both the young participants as well as those feeling the long term 
impacts from changes in attitudes or policies about similar children and young people and 
services for them so it is crucial that all of this be taken into consideration.99  The effects of 
research may or may not be intended and there may be impacts throughout society.  One 
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example that Anderson discusses is misinterpretation of the findings and results by the media to 
portray what the media wants, not what actually was found when the entire study is taken into 
consideration.  Many researchers who work with children are wary and concerned of presenting 
their findings because of how the media can misrepresent the information in ways that could 
harm young people.  In many cases these researchers feel that their work is not valued and seen 
to be of little influence or importance.  Despite these feelings, in the last 15-20 years, there has 
been tremendous growth in research with children, the reporting of children’s own views and 
experiences, formal pediatric research ethics committees and ethics training for pediatric 
research.100  There is a need for change and continued development.  It is argued that the current 
research model does not adequately protect children from harmful and useless research nor 
promote their participation and interests overall, but that does not mean research should be 
stopped as it is a necessary component to the growth of the field.  The ethical aspects of research 
with children will be elaborated in the following chapter as a key component to the expansion of 
pediatric medicine. There is a need for balance between protecting young people and preventing 
and reducing harms while respecting and involving them and listening and learning from them, 
to not silence and ignore them.101  There are basic issues with pediatrics in general, specifically 
that children must be seen as different than adults and they must receive their own attention, and 
research provides additional issues.  Children require specific safety measures due to their 
limited capacity to give informed consent. Well-designed and well-regulated research with 
children is needed to improve children’s health, specifically with a focus on prevention methods 
for children. Prevention has been identified as a central way to improve the lives of children and 
adults, seeking to prevent illnesses before they happen. With more research, and the increased 
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desire to protect children and improve their overall health, the focus shifted to preventative 
measures.  
Over time, preventative measures became the focus of developments with children.  As 
the field of pediatrics medicine has expanded, significant developments have been made, 
impacting the lives of thousands of children and their families.  Science and technology have 
been able to enhance pediatrics on such a great level due to the heightened attention given to the 
care of children.  It has been acknowledged that children are unique and require additional 
attention, precautions, and levels of expertise.  Some of the major impacts of science and 
technology for children concern the development of prevention methods and tests for certain 
illnesses and conditions.  In this section three major pediatric preventative measures will be 
examined briefly: vaccines, genetic and newborn screening, and the increasingly popular practice 
of pediatric brain scans.  Many preventative measures have been developed for children 
including the creation of hearing and vision screenings in the 1940s and height and weight charts 
in the 1930s all to see if they were developing abnormally, but the preventative measures looked 
at in this section are those that specifically lead to ethical issues 
 Vaccines are arguably the biggest technological breakthrough and most effective 
preventative measure, however over the past 10-15 years they have been challenged and the 
benefits have become less obvious.102  In the early 1900s, advances in immunizations resulted in 
improvements in the smallpox vaccine and the deployment of a diphtheria immunization.103  
Following this, researchers intensified their efforts to control common communicable diseases of 
children, many of which even killed them, and found immunizations for more diseases.104 
Because of this, vaccines are considered one the greatest public health achievements of the past 
100 years, and the benefits of vaccination seem obvious once their successes are discussed.105  
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Vaccines led to the eradication of an entire organism (variola virus) and the global control of 
many others (such as measles and polio), and the significant reduction of common diseases in 
some countries.  But vaccines do not come without risk, and as vaccine-preventable diseases 
become rare, the benefits individual children receive from vaccines becomes less apparent. On 
the risk side, vaccines are not inert and they are actually intended to endanger the immune 
system of the recipient to induce immunologic protection, so all vaccines have side effects, and 
are rarely 100% effective.106  Some individuals who receive a live viral vaccine may develop 
mild symptoms associated with the transient replication of the virus, for example 6% of the 
children who receive the varicella vaccine will develop vesicles near the site of the vaccine 
administration.107  For the benefits, although the diseases that are typically immunized for are 
severe, due to the success of vaccinations and how rare the illness are, it is unclear why parents 
should put their child at risk.  Benefits are very specific to each child and unpredictable with 
regard to different interventions. It is not possible to predict a given child’s future exposure to a 
specific organism or other high risk behavior that would lead to a greater risk of developing a 
disease..  One argument is that of an “umbrella effect” specifically that by protecting most 
patients possible, those who are not immunized are covered and not as susceptible to the disease, 
specifically those who cannot be vaccinated due to medical conditions or age.108  On a global 
level, international public health officials have questioned whether the benefits of vaccines may 
outweigh the risks in some developing countries. However, clinical trials in such locations are 
lacking, so the results of administering the vaccine are unknown or unpredictable.109  Despite the 
lack of research done on an international level, many infections, including those with rotavirus, 
remain a serious threat to children at the global level, so it is crucial that enough research is done 
so vaccines can be used on an international level in a safe and effective way.  In light of 
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challenges and skepticism of vaccines over the past few decades, vaccines remain one of the 
most important ways in the 21st century to improve child health and the future of vaccines will 
rely on the preservation of public trust in the mechanisms used to assess vaccine safety and the 
science and development of vaccines that are effective for the most vulnerable children.110 
Vaccines however bring up ethical issues including those of consent and parental authority, but 
also new issues including justice and how far preventative measures should go to help others 
when there may not be a direct benefit to the child, similar to research.   
 The next preventative method that emerged is genetic testing and newborn screening.  
This too will be elaborated in the following chapter, but is emphasized here since it was one of 
the first major prevention methods with children.   Screening is a public health initiative that 
surveys an entire population for evidence of an illness before symptoms are exhibited 
symptoms.111  The purpose is to identify those who are suffering from or are likely to develop a 
disease and who are likely to benefit from early detection and intervention.112  In the 1960s a 
simple genetic test involving the absorption of a few drops of blood was developed for PKU, a 
disorder that causes severe mental retardation if left untreated but can be easily regulated by 
diet.113  Following this development, screenings began in the US and most states passed laws 
requiring the prick of the heel of all newborns so that their blood could be analyzed.114  Currently 
about 200 cases of PKU are diagnosed in the United States each year and education is provided 
to the family on how to regulate this and prevent the side effects of the illness.115  Soon other 
illnesses were found to be identifiable through blood and over the years the practice has steadily 
expanded. Depending on the state, newborns are screened for 29 up to 54 conditions.116  Almost 
all babies born in the US undergo screening soon after birth to identify genetic defects that could 
cause serious illnesses if left untreated in order to detect the diseases as soon as possible so that 
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treatment could potentially be given even before symptoms arise.  In most states newborn 
screening is mandated by law and of the 4 million screened each year 5,000 are found to have 
heritable disorders.117  Tremendous ethical issues arise when determining what should be 
screened for and should be part of the standard panels for all newborns, which will be looked at 
in the following chapter.  
The other area of development with predictive power is that of functional MRIs, also 
known as brain scans. Brain scans offer a way to analyze how different parts of the brain work 
together functionally and can then be applied to patients who lack certain abilities or have 
deficits.  By comparing data with standardized models of how the brain functions or how a 
specific disease develops a variety of new clinical insights becomes available and it can be seen 
how the child’s brain is out of sync with the normal developmental curve.118  This approach is 
expected to enable treatment before any onset of symptoms and help physicians track the results 
of clinical trials of new therapies, but for the time being, the focus is on understanding the brain 
and being able to relate behavior to brain activity.  Pediatric brain scans are not an extremely 
large practice at this time, but there is a great possibility that this will be one of the new 
interventions more commonly used to care for children, along with genetic screenings, to 
understand, diagnose, and inevitably treat.119  It is currently not known how all of the different 
systems of the brain interact, or what an identified brain abnormality can predict about the 
patient, but there is great potential for predictive and eventually preventative power with these 
scans.120  It is difficult to assess and diagnose individuals with disorders of the brain and even 
more challenging to use new therapies to treat them, but brain scans have made great progress.  
The many advancements of neuroscience, just as those of other fields of medicine, bring with 
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them both new possibilities and issues to address, but great hope for the future and current 
abilities to predict and eventually prevent disorders in children.121   
 Pediatric medicine has a strong growth in the area of prevention methods, only to expand 
with the continued developments and new technologies looked at in the next chapter, which will 
expand upon the methods just introduced. Research led pediatric medicine to where it is today, 
but it has not been an easy journey and it is one filled with regulation and continuous changes. 
Additionally prevention methods to protect children were developed including vaccines and 
newborn screening, showing their importance.  There is a strong desire to prevent illnesses and 
identify those that may not be preventable but where an intervention could be performed or 
identification can enable some kind of action.  With the newborn screening come additional 
ethical issues, specifically with the expansion of the field which will be looked at in the next 
chapter, however it was introduced here to show the initial developments and focus of the field 
of pediatrics.  The emphasis on prevention and the desire to help children and improve their lives 
directly relates to the overall goals of pediatric medicine, which will be elaborated in the 
following section.  Children were once orphans from the medical world, left out and lacking their 
own specialized care, however over time this changed and they have taken their seat as a central 
component of society, receiving a great deal of medical attention and focus throughout the world.  
 
2.2.4. The Goals of Pediatric Medicine and the Emergence of Pediatric Ethics 
 Pediatric medicine began in the image of adult medicine treating children in the same 
way that adults were treated.  Over time though, this view of children as the same as adults 
slowly transformed, and advancements were made that specifically addressed the different needs 
of children.122 Pediatric medicine, as a unique specialty of medicine, requires its own set of goals 
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and principles, however in many ways, the goals of adult medicine have been applied to 
pediatrics and explicit goals of pediatric medicine do not exist distinct from those of adult 
medicine.  This is problematic because the goals and guiding principles of adult medicine do not 
directly apply or fully capture the goals and dynamic attributes of pediatric medicine and care. 
Medicine needs to be guided by values and universal goals that directly apply to the populations 
being served, making it crucial to develop goals specific to the needs and attributes of 
children.123 
 Before discussing the goals of pediatrics, the goals of adult medicine will be introduced 
and argued to be insufficient to accommodate the unique elements of pediatric medicine.  Adult 
medicine has many overarching goals, including the prevention of disease, promotion of overall 
health, the relief of pain and suffering, care or cure of disease, the avoidance of premature death, 
and the inevitable pursuit of a peaceful death.124 Not all maladies or illnesses can be cured, so 
many times just the care and treatment should be the goal.125  Additionally, it gets to a point 
when patients can no longer be helped, and the goals shift to avoid a premature death and when 
no longer possible, help the patient achieve a peaceful and painless death.126  These general 
principles guide medicine on a basic level, however, it can be argued that the ethical principles of 
autonomy, beneficence, non-maleficence, and justice encompass them all, at least within the 
realm of adult medicine, and offer actual goals and more structure.  The principles of autonomy, 
beneficence, non-maleficence, and justice are prevalent throughout medicine and are even 
identified by some in the Hippocratic Oath attached to duties of physicians.127 Additionally, 
these principles are used to justify informed consent enabling adults to make their own medical 
decisions in light of their values and beliefs, one of the central components of adult medicine and 
decision making.   Respecting the autonomy of the patient means supporting and facilitating the 
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patient’s exercise of self-determination in decision making, overall allowing him or her to weigh 
the benefits and burdens in light of personal values and beliefs and make a decision that aligns 
with them.128 Beneficence, specifically the physician’s duty to promote the patient’s best 
interests and protect the patient from harm when possible, can sometimes make the initial 
principle of respect for autonomy challenging, especially when they are contradicting, however 
physicians should still advocate for the best option.129 Beneficent acts are demanded by the roles 
involved in fiduciary relationships between healthcare professionals and their patients. The exact 
scope of this beneficence is not clearly defined as physicians are morally obligated on some 
occasions to assist others and promote positive benefits while preventing harms, but not in 
others.130 The next principle is non-maleficence, specifically to not cause any harm to patients.  
This principle is additionally challenging in that sometimes there is no good option, or one 
without any harms, however to “do no harm” means to have a balance of benefit or good over 
the harms caused.131 Beneficence assumes an obligation to weigh and balance benefits against 
harms, benefits against alternative benefits, and harms against alternative harms.  The final 
principle and goal of adult medicine is justice, referring to the fair, just, and appropriate 
treatment of individuals based on what is owed to them.132   
 The goals and principles of adult medicine outlined do not seamlessly apply to pediatric 
medicine and do not encompass all of the objectives of pediatric care.  Goals of medicine must 
serve the good of the patient, as defined by the patient’s values constrained by benefit and harm, 
as found in and defined by the doctor patient relationship, emphasizing the need for unique goals 
within the field of pediatrics.133  Providing medical care for children is not the same as treating 
adults, therefore the goals of pediatrics should be framed differently than those in adult 
medicine.134  The goals of pediatrics are complex and include protecting the child and furthering 
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his or her best interests, protecting the child from unjustified harms in regard to medical 
interventions, and showing respect for family autonomy.135  Within adult medicine, the patient’s 
preferences guide the decision making process, enabling the autonomous patient to choose what 
is most beneficial to him or her, but in pediatrics, parents are tasked with weighing benefits and 
burdens and making choices for their child who is the patient.  Selecting the best therapy and 
weighing all of the benefits and burdens is especially challenging within pediatric medicine and 
many times, parental preferences may or may not reflect the good of the child, nor take into 
account the patient’s values which may or may not have had the opportunity to mature.136 This 
calls into question the utilization of autonomy as a guiding principle within the field of 
pediatrics, since by definition, children lack complete autonomy. Personal autonomy, defined as 
an individual acting freely in accordance with a self-chosen plan, cannot be seamlessly applied to 
children, and by definition as children, they do not have full autonomy, although since they are 
in the process of developing, are somewhere along the spectrum with varying levels.137 
Additionally, justice is not an arguable goal of pediatrics that impacts decision making or the 
roles of parents or physicians because in most cases, justice for children is addressed by society.  
For instance, society limits the rights of parents to refuse lifesaving interventions for their 
children, such as blood transfusions or actions that put the child’s life in extreme danger.138 
Additionally, legislation like the Baby Doe Regulations, which determines that the withholding 
of medically indicated treatment cannot be done unless (1) the infant is chronically and 
irreversibly comatose; (2) the treatment would merely prolong dying and not be effecting to 
correct the infant’s life threatening conditions; or (3) the treatment would be virtually futile in 
terms of the survival of the infant or the treatment itself would be inhumane under such 
circumstances, guarantees that care is given to infants regardless of parental decisions.139 
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Legislation also exists that ensures children receive medical care even when their parents cannot 
provide it. These societal impacts lead to a limited application of the principle of justice to 
pediatrics as a main goal.  It is not to say that it should not be a goal at all, however it is not one 
that will be further elaborated here or used to frame parental decision making.   
 Some of the mentioned goals and principles of adult medicine do however apply to 
children and the practice of pediatric medicine.  The goals of pediatrics should include 
beneficence and non-maleficence, however autonomy cannot be directly applied or used as a 
guiding principles for the reasons elaborated.  Even though autonomy cannot directly be applied, 
that does not mean it is not important, if not crucial, to decision making in pediatrics.  Some 
argue that parents can exercise the autonomy of the non-autonomous patient, as a surrogate 
would in adult medicine, however it is first, not clear that that is where the authority of a 
surrogate is based, and additionally, unlikely that parents could exercise the not yet developed 
autonomy of their child.140 The principle is the “respect for autonomy” rather than the exercise of 
autonomy, so it is possible that parents are selected as the most appropriate individuals to make 
decisions that would respect the child’s future autonomy.  This would not ask them to apply the 
child’s not yet developed values and beliefs, but rather, act in his or her best interests.  This is 
why, for pediatric medicine, a reformulation of the concept of autonomy will be argued for and 
applied as a fundamental goal that respects the autonomy of the family, the future autonomy of 
the child, and the overall promotion of the current and future interests of the child.141 Within 
pediatric medicine, there are additional levels of the duties and responsibilities of physicians, 
strongly connected to the goals of the field that complicate decisions and processes.142  The 
professional goals are different for pediatricians as they must work with the parents, in most 
cases more than their actual patient, while upholding, balancing, and sometimes arguing for the 
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child’s best interests.143 In pediatrics, pediatricians and parents both are crucial to the selection of 
treatments for the child, as co-fiduciaries.144  Pediatricians have an obligation to protect and 
promote the health-related interests of their child-patient and parents also have a fiduciary 
obligation to promote and protect the non-health-related interests of their child, who is the 
patient.145 The doctor-patient relationship is a focal point of medicine in general, however this 
becomes more challenging within pediatrics when the parents are added to decision making 
processes, and both are simultaneously working to do what is both right and best for the child.146 
 The goals of pediatrics are different than adult medicine because in this field, the 
children-patients rely completely on adults, specifically parents and doctors, to define what is 
right and good for them, enhancing the roles of all involved.147  A partnership exists between 
healthcare professionals, children and families which implies the need for shared objectives.148  
It is not clear that parents are in the best position to make decisions for their children in all 
instances.  Parents have to deal with a great amount of emotions including feelings of sadness, 
anxiety, anger, and guilt combined with feelings of love, responsibility, and devotion.149 Many 
times parents are confused or have conflicting interests, calling into question the family centered 
model as the basis utilized for decision making currently in pediatrics.  Additionally, depending 
on the complexity of the disorder or condition presented to them by the physician, they may be 
confused or shocked due to the rarity or complexity of their child’s illness and unknown 
components. It is not an internationally agreed upon idea that parents are the best decision 
makers, however it is the typical North American perception.150 The goals of pediatrics, which 
will be fully elaborated in Chapter 4, are complex and should include protecting the child and 
furthering his or her best interests, protecting the child from unjustified harms in regard to 
medical interventions, and showing respect for family autonomy.151  These fundamental goals 
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are incorporated within the specialty of pediatric ethics, a field that developed just as most pieces 
of pediatrics, out of the adult model as it was recognized issues of pediatric medicine could not 
be handled in the same way as adult issues.   
 
2.3. Pediatric Ethics 
 Pediatric ethics deals with normative questions specifically related to pediatrics and 
addresses how ethical issues of pediatrics medicine are different and unique from adult medicine 
and should be handled in specific ways.152  Pediatric ethics developed shortly after the 
emergence of the field of pediatrics itself and the realization that children cannot be treated in the 
same way as adults and that there are many issues unique to pediatrics.153  The ethical dilemmas 
that children and their families face are different from those in adult cases in many ways and 
cannot be handled in the same manner.  Pediatric ethics is distinct from general medical ethics 
for several reasons. It must account for a three way relationship involving the physician, patient, 
family (normally parents) rather than the dyadic relationship that is more common in adult 
medicine.  When dealing with children, the parents are the consenting party, making the 
pediatrician more explicitly responsible to the parents and family than in other areas of 
medicine.154 Within adult medicine and medical ethics, there is a focus on autonomy, in most 
cases giving the patient the ability to do what he or she wants. However within pediatric ethics, 
complete deference to patient autonomy is not an option since children are not presumed to be 
autonomous and capable of making decisions.  In these cases, families must make decisions for 
and about their child that has never been autonomous or able to make such decisions for him or 
herself.155    Instead of patient autonomy the issue becomes parental decision making, which is 
not as absolute as patient autonomy and in many cases can be overruled by the patient’s best 
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interests, which are not typically easy to determine.156  Determining the best interests of a patient 
involves weighing the anticipated benefits and burdens to select a course of treatment, however it 
is often a point of disagreement among family members and medical professionals, who consider 
different aspects and can weigh them differently since it is a very subjective analysis.157  It is not 
easy to determine the best interests in adult medicine and it becomes even more difficult to do so 
for a child who has never had the capacity to make decisions for him or herself.   
 Another dimension of pediatric ethics is that as the field of pediatrics develops and 
grows, the ethical issues become more complex and challenging.  As technology progresses, 
pediatrics has become a field full of experimentation and the use of the latest and most up and 
coming technologies, placing parents and physicians in an even more challenging role.158  These 
technologies have benefited many children and infants throughout the world, for example, 
decreasing the infant-mortality rate, providing the ability to keep much younger premature 
neonates alive, and to cure or contain many childhood illnesses that at one time killed almost all 
patients with the disease. However, along with these technological breakthroughs and 
enhancements comes more medical concerns. Currently, many of the newest developments are 
connected to breakthroughs in neuroscience, raising ethical issues and questions of not only what 
to do, but how and when to utilize them.  These new ethical issues of neuroscience will be more 
fully developed in the following chapters. 
 The field of pediatric ethics emerged to handle the ethical issues of pediatric medicine 
created by scientific breakthroughs, research, and an increasing interest in and the awareness of 
children and their individual needs.159 The ethical issues that children and their families face are 
different from those in adult cases and cannot be handled in the same manner, inevitably leading 
to the specialty and emergence of pediatric ethics and the use of pediatric ethics committees 
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(PECs).  As science progressed, pediatrics became a field full of experimentation and emerging 
technologies.160  .  Children, as distinct from adults, have their own specific problems and ethical 
issues, thus the specialty of pediatric ethics emerged.  Even similar problems that exist in both 
regular medicine and pediatrics, such as the removal of care at the end of life, must be handled in 
different ways in pediatrics and adult medicine.  In addition, there are more stakeholders, 
enhanced professional duties and obligations, and potentially more on the line due the potential 
for such a long life of a child. Pediatric ethics looks at these specific issues addressing both the 
pediatrician and parents as fiduciaries of the child within their specific realms working both 
together and at the same time for the child patient.161 Pediatric ethics is a necessary field that 
addresses the unique ethical issues and challenges that arise within pediatric medicine and work 
to further the interests of the child.  
 
2.4. Conclusion  
 The field of pediatrics emerged in the mid-19th century as the views of children as different 
from adults and in need of specialized care developed. Children in modern society receive a great 
deal of attention from the government, their families, and society in general, including the 
medical world, however this was not always the case. Societies changed from being completely 
ignorant about and uninterested in children and childhood to seeing children as a central feature 
of the family.  The evolution of healthcare and medicine for children has been greatly impacted 
by society’s lack of differentiation of the needs of children from adults. But once this was 
realized, the lives of children were greatly improved and they were no longer excluded from the 
medical world. Children went from being property of their parents and of economic value to 
individuals with rights and privileges. The field of pediatric medicine emerged as the 
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conceptions and ideas about children changed but also because it became understood that they 
need their own specialized care. The field of pediatric medicine has improved the condition of 
thousands if not millions of children worldwide, with new therapies and treatments continuously 
developing, leading to the creation of more ethical issues and even more difficult situations for 
parents and physicians.  These unique ethical scenarios and more complex areas lead to the need 
for the reformulation of the goals of medicine to be applied directly to pediatric medicine.  The 
goals of adult medicine do not apply, nor do they address all of the challenging issues presented 
in pediatrics.  Pediatric medicine has many unique issues and problems such as heightened 
emotions, decisions with potentially higher stakes and longer impacts, and making decisions for 
someone else, specifically one’s own child.162 In response to these unique challenges, 
considerations, and goals, a special area of ethics was developed. Pediatric ethics emerged out of 
the realization that issues within a pediatric medicine are not only different but must be handled 
in a way that is not similar to adult medicine.  Pediatric medicine emerged as children were given 
a place in society, however there is still a great need for developments in the field, not only of 
science, but also of ethics.  The medicine, ethics, or decision making processes of adult medicine 
cannot be used as a model for those within pediatrics, and it is crucial that pediatric medicine 
have its own standards and models in order to balance the roles of the family, child, and society 
while providing the best possible care for the child.  
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Chapter 3 - Medical Decision Making  
3.1. Introduction 
 Throughout the medical world, patients, providers, and family members are continuously 
making decisions about therapies and medical interventions.1  They select treatment plans, 
decide whether or not to have an invasive procedure, and can choose if and when to discontinue 
treatment.  These decisions have ranging levels of complexity, time available to decide, and 
potential impacts.2  Many decisions must be made in an instant and can impact the patient in 
many ways, while others are much more straightforward and do not place a tremendous burden 
on the decision maker.  There are few easy decisions in medicine, but with the expansion and 
growth of science and technology, they become much more complex.  New technologies and 
scientific breakthroughs create more available options, but with them come new decisions and 
benefits and burdens to determine.  Challenging medical decisions due to technological 
advancements are not unique to the field of pediatric medicine, however the way in which they 
are dealt with is.  Within adult medicine, the patient is typically given the authority to make 
decisions for him or herself, however this is not the case in pediatrics, where the patients are 
children.  In pediatrics, parents are typically looked to as the decision maker for their children, 
placing them in a tough position.  Not only do parents have tremendous emotional burdens, but 
they are asked to make choices that could have impacts lasting the duration of their child’s life.  
New therapies and developments not only bring with them more options, but also possibilities 
and overall hope for parents who want to protect their children and do what is best for them.  
Technology has created great opportunities and enhanced the lives of children around the world, 
however until they are fully understood and proven, they place parents in difficult situations 
making decisions on incomplete or insufficient information.  Parents need a model to make 
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medical decisions about interventions for their children that offers them support and guidance to 
make decisions consistent with the child’s interests.  In most cases, the models of adult medicine, 
specifically the best interests standard, are applied to pediatric cases and parents are asked to 
make decisions in the best interests of their child.  These models however, do not provide enough 
structure or guidance or properly facilitate the involvement of all stakeholders, making them 
insufficient for pediatric medicine.  Decision making is a major aspect of healthcare with many 
more ethical issues that arise when the patient is unable to make his or her own decisions, with 
even more ethical dimensions when the patient is a child.  
 In order to understand the ethical dimensions of decision making within pediatric ethics, 
decision making of adult medicine will be examined, followed by an application of the principles 
and concepts of adult medicine to pediatrics.  In the first section of this chapter, the basics of 
medical decision making will be addressed, including the basis for and importance of allowing 
individuals to make their own medical decisions rather than the medical team. After looking at 
the development of this practice, and the shift away from paternalism, decision making capacity 
will be defined, followed by an analysis of the models utilized by surrogates when decision 
making capacity is lost.  Within the analysis of the models, many of the problems that arise with 
them in practice will be discussed.  These problems with application have led to a more 
comprehensive, subjective model.  In the second section of this chapter the concepts and models 
of adult decision making will be applied to children, specifically looking at issues of consent and 
capacity, balancing the many stakeholders, and then the application of the substituted judgment 
and best interests model to cases with children.  It will be argued that the models for surrogate 
decision making are problematic for adults and inevitably insufficient for parents to use when 
making decisions for their children.  A new formulation is needed.  
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3.2. Adult Decision Making 
 In modern medicine it is well accepted that adult patients make their own medical 
decisions based on concepts of personal autonomy.  There is a strong desire to allow patients 
make their own medical decisions and select therapies that they believe are best and fit into their 
lives.  Despite this current practice of modern medicine, allowing all to make their own medical 
decisions, this was not always the case.  At one time, patients relied on their physician to 
diagnose and select a proper course of action for them.  Eventually, western societies gained an 
appreciation for personal autonomy, and believed individuals with decision making capacity 
should be able to make decisions for themselves in light of their personal beliefs and values 
through a process of informed consent.  This placed the patient in control of his or her medical 
care, but also set guidelines for decisions that the patient could or could not make.  With regard 
to decisions for him or herself, the patient is typically allowed to make almost any decision and 
weigh benefits and burdens in a way that is meaningful to them, but this is not the case if 
someone else must step in.3  When patients lack the ability to make decisions, specifically do not 
have decision making capacity for a specific decision, a surrogate must come in to make the 
decision.  Surrogates do not have the same freedoms and flexibility of the patient, and these 
decision making processes are more structured since surrogates are not the patient.  
This section will look at the development of informed consent out of respect for personal 
autonomy, and the concept of decision making capacity as the foundation for informed consent.  
Decision making capacity, as the threshold to allow individuals to make their own decisions is a 
central component of adult decision making and will additionally play a crucial role in pediatric 
decision making and the enhanced model.  The second half of this chapter will examine the 
models that guide surrogates to make decisions for adult patients who lack decision making 
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capacity, substituted judgment and the best interests models.  There are many problems with the 
application of both of these models, leading to a much more comprehensive and shared decision 
making model in practice, which will be addressed in the final section.  
 
3.2.1. Autonomy, Informed Consent, and Decision Making Capacity  
 Adult patients are given a tremendous amount of authority over their medical decisions 
and in most cases in modern medicine they are able to select, adjust, or even refuse certain 
therapies and treatment plans.  Physicians advocate for what they believe to be the best option, 
however in the end, the adult patient more times than not will make the final decision.  This 
authority is based on concepts of autonomy, which developed over time as a central component 
of medical decision making.  This section will look at the key elements of decision making 
within adult medicine, initially addressing the change from the paternalistic model of physicians 
making choices for patients, to a focus on respect for personal autonomy, as the justification for 
allowing adults to make their own medical decisions.  After elaborating the development of 
personal autonomy and the justification for individuals to make their own decisions, the concepts 
of informed consent and decision making capacity will be evaluated as major and necessary 
components of adult decision making. Decision making capacity is necessary for adults to make 
their own decisions, which is evaluated in relation to the decision made.  Informed consent on 
the other hand is the mechanism in which decisions are made, set up to ensure the 
comprehension of the options and treatment courses by the patient before making a decision. 
Decision making in adult medicine is very complex and in order to look to pediatric medicine, 
adult decision making must be fully understood.  
3.2.1.1. Personal Autonomy from Paternalism  
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 Decision making in adult medicine is based on the concept of personal autonomy, 
enabling adult patients to make choices and select therapies that align with their own personal 
values and beliefs.4  In the beginning of medicine, and throughout the early 1900s and almost 
until the 1980s physicians were thought of as the leaders of care for their patients due to their 
medical knowledge and experience, and made decisions for the patients.5  This model for 
decision making is referred to as a paternalistic model.  Dworkin defines paternalism as “the 
interference with a person’s liberty of action, justified by reasons referring exclusively to the 
welfare, good, happiness, needs, interests, or values of the person being coerced.”6  In a 
paternalistic model, the patient receives the treatment or intervention that the physician has 
determined to be in the patient’s best interests based on the medical facts and specific case.7 The 
physician presents the information to the patient, encouraging him or her to consent to what they 
view as best, however at extremes the physician will make the decision, especially when the 
patient does not agree.  In some cases, the physician does not even consult with the patient and 
just makes the decision and proceeds with treatment.8   
There are many problems with this model, specifically that it limits the freedom and 
autonomy of the patient, but it additionally makes some assumptions that may have been 
accurate in the beginning of medicine, but can no longer be held to be true today.  One of those 
assumptions made when justifying the paternalistic models is that the goals and objectives of the 
specific case are shared between the physician and patient, which is not always the case.9  
Physicians should place the patient’s goals and views ahead of their own to help them structure 
the decision, however there is not a mechanism to ensure that happens with the physician as the 
sole decision maker.  In most cases, the physicians select courses of treatment with little to no 
involvement from the patient, and typically without much thought about what is in line with the 
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patient’s values, beliefs, or personal goals. Additionally, others believe that the physician is 
justified in overriding the patient only if they are convinced that it is the best course of action and 
the patient would agree later due to the outcome or results of the intervention.10  Overall, the 
paternalistic model was widely recognized as the physician controlling and acting as the patient’s 
guardian, which was not ideal, so it should only be leveraged in instances of emergency when 
there is no other option.11  These arguments were made because it was thought that the physician 
knew more about the medical care than the patient, but medical knowledge is not enough to 
make a decision specific to a patient.12  The overall goal must be to respect the patient’s 
autonomy and allowing their views and opinions impact decision making processes, inevitably 
leading to a change in overall goals of medical decision making.13  
During the latter half of the 20th century, there was a drastic shift in societal views and 
the patient-physician relationship placing an emphasis on the rights of individuals and his or her 
role in decision making processes.14  Patient control was advocated, not only empower patients 
to make decisions in light of their own beliefs and views, but also to reduce the physician control 
and dominance.15  Individuals should be informed of all options and relevant information and 
also be involved in their care and choose what does or does not happen to his or her body.16 A 
new appreciation was gained for personal autonomy and the ability of individuals to weigh 
options in light of their own beliefs and values.  With this change and focus on the rights on 
patients came new requirements of medical professionals to involve and inform their patients.  In 
many parts of the world, paternalism is still common, although there has been a shift towards a 
more shared model with patients playing a larger role in care.17  Over time, paternalistic 
approaches faded leading to the personal autonomy based model of today, however currently this 
model has slowly shifted back towards a more shared, centered model.  It does not have to be at 
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one end of the spectrum or the other, specifically controlled by either the patient or physician, 
leading to a more common and advocated for shared model, which will be discussed in a later 
section.  
 
3.2.1.2. Development of Informed Consent out of Autonomy 
 Personal autonomy is an extremely important concept in medicine, specifically with 
regard to decision making.18  It is the basis and main argument for patients making his or her 
own decisions, and led to the shift away from paternalism.  On a basic level, autonomy refers to 
self-rule or self-governance based on one’s own goals and values.19  In a medical setting, respect 
of personal autonomy acknowledges that individuals have the right to take actions based on their 
personal values and beliefs.20 Individuals with decision making capacity are allowed to make 
their own decisions about medical treatment and care, and do so through a process of informed 
consent.21  Informed consent is crucial to the medical field and medical decision making 
processes for many reasons.22  According to Beauchamp and Childress, informed consent is an 
individual’s “autonomous authorization of a medical intervention.”23  Without informed consent, 
it is not clear if patients comprehends the options presented or what they inevitably selected as a 
therapy, calling into question their decisions.  Despite its importance, it should be acknowledged 
that informed consent is a process, rather than a specific action or authorization by the patient, 
and must be treated as such.24  Informed consent is a process by which the patient works with the 
doctor, medical team, and in many cases family, to make the best decisions in light of personal 
values and ideals or at a minimum articulates a full understanding and demonstrates that they 
have decision making capacity, before making a given decision.25  On a basic level, informed 
consent is a practical and effective recognition of human dignity that respects autonomy and 
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personal freedom, permitting the individual patient to play a primary role in health care choices, 
enabling the establishment of mutual respect among the physician and patient.  The moral 
purpose of informed consent is to protect individuals from abuse, however it is also important 
that patients are not subjected to coercion, deception, or other kinds of manipulation.26 Informed 
consent enables the patient to be a valuable and central component to the decision making 
process, working with the physician in a partnership.  
 There are two key elements of informed consent, (1) the disclosure of information from 
the physician and the comprehension of such information by the patient, and (2) the willing 
consent of the patient.27  Disclosure is an important aspect because physicians are patients’ only 
real way to gain an understanding of the medical elements in order to apply personal values to 
the situation and make a choice.28  Choices and behaviors are guided by past experiences, 
knowledge, and are almost automatic in many instances, differing among individuals.29  No two 
people will rank options in the same way, or come to a conclusion based on the same values or 
reasoning.30  These differences emphasize the importance of informed consent processes and the 
need for their facilitation in all medical decision making processes.  The informed consent 
process exists to attempt to acknowledge these differences, but because individuals all think 
differently, it is not always evident what information should be shared with the patients about the 
diagnosis, condition, and potential therapies.31  The reason for emphasizing informed consent is 
that patients can make an autonomous choice, but if they do not have all of the information 
relevant to their personal situation it may not be possible to make such a decision.32  In order for 
an individual to make an autonomous choice, consistent with personal values, patients must have 
access to the information that they find relevant and would be important in their decision making 
process.  Physicians however, are human, and cannot be required to know absolutely everything 
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about medicine, and additionally cannot know exactly what the patient would find relevant and 
important to the decision making process.  Legally, doctors must disclose enough information to 
enable the patient to decide whether treatment is in his or her best interests.33  Typically, medical 
professionals should provide the facts or information that patients usually consider, in most 
situations, important while deciding whether to refuse or consent to a proposed intervention, as 
well as any information the physician believes to be relevant to the decision making process.34  
This must be presented to the patient in a way that he or she, typically lacking medical 
knowledge, understands and comprehends.  It is important that physicians support and 
collaborate with the patients, enabling a smooth informed consent process that recognizes the 
patient's particular wishes and desires.35  Medical treatments should focus on pursuing a better 
overall health and quality of life for the patient rather than only treating a medical pathology.  
Health and the desire for life are not always congruent and differ among patients; the definition 
of “healing” for one individual may mean the acceptance of his or her illness, even if that is the 
acceptance of death, while for another it means doing everything possible until the end.36   
 The growing importance of informed consent and the recognition of respect for personal 
autonomy exemplifies the shift from a physician centered, potentially paternalistic, approach to a 
patient centered model with the patient as the focus of decision making and medical care.37  
Respect for autonomy must be balanced with other principles including beneficence, non-
maleficence, and justice, however as long as individuals retain the ability to make decisions his 
or her choice is to be respected.38  Physicians cannot substitute personal values or conceptions of 
quality of life with that of the patient and must work with the patient to make decisions that align 
with their beliefs.39  The process of informed consent is crucial to medicine as it recognizes the 
autonomy of the patient and also enables the patient to make a decision that is meaningful to him 
 72 
 
or her.  Each person values and ranks pieces of their lives and health differently, and must be 
able to evaluate options with their physician to ensure that they select the course of action that is 
best suited for them medically, emotionally, and personally.  Decision making is not easy and 
must be a collaborative and informed process between physicians and patients, focusing on the 
patient and his or her own conceptions of quality of life and health, thereby respecting the 
autonomy of the patient.  
 
3.2.1.3. Decision Making Capacity 
 Decision making capacity is a necessary component of informed consent. In order for 
individuals to make medical decisions and give informed consent, they must have the appropriate 
level of decision making capacity, specifically, they must be able to understand all of the 
relevant information and make a decision voluntarily.40  Decision making capacity is different 
than and important to distinguish from competence.41  Competence is misleading to use in the 
medical setting because it has legal implications; lacking decision making capacity to make 
health care decisions does not mean that an individual does not have legal competence, and vice 
versa.  Capacity or decision making capacity is used throughout the rest of this dissertation to 
accurately identify and discuss what patients need to make medical decisions. Capacity for 
making healthcare decisions has three primary aspects: understanding, evaluation, and 
reasoning.42  For a patient to be decisionally capable, they must be able to understand the 
relevant information about the disease or diagnosis, treatment options, and the recommendations 
and reasons of the doctor.43  The patient must be able to evaluate this presented information 
against a framework of values to judge the elements of a particular health care decision.  In 
addition, patients must be able to deliberate and reason about the impacts of all available courses 
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of action, including the option to not treat or elect to not participate in the proposed therapy, and 
grasp cause and effect relationships and ideas of probability and percentages.  Concepts of 
probability are difficult to comprehend by patients and challenging to present by physicians since 
there is no way to give a percentage with complete certainty, however they are very common, 
necessitating that patients understand the implications and concept overall.  In many instances a 
psychologist evaluates this capacity, however it can also be done by physicians.  If it is 
contentious, it is not advocated that this evaluation be done by the service provider alone, to 
ensure an outside, documented perspective is taken into account, however many times this 
evaluation is done in this way.  In an ideal world, two providers would be involved in capacity 
assessments, however this is more common when a lack of capacity is noted, rather than to 
confirm that it is present.  It is important to note that decision making capacity it not necessarily 
a global issue, but rather task specific making it important that the specific decision is kept in 
mind by the provider assessing and evaluating capacity.  Decision making capacity is on a 
spectrum, rather than an absolute that applies to all cases for a given patient.  Specifically, more 
capacity is needed for higher risk decisions with many options to deliberate and consider, and 
less for those that are seemingly straight forward and of a lower identified risk.44   The provider 
must take into consideration the decision itself when inevitably determining if the patient can 
make a decision for him or herself, so it must be fully flushed out and understood.  Rationality is 
an additional  important dimension of decision making capacity and overall medical decision 
making, however decisions made by individuals determined to have decision making capacity do 
not have to be rational, therefore it cannot be used as a definitive gauge of decision making 
capacity, but it can be taken into consideration when evaluating overall capacity.45  Specifically, 
if patients are irrational and incapable of framing decisions or discussions about the given 
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treatments and options, that can impact their ability to make medical decisions, however if the 
patient is found to be rational and able to understand, overall having decision making capacity, 
the patient will be allowed to make whatever decision he or she wants, even if irrational.   
Capacity judgments serve as gatekeepers to health care by identifying patients whose choices 
must be upheld and when another decision maker is needed, making them crucial to medical 
care.46  Decisionally capable patients can make any decision that they want, based on the 
principle of respect for autonomy, but this is not true for patients who lack this capacity.47  
 When a patient is found to lack the capacity to make a medical decision, someone is 
appointed to make decisions for the patient, either by a legal document created by the patient 
before the loss of capacity or by legal standards of the area.  In these cases, the individual who 
makes decisions for the patient is known as his or her surrogate.  Surrogate decision makers are 
held to higher standards and are asked to act in a manner that is consistent with how the patient 
would have acted if capable.  In most cases, surrogates may not choose to withhold or withdraw 
treatment when it is in the objective best interests of the patient, unless the patient made an 
advance directive before losing decision making capacity explicitly outlining what he or she 
wanted.  Surrogates are argued by many to be able to exercise the “autonomy” of the patient 
lacking capacity however it is not clear that a surrogate, or anyone other than the individual, can 
exercise the autonomy of another. 48   Ethical obligations of respect for autonomy do not extend 
to persons who cannot act in a sufficiently autonomous manner, so it is not necessarily and 
unlikely possible that the surrogate is executing the autonomous wishes of a non-autonomous 
patient.49  Making decisions for another is not an easy task, as it is seemingly impossible to know 
what the patient would do in every instance, but surrogates are asked to do just that.  In response 
to this, ethical standards have been developed to guide the decision making process of surrogate 
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decision makers so that they make good choices for the patient.50  In the following section the 
guidelines and models for surrogate decision making will be explored. 
 
3.2.2. Surrogate Decision Making 
 When patients lose decision making capacity, a surrogate must make medical decisions 
for the patient.51  Individuals can identify a person to be their surrogate before losing decision 
making capacity with an advance directive (AD).  Advanced directives can appoint someone to 
make decisions and can even go as far as to tell the decision maker what he or she would want, 
and in some instances only enable the surrogate to make specific decisions.  Advance directives 
are a way for patients to express and outline their wishes for care and treatment when they are 
still able to do so, to be upheld even if they lose capacity.  Despite the powers of an advance 
directive, and a significant increase in the past decade, most people in the United States do not 
have a directive.52   Although more people have advance directives than ever before, a study by 
Rao et al, it was found that only 26.3% of the 7946 respondents had an advance directive, with 
lack of awareness as the most frequent reason for not having one.53   Silveira et al 2014, found 
that this trend was not associated with hospitalization and hospital death, suggesting that AD 
completion is unlikely to stem from hospitalization before death, which was hypothesized to be 
one of the major areas for their creation.54  When looking only at an elderly population who 
needed a surrogate, Silveira et al 2010 found that 67.7% of respondents had an advance directive, 
however less than 30% of those studied required a surrogate, so the sample was small.55  These 
numbers emphasize that many people, even those who are of an age or medical status that most 
greatly need the advance directive, lack explicit directions or identified decision makers, 
therefore necessitating the identification of a surrogate. Without an advance directive, a surrogate 
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must be determined through an ancillary process, typically guided by legal regulations. Currently 
in the United States, each state has legislation that establishes a hierarchy for identifying a 
decision maker for a patient without the capacity to do so for him or herself.  This legislation 
however does not take into account the social relationships with the patient, specifically whether 
or not the potential surrogate is close to or has a relationship, other than biological, to the patient.  
This creates confusion and can lead to the selection of therapies that the patient may or may not 
have wanted as surrogates navigate and make decisions for others.56  
Advance directives allow patients to prevent unwanted treatments, and enable them to 
plan for their medical care should they ever lose capacity. Advance directive have a tremendous 
amount of power, however are not nearly as prevalent as they should be nor do they have the 
level of detail that they are needed for on a regular basis.  Even when patients have an advance 
directive, substantial decisions will still need to be made that were not explicitly outlined or 
discussed with the surrogate, leading the surrogate to need guidance and assistance.57  The 
number of decisions that must be made with minimal or a complete lack of guidance from the 
individual patient make the standards by which these decisions are made crucial.  It is widely 
accepted that surrogates are held to higher standards and regulation than individual, autonomous 
patients would be, but it is not completely clear how decisions are made and what should guide 
these overall processes.  In most instances surrogates are guided by the two most widely 
recognized standards, substituted judgment and best interests, both of which are patient-centered, 
to make decisions for the patient.58  Substituted judgment focuses on executing the wishes of the 
patient, while best interests asks the surrogate to select the course of action that will most benefit 
the patient overall.  These two models, substitute judgment and best interests, will be further 
elaborated and discussed in the next two sections, followed by a discussion of the problems with 
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these models, and finally the reality of surrogate decision making and what typically happens in 
practice, a more shared decision making process. 
  
3.2.2.1. Substituted Judgment 
 The substituted judgment model, as the ideal model for surrogates, asks decision makers 
to make the decision or choice that would be the same as the patient if he or she were able to 
make decisions.59  This model focuses on respecting and upholding the autonomy of the patient.60  
Surrogates should make decisions that take into consideration the patient’s life, goals, values, 
beliefs, and the things that he or she considered most important in life.  Specifically, the 
surrogate is asked to be a “substitute” for the patient and make decisions in the same manner as 
the patient if he or she retained capacity.61  This model acknowledges the rights of the patient to 
have his or her autonomous decisions executed, but because he or she is decisionally incapable 
and unable to exercise these rights, someone else should for them.62  This model is usually 
utilized when the decision maker knows about the patient’s values, beliefs, and overall wishes.63  
Due to this, in a practical setting however, this model is almost impossible to execute.  It is 
seemingly unrealistic to believe that an individual has told his or her surrogate what he or she 
would want in every situation or for the surrogate to know the patient well enough.  Without 
such knowledge, it is not substituted judgment.  Without such knowledge, the surrogate applies 
the life of the patient to the current medical situation, making inferences and guesses in an 
attempt to determine what the patient would have wanted.  Many times surrogates are unfamiliar 
with the patient’s wishes and will even express this to hospital staff.  In these cases, the 
substituted judgment model is no longer relevant and the best interests model is utilized.  
Additionally, many times decision makers are impacted by the decision that is being made,  
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specifically, they may be the future caregiver or have another stake in the decision that is being 
made.  It is almost impossible to completely substitute the opinions and thoughts of one person 
for those of another without some overlap.64  Ideally the decision making process is guided by 
how the patient lived his or her life and the beliefs and values of the patient, however this is 
challenging for surrogates without the close knowledge of the patient’s wishes.  
 
3.2.2.2. Best Interests 
 When a patient’s preferences are not known the substituted judgment model is not 
applicable, so surrogates are asked to use the best interests model to guide decision making 
processes.65  According to this model, the surrogate must weigh the potential benefits and 
burdens of each available option and select the best course of action.  The best interests model 
focuses on the current and future interests of the decisionally incapable individual and is guided 
by the overall “good” and “benefit” to the patient, but this is not always straightforward.66  Best 
interests assessments are continuous processes rather than a one time decision to be made, as 
they are impacted by many components throughout the treatment cycle.67  There are many pieces 
that must be taken into consideration when making these determinations including, but not 
limited to, potential outcomes and impacts.68  It is not easy to determine all of the benefits or 
burdens of a course of action and no two individuals weigh them in the same way.69  The benefit-
burden analysis is intended to protect the well-being of the decisionally incapable individual, 
however because it is a subjective analysis, it can be very challenging or even confusing to the 
surrogate.70  The concept of “best” is somewhat misleading in itself because it does not mean 
that the surrogate must provide the best treatment possible for the patient, for instance finding the 
best surgeon or hospital, but the surrogate should decide on the basis of what he thinks is good 
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for the particular patient, specifically what he or she thinks will truly benefit the patient.  In the 
next section some of the problems with the best interests and substituted judgment model will be 
looked at and it will be explained why in practice, a combined, shared model is used to make 
decisions.  
 
3.2.2.3. Problems with the Decision Making Models 
 There are many problems with both the substituted judgment and the best interests 
models as the guiding models for surrogate decision making in practice. In most instances 
substituted judgment is an unachievable ideal for surrogates because even when advance 
directives exist or the patient had discussions with their surrogate, they could never plan for 
every potential circumstance that may occur or map out every possible decision that may need to 
be made.  If decisions are executed in accordance with this model alone, it should not be the 
surrogate formally making the decision, he or she is merely executing a decision that he or she 
knows the patient would want or would have made, however this is likely unrealistic.71  This 
model in itself appears to undermine the autonomy of the patient, asking another to make the 
patient’s autonomous decisions, despite them not even entirely knowing what a person would do 
in a specific instance.72  The surrogate could know what the patient would want from several 
places including being told directly or through a written advance directive, or indirectly, the 
patient could have made his or her wishes implicitly known through comments, or it is possible 
that the surrogate knows enough about the patient's thinking and value system to figure out what 
he or she would have wanted.  None of these appear to be extremely solid bases for decision 
making and the pure execution of the autonomous wishes of a patient, although it is argued by 
some to be possible in specific instances, such as when done by the patient's spouse or partner.73  
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This model gives families, who may not be reliable sources of information about the patient, a 
great deal of power 74  In the absence of an advance directive, the legal surrogate could be 
someone who the patient has lost contact with, never finalized a divorce from, or does not agree 
with on a fundamental level.  In these instances, the surrogate may not be in the best place to 
make a “substituted judgment,” or misrepresent what the patient would want if decisionally 
capable.75  The substituted judgment standard is overused in statement and reference; however it 
is almost impractical in practice.  The surrogate would have to have a very deep relationship with 
the patient and know the specific views and values that led them to make judgments when they 
were able to do so.76  They additionally would have to be able to differentiate and separate the 
opinions and beliefs of the patient from their own, and leave their own emotions and personal 
biases out of the equation.77  Many times surrogates are also care takers or financial supporters, 
who have additional considerations and motivations, complicating the process of pure substituted 
judgment.  For a true execution of substituted judgment there must be evidence that the patient 
would have chosen the specific therapy or treatment option.78 This is difficult though due to the 
high levels of uncertainty present in many of the decisions surrogates are routinely asked to 
make, many times with complex details or gaps in information.79  There are additionally many 
times social expectations to make a certain decision, and factors that can impact decisions 
outside of the medical facts such as support system or finances. In addition, surrogate must have 
evidence and reasons, both of which are subjective, to believe that the patient would have chosen 
a specific action, which becomes unreliable, especially in instances when the surrogate was 
appointed by the law and not the patient him or herself.80 All of these components make 
surrogate decision making very challenging and the substituted judgment model almost 
impossible to utilize as written.  
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 The best interests model, though it has benefits, is challenging in practice as well.  When 
determining an individual’s best interests many things come into play, including what the patient 
personally thought of as “best,” how he or she has defined quality of life, and what he or she 
valued overall.  For some, being in a nursing home where they can no longer be in control of all 
elements of their day to day life and do tasks for themselves is an unacceptable quality of life, 
but for others that might be perfectly acceptable as long as their pet can sit on their lap or they 
can visit with their family.  Weighing benefits and burdens is personal and subjective, and 
actually involves some of the ideas and concepts of substituted judgment that are challenging for 
surrogates to determine, weigh, and consider.  Both models have their flaws, giving too much 
power to or placing too much of a burden on the surrogate or overall families, who may or may 
not be reliable sources of information about the patient.81  Even in cases where they have the 
knowledge, these decisions are challenging and burdensome for surrogates to make, 
necessitating some guidance and structure to the process.  Both models are impossible to execute 
ideally or exactly as described in practice, and regardless of the decision-making model utilized, 
decisions will typically be made in a shared effort, elaborated in the following section.  
 
3.2.2.4. Shared Decision Making in Practice 
 Regardless of which model is followed, in practice, decision making is likely to be a 
shared process.  Physicians and medical team members generally play a large role in shaping 
decisions due to their expertise, but also because families wish to diffuse the responsibility for 
making difficult or painful decisions under conditions of uncertainty.82  Shared decision-making, 
by definition, is a process of medical professionals and patients working together to select 
therapies, treatments, tests, and make other medical decisions based on clinical evidence and the 
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patient’s preferences.83  Shared decision making (SDM) involves an exchange of information 
between the medical team and the patient or surrogate where they each express preferences and 
negotiate treatment plans.84  There are four main characteristics of shared decision making, all of 
which are important when thinking of it as a guiding principle for medical decision making.  
Charles et al believes that shared decision making involves on a basic level, (1) the physician and 
patient making treatment decisions, (2) both the physician and patient sharing information with 
each other during the decision making process, (3) they both take steps to participate in the 
decision making processes and express individual preferences and opinions, and (4) a decision is 
made and both the physician and patient agree on the selected course of action.85  This method, 
even though executed inconsistently and differently throughout medicine, enables the physician 
to provide his or her medical expertise, but for the patient to be involved and elaborate their 
personal desires and beliefs.86   
Many times, clinicians do not know how involved patients or their families want to be in 
decision making processes and are uncertain how to work them into the process. All individuals 
have varying capacities and desire different levels of involvement in their care and amounts of 
details and information, but it is very important for providers to determine this so the patient is 
able to be involved in a way that is meaningful to them.  SDM processes enables patients and or 
their surrogates and families to be involved in decision making even when they many times lack 
the confidence to question health care providers, having a limited understanding of the medical 
field.  Patients and providers do not typically have an equal relationship initially due to the 
education and emotional differences and barriers, making a shared process where this 
relationship can be built and expanded upon.87  Shared decision-making involves negotiation and 
compromise, recognizing that clinicians have a lot to offer, including knowledge of the 
 83 
 
diagnosis, likely prognosis, treatment and possibly outcomes, while the patient is able to 
determine the impacts of the condition and therapies on his or her everyday life, and incorporate 
his or her own values, preferences, and beliefs.  SDM recognizes the patient’s right to make 
decisions and respects them as autonomous individuals, while still involving the physician and 
medical team, to enable the patient to have the most accurate information and ideally information 
on the benefits and harms of interventions or actions, including any uncertainties and risks.  The 
most common areas where shared decision making is utilized in adult medicine are when major 
health decisions must be made that have more than one feasible alternative, the utilization of 
screening or preventative therapies, and for the management of long term conditions, however 
many other medical decisions involve the core components of shared decision making.   
 Shared decision making is highly desirable if properly structured to ensure accountability 
and lessen impacts of conflicts of interest or personal biases.  Additionally, the shared decision 
making process has been shown to lead to much higher levels of satisfaction in patients and 
families.88  Medical decision making is not an easy task and becomes even more challenging 
when the sick individual is not able to make his or her decisions, however by utilizing a shared 
decision making model based on complete medical facts, some understanding of the individual 
and his or her values and beliefs, and a general idea of what is best for the patient both personally 
and medically, decisions can be facilitated.  This shared process, as just explained, is not directly 
possible with children because the child patient has never had decision making capacity but are 
in the process of developing it, making their role in the process unclear and ill defined.  This 
problem of pediatric medicine will be looked at in the following section.  The ideas and concepts 
of adult medicine that are currently applied to pediatrics will be analyzed and argued to be 
insufficient for decision making in pediatric medicine.  
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3.3. Pediatric Decision Making   
 Decision making is challenging throughout medicine as patients struggle on a regular 
basis to weigh benefits and burdens of treatment options and inevitably select a course of action.  
It is rarely straightforward as more options are available each day, giving patients more 
complicated and challenging decisions to make.  Decisions are not easy or straightforward in 
adult medicine, especially when a surrogate is involved, meaning that someone other than the 
patient must weigh the benefit and burden for the patient, which is seemingly impossible to do 
accurately.  This section will argue that it only becomes more complex when the decisions being 
made are for children and the stakes are higher.  In the first section, ideas of autonomy and 
consent will be applied to children, reviewing the basic status of children as minors and the 
connected issues.  It is unclear how the concepts of autonomy and consent apply to children 
since by definition, they are not applicable.  There are however ways that these concepts can and 
should be used throughout the medical world and understood in a way to enhance shared 
decision making.  An additionally challenging element of pediatric decision making is the fact 
that there are many, legitimate stakeholders involved in the care of children.   
Specifically the child him or herself, parents or guardians, the physician and medical staff, and 
society as a whole have interests, obligations, and responsibilities to the child patient.  All have 
vested interests and obligations in these decisions, which must be balanced and upheld by the 
decision making process, making the associated relationships crucial to the field.  In the final 
section, the decision making models of adult medicine will be applied to pediatric medicine and 
decision making processes, and it will inevitably be argued that there is a need for an enhanced 
model for pediatric decision making that recognizes the status of the minor, incorporates the 
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many dimensions and stakeholders, and offers enough structure and guidance for the parents or 
legal guardian.  
 
3.3.1. Autonomy, Consent, and Assent  
Children, unlike adults, are not considered to be fully autonomous individuals in society.  
They are additionally in the process of developing the capacities needed to be decision makers 
and have full autonomy.  This section will look at the status of children in society and how the 
concept of autonomy can be applied to them.  It does not directly apply in the way that it does to 
adult patients, however there are still relevant components that must be addressed in order to 
fully show respect to the child as a person, and as an individual in the process of developing 
capacity. After addressing the place of children in society, concepts of consent, assent, and 
respect for persons will be applied to them as they will be used as a basis for their involvement in 
the decision making process.  Children must be included in decision making processes and in 
order to do that, they must have a way to participate that respects them as persons. The final 
section looks more fully at the application of decision making capacity to children.  In order to 
do this, the developmental stages of children will be elaborated, focusing on mature minors who 
are approaching adulthood and have varied levels of development and inevitably decision 
making capacity that must be evaluated so that the child patient can be included in the decision 
making process in a meaningful way.  
 
3.3.1.1. Status and “Autonomy” of Children 
To fully understand the dimensions of issues surrounding the capacity of minors, the 
legal status of children will first be briefly discussed.  Legally, children do not have the ability to 
make their own medical decisions.  The law presumes those under the age of 18, defined as a 
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child, to be minors in the United States and many other countries.89   This age of 18 is not 
necessarily attached to a specific level of development or mental status, which will be looked at 
in a coming section, however this is the age at which a child becomes an adult in many societies. 
For children, specifically those under the age of 18, parents and or guardians make their 
decisions.90 The justification for this varies, but primarily minors are argued to lack the ability to 
make judgments and experience necessary for responsible decision making and generally are 
denied legal power, requiring the consent of one or both parents or a legal guardian to authorize 
medical care.  There are some instances where minors are allowed to make their own decisions, 
and there are exceptions to the age requirement, however this is not the norm.  In many places, 
there are minor treatment statutes that allow children of a certain age to give consent for certain 
medical treatment without consent from their parents, and without notifying them.    In instances 
such as sexually transmitted diseases, drug use, prenatal care, contraception, and abortion, 
children may be allowed to make their own decisions without the notification or involvement of 
parents or guardians, however that is not consistent in all places.  Outside of the defined 
exceptions, there is also a “mature minor” status where the minor has been found to be mature 
enough to make his or her own medical decisions through an evaluation process, however the 
criteria and age limits for this varies between locations and are ill defined.91 Outside of those 
exceptions and specific instances, children are not allowed to make their own decisions and 
many times do not even have a voice in the decision making process.92   
 In adult medicine, patients are seen as autonomous, and out of respect for their autonomy, 
are involved in the decision making process and afforded the ability to participate in the process 
of informed consent.93  When patients make their own decisions, they are allowed to make any 
decision or choice, executing their autonomy.  This becomes more challenging when surrogates 
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make decisions for the patient and additionally troubling when the patient has never had decision 
making capacity, which is the case with children.  Patients who have never had decision making 
capacity and lack autonomy do not have the ability to give formal consent or participate in a 
standard way in the informed consent process.  In general, minors lack the attributes associated 
with full autonomy and decision-making capacities and are therefore, not formally included in all 
decision making processes.94  Parents or guardians are typically given the legal authority to make 
decisions for their child, however, it is unclear where this authority comes from.  Many argue 
that because they are the guardian of the child and person responsible for their care, they should 
additionally make medical decisions.95   It is also argued that the parent or guardian is in some 
way executing the future autonomy of the non-autonomous child, as some argue the surrogate is 
for adult patient who have lost decision making capacity. It is argued that surrogates execute the 
autonomy of the patient when making decisions based on the previous wishes and decisions of 
the autonomous patient, but minors have never had autonomous decision making capacities, so 
this application is not clear.  If parents are simply the final decision makers because they are the 
legal guardians of their children, decision making capacity of the child becomes a much more 
crucial issue as the child should be able to act on his or her own behalf, or at least participate in 
the process, when he or she is capable of doing so.  
 Due to their legal status, children are not always included in decision making processes 
nor are their opinions consistently taken into consideration despite the tremendous benefits from 
their involvement.96  Some physicians involve minors in the decision making process even when 
they do not have capacity, but this is not legally required nor standard practice in all placed.  If 
the child disagrees with his or her parents it is not clear what would happen or how this 
disagreement would be handled since the parents are the legal decision makers.97  At one point 
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children were thought to be the property of their parents and it was never questioned what 
parents did or what the child thought.98  However over time, children have gained a status in 
society as well as the medical world and it is now argued by many, including the American 
Academy of Pediatrics Committee of Bioethics, that they should be involved in the decision 
making process to the highest degree they are capable.99  Involving children in medical decisions 
leads to better medical results and also prepares them for later in life when they will be in control 
of their decisions, allowing them to take some responsibility for their life, especially when they 
are of an age that is approaching adulthood.100  In many countries there is a strong 
recommendation, if not requirement that the assent of the child is taken into account when the 
child enters a research study, however this is not standardly applied to all areas of pediatric 
medicine, specifically cases of mature minors and new technologies where it becomes most 
relevant and beneficial.101  Assent, which will be looked at in the next section, acknowledges the 
child as a participant in the decision making process and shows respect for them as a person, 
acknowledging their future autonomy.  
 In order for children to be given a voice in the medical world there needs to be a process 
or system to determine decision making capacity that then translates into a role in the process of 
making medical decisions.  Most of the major issues surround adolescents, as they are 
approaching the age of consent and in the process of gaining decision making capacity.  
Adolescents and older children occupy a position on the decision making continuum that is both 
legally and ethically ambiguous.102  They are not legal decision makers, nor do they have full 
decision making capacities in all cases, but they also have some capacity in most cases, making 
their involvement challenging. Legally they do not have a right to be involved in their healthcare 
decision making but there are many benefits to having them involved, including better results 
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from care.103  Additionally, since they are close to adulthood this enables them to feel 
empowered and in control of their healthcare and overall lives.  Despite their legal status they 
have a legitimate interest in the matter at hand, specifically their own medical care and decisions, 
and ideally they will be able to participate in a meaningful way that carries legal weight.104 It is 
argued that children have a moral and ethical claim to being involved in their care if they have 
the ability to do so, even if it is only on a minimal level.   
 
3.3.1.2. Consent, Assent, and Respect for Persons  
 It is regularly accepted that children, as a population, do not have decision making 
capacity and are not fully autonomous individuals, therefore unable to give legal consent in 
almost all instances.  This does not however mean that they should be excluded from decisions 
surrounding their heath and medical care. It is crucial that children are involved in the decision 
making process to any extent possible, and that they are listened to throughout the process.105  
Much of this is dependent on the developmental stage and overall abilities of the specific 
child.106  As all children grow, they develop, learn, and progress at different paces, all of which 
must be taken into account and will be looked at further in the following section. Even though 
concepts prevalent throughout adult medical decision making, such as autonomy and informed 
consent, are not legally applicable to children, much can be gained from applying them to 
pediatric populations.  A person who consents bases the decision upon his or her personal 
beliefs, values, and goals.  Concepts of respect for autonomy and informed consent are both 
aimed at showing respect for persons, which is applicable to children and the field of pediatric 
medicine.  Respect for persons demands that patients lacking decision making capacity be given 
the opportunity to participate in the decision making process to the extent that they can.  This 
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concept and application of the theory leads to the more common conception of consent in 
pediatrics, assent.  Assent is the expression of the child’s will to participate in the given therapy 
or treatment and is driven by the principle of respect for persons, making it possible for children 
to express their opinions and desires.  Assent of the child is a desired outcome in pediatric 
medicine, but as discussed it is not legally required.  
 When pediatric decision making is grounded in autonomy, it holds children to a higher 
standard for involvement in decision processes than what is developmentally appropriate, 
making their involvement unlikely.  On the other hand, the concept of respect for persons 
incorporates a full range of potential decision making roles for children and supports a linked 
approach to assent and permission while acknowledging the future status of the child as his or 
her own decision maker.107  Children will one day be fully responsible for their own care and life 
choices, making it important that they are involved in medical decisions as they approach 
adulthood, especially when they are in the ambiguous stage of adolescence.  This participation 
and empowerment is consistent with the intent of the United Nations Convention on the Rights 
of the Child (1989) to give children a voice in the medical world.108  Providing children with a 
shared role in the process treats them with dignity and respect, and upholds their moral worth as 
children.  Additionally, it encourages their development and leads to enhanced abilities for self-
governance in the future.  Overall, mature minors are the most problematic and challenging 
group of children to involve in the decision making process since they are much closer than other 
children to being legally adults and their level of competence and development is continuously 
changing and varies greatly among children.  Mature minors are approaching the threshold of 
becoming the stewards of their own care, so the balance of these future interests and roles must 
be taken into account with the current state and interests of the child.  Children must be stewards 
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of their own care and involved to the highest degree possible.  On the other hand, too much 
control and power should not be given to children, even adolescents, because they are not fully 
autonomous or experienced to make decisions in all cases. It is crucial that the child be evaluated 
in a diligent and meaningful way so that they are able to participate in a meaningful way 
however not so that they are carrying heavy burdens or making complex decisions that they may 
not understand the long-term effects of.  As children develop, specifically mature adolescents, 
they should gradually be granted decision making authority, and seen as partners in the medical 
decision making process in a way that they can until they are able to achieve full decision 
making abilities. 
 
3.3.1.3. Developmental Stages and Decision Making Capacity 
Children have a right to involvement in their medical care, making it necessary that there 
is a reliable and effective way to evaluate them, determine capacity levels, and facilitate a bigger 
role in their own care.  Children have never fully had decision making capacity, rather are in the 
process of developing it, placing them in an uncertain place on the spectrum of decision making 
capacity.109  Decision making capacity is not global and decisions require different levels of 
competency based on the level of risk, options, and uncertainty associated with the specific 
decision.  For instance, the same amount of capacity is not needed to decide to take medicine for 
pneumonia compared to that of selecting a cancer therapy after years with the disease.  Many 
adults without full capacity are able to make certain medical decisions after capacity has been 
assessed, making it crucial that such capacity is reviewed with developing minors and they are 
empowered be involved when possible.110  Within the classification of “minor” there are 
“infants,” “children,” and “adolescents.”  The American Society of Pediatric outlines four stages 
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of development: infancy (prenatal-1), early childhood (1-4), middle childhood (5-10), and 
adolescence (11-21).  The transition from infant to adolescent can be explained by going from a 
state of complete dependence, infancy, to that of being an autonomous individual.112  According 
to Belsky et al, the developmental stages begin with infant then transition to early and middle 
childhood, adolescent, and finally adult.113  According to Scarre, childhood starts at about 3, 
when children can move about on their own and communicate, prior to that they are infants.  
Infants are fully dependent whereas children are less dependent and considered active agents that 
can begin to lead their own lives with choices.  In these conceptions of infant and child, language 
skills and mobility are key components because they make the separation from the mother 
possible, therefore the infant moves out of “infancy” and into childhood.  After childhood, or 
within later childhood, children reach a point of adolescence.  Adolescents are described as 
individuals between the age of 10 and 21 years of age by Fleischman and Collogan.114  Their 
constant state of physiological and psychological development sets them apart from younger 
children and adults, but development is something that is not the same for all children, everyone 
grows and changes at different rates.  This view promotes the idea that childhood is about 
development, making it different for each individual, so not necessarily tied to a specific age, 
which also explains discrepancies throughout cultures and societies.115  In different places 
children are raised differently, taught different things, and expected to do certain things at 
specific ages or times in their lives, all leading to their pace of development.  It appears that the 
key to defining a child lies within developmental and mental changes.116  As children grow up 
and gets older they begin to look and feel differently and they begin to define their self image 
and attempt to understand the self.  This is also accompanied by cognitive changes, making them 
able to imagine what “could be”, thus possibilities. They comprehend more, also the hypothetical 
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and abstract become possible to envision.117  There are other conceptions and ideas of when 
childhood begins, but there does not appear to be much agreement, even within similar societies.  
This general disagreement, or agreement that it is dependent on the child, makes it evident that 
children are different than adults in numerous ways, including that they are constantly growing, 
changing, and developing, calling for additional levels of care, specifically for the development 
of pediatric medicine. 
Adolescents are especially troubling because there are many mature adolescents with 
more capacity to make decisions than some adults, however society has an inclination to let the 
adult decide more while sheltering or protecting the child and allowing parents to guide.118  The 
growth from infant to child is facilitated by the parents however the transition to adolescence has 
much more independence.  The entire transition from infant to adolescent can be explained by 
going from a state of complete dependence (infancy) to that of being an autonomous 
individual.119  The main problem with this however is that it does not explain if a child is 
considered autonomous once they reach adolescence or if it is not until adulthood, or the even 
more troubling response of “it depends on the child.”  Some conceptions of childhood argue that 
individuals are considered children after the stage of infancy, and this is supported by historians, 
language, and common speech as well as, specifically the use of words such as “infant” and 
“child” and them not being used interchangeably.120  This only emphasizes the ambiguous and 
complicated dimension of adolescents.  Adolescents are somewhere on the spectrum of capacity, 
however it is very unclear where since all individuals are different and develop at different 
rates.121  Good decision making comes with time, practice, and experience, all of which children 
lack, inevitably limiting their overall ability to make decisions, but adolescents may have some 
levels of decision making capacities.  Adolescents are neither children nor adults and appear to 
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have a “foot in each world” because their intellectual and emotional development is greater than 
that of young children, yet most are not fully mature and have not been exposed to the same 
types of things that adults have.  Children between the ages of 9 and 17 have varying degrees of 
decision making capacity.122  When it comes to decision making, older children present many 
problems related to their emerging cognitive abilities, self-awareness, and moral authority.123  
Many times older children can grasp core pieces of the information and can have the ability to 
give consent with regard to a specific decision, yet lack the maturity or ability of an adult to 
make decisions.124  In these cases, children should be involved in the process, but they should be 
provided support and guidance, enabling them to overcome their maturity levels but still 
participating.  The evaluation of decision making capacity with minors is a different process than 
with adults; adults are presumed to have capacity until it is proven that they do not, whereas 
children are presumed to lack capacity until they are able to demonstrate that they have such 
ability.125  In both cases, evaluation of overall capacities is necessary, however due diligence 
must be done to ensure that the child is not overlooked or incorrectly assumed to not be of the 
correct capacity because if differs that that of an adult.  
 Capacities in some way necessary for decision-making include communication, 
comprehension of information, reasoning and deliberation, and the ability to have and apply a set 
of values or conception of the good, all of which are difficult to assess in mature minors.126  
Comprehension is a questionable requirement because many times patients, adults and children 
alike, are unable to comprehend and understand much of the medical terms, concepts, or 
information in general due to circumstances and a lack of medical knowledge.127  The analysis of 
adolescent decision making capacity is complex and nuanced and evaluation must look beyond 
basic cognitive abilities.  These evaluations must consider personal values, patterns of decision 
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making, and behavior including risk taking behavior, biological and emotional maturity, life 
experiences such as health care and treatment, their ability to appreciate the cause, effect, and 
consequences, and abilities to think about the future.128  These attributes and characteristics have 
direct implications for the capacity to make decisions, especially those with high stakes and 
potential negative consequences.   
 The difficult issue then becomes when or at what level decision making abilities have 
reached a point that the minor can be considered capable.129  There are basic estimates about 
what ages children acquire different skills and capacities, however all children reach different 
stages of development at different times, especially the capacities needed for decision making 
such as reasoning and deliberation, which are not purely biological capacities but greatly 
influenced by experiences and environment.130  Children by the age of 14-15 usually have 
developed some of the capacities necessary for healthcare decision making to a level roughly 
comparable to that attained by most adults.131  Starting as early as 12, many children demonstrate 
the capacity to reason, including the ability to understand the cause and effects of illness, that is 
both as good as and as flawed as it can be in adulthood, however their autonomy is limited by 
their inability to  make authentic statements about values and commitment.132  Some studies 
argue for an absolute minimum of 12, but it is not definite for everyone.133  Age in general is 
troubling because even at 18, there is not a switch that goes off that turns an adolescent into an 
adult, merely a legal cut off that is accurate in most cases.  Every situation is different, and must 
be evaluated in and of itself, although it is good to have a basic understanding of the 
developmental stages and how children develop capacities while doing so.  Many believe that 
children who have had chronic illnesses for many years achieve an understanding and an ability 
to make decisions about their treatment long before other children.134  It should not be troubling 
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to evaluate and find adolescents to have some level of capacity because decision making capacity 
of children does not imply their ability to make decisions alone without the influence of the 
health care team, medical professionals, or primarily their parents who remain the legal 
authority.135  Ideally all children will be evaluated, but it does not appear that this is what 
happens in practice.  The presumption that children under the age of 18 are unable to make their 
decisions needs to disappear and criteria and evaluation methods need to be created to determine 
the capacity of minors.136  In order for pediatric medicine to be as effective as possible and 
enable patients to achieve meaningful outcomes and do what is right for the patient, children 
need to play a bigger role in their medicine, therefore it is extremely crucial that a method for 
evaluating the capacity of children be created that can effectively determine an appropriate level 
of involvement.  The role of the child should vary depending on the circumstances and overall 
situation, including the complexity of potential risks and benefits, and the availability of 
alternatives, however they should not be immediately excluded without evaluation.  The 
presumption that all under the age of 18 are unable to make their decisions needs to be replaced 
with ideas that all should be evaluated based on the decision that needs to be made and allowed 
to participate at the level of their developmental capacities.137  There also should be legal 
standards giving children an acknowledged not a final say, however some level of involvement 
in a meaningful and legal way is important.138  Parents, as legal decision makers for their 
children rather than executors of their child’s autonomous wishes, must work hard with all 
involved in the care of the child and with the child if possible to select the most appropriate 
option.  The next section will look specifically at the stakeholders involved in the decision 
making process and the many relationships that must be upheld and balanced for optimal care 
decisions to be made for children.  
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3.3.2. Decision Making in Pediatrics  
 Decision making is a complex issue throughout medicine, and is even more challenging 
when the care involves mature minors who have an undefined amount of capacity and ability to 
make decisions.  These minors are not autonomous like most adults, however they have some 
level of capacity and in many cases, enough to make a given medical decision.  It is crucial to 
both the care and future outcomes for the child that he or she be involved to the extent 
possible.139  Involvement leads to better overall medical results as well as the child taking 
responsibility for his or her life, empowering the child to grow into a successful and autonomous 
adult. This section will develop the additional complexities of decisions for children, including 
the roles and relationships of the parents, medical team, the child patient, and society.  All 
involved have varying interests in the outcomes of the child and future development, therefore 
all have some interest and stake in the decisions that are made and the overall process.  There are 
additionally more levels of complexity within pediatric care that must be incorporated into a 
decision making model.  In the final section, the decision making models of adult medicine will 
be applied to pediatrics and argued to be insufficient for framing decisions made for minors.  
 
 
3.3.2.1. Dimensions of the Pediatric Decision Maker 
 Pediatric decision making is a complicate process with involvement from many different 
individuals and roles. Children do not have autonomy or the legal right to make their own 
decisions, but are at a stage in life where they are approaching the necessary capacities and they 
must be properly evaluated so they can be involved in the decision making process.140  Decisions 
for children are not typically straightforward or easy to quickly make, carrying great importance 
 98 
 
and the potential for lifelong impacts.  Many individuals have large responsibilities in the 
process, primarily the parents or guardian and physicians, however the child and society as a 
whole also have impacts, although the boundaries of these roles are not well established.141  The 
child, as the patient, should be looked at first during the decision making process to determine an 
adequate and appropriate level of involvement.  Adolescents, in an ambiguous place on the 
spectrum of decision making capacity, are especially challenging to evaluate as they grow and 
transition from child to adult.142  Parents are a central component to the transition from infant to 
early and middle childhood, however during transitions to adolescence and adulthood, minors 
have much more independence but are still closely connected to and supported by their legal 
guardians or parents in most instances.143  According to the US legal system, an individual is an 
adult at age 18, however according to the American Society of Pediatrics adolescence extends to 
the age of 21, emphasizing the non-existence of a standard definition and the ambiguity of 
age.144  As a child gets older he or she begins to look and feel differently, developing a self-
image and conception of the self.  These changes are also accompanied by cognitive 
developments, enabling them to look to the future, picturing what could be or is possible.  As 
they develop, children comprehend more, including the hypothetical and abstract, making them 
valuable to the decision making process.  By including children in decision making they are 
validated as individuals, they can feel in themselves, and trust the staff, and additionally will 
cooperate better with the treatment or therapy selected, all leading to better medical results.145  
The child’s self-determination, and when possible opinions, should be considered but the 
interests of the parents who are making important decisions for their minor are also involved and 
many times interconnected with the interests of their children.146  For the most part, parents are 
thought to be the best decision makers for their children, argued to be best suited to judge the 
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child’s interests.147  Children and their parents are closely related and many values and personal 
preferences flow from parents to child as they are the individuals caring for all aspects of the 
child’s life.148  There is additionally a presumption that parents will do a better job of making 
decisions for their child than anyone else could because in most cases they deeply care about 
their children and know them better than others, placing them in a unique overall position to 
serve the child’s interests and advocate for him or her.149  In addition, parents must deal with the 
consequences of treatment choices for the child on a daily basis and many times there are severe 
financial or long-term effects to consider.150  Many parents often willingly become parents 
prepared to sacrifice their own interests for the sake of their child in ways they would not, nor 
could they be expected to, do for others.151  The job of parents as parents is to stand between 
their children and danger and protect them from injury and illness, and often with that comes 
feeling of obligation and duty.  Parents are likely to feel the obligation to advocate strongly for 
anything that holds even the slimmest prospect of success and they can perceive refusal to 
provide therapy as not fulfilling their nurturing, parental duties.152  It was ruled by the US 
Supreme Court that parents have a right to make decisions for their children, specifically, “the 
law’s concept of the family rests on a presumption that parents possess what a child lacks in 
maturity, experience, and capacity for judgment required for making life’s difficult and 
challenging decisions... more important, it is historically noted that the natural bonds of affection 
lead parents to act in the best interests of their children.153”  Parents have an incredible role in all 
aspects of their child’s life and are argued by many to be in the best position to make decisions 
for them, however this becomes much more challenging in cases where they may not understand 
what doctors are telling them, or instances where personal choices of lifestyles impact the 
decisions.  It is unclear if parents can force their religious choices or morals on their children 
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who are unable to make decisions and choices for themselves.  Parents have a legal right and 
authority to make decisions for their children, but it is not always black and white as they cannot 
make any decision that they want.   These grey areas are where additional roles come into play, 
instances where others may have stakes or responsibilities to advocate for the child or participate 
in the decision making process.  
 In addition to parents and the child him or herself, physicians have obligations to the 
child as his or her doctor.  The goals of medicine and the doctor patient relationship are a focal 
point of good care and medicine and doctors must do what is both right and good for their 
patient.154  Physicians not only have to make an accurate diagnosis and treat the child, they also 
must communicate with the patient and family.  In cases with minors though, it is unclear who 
the doctor should involve and where his or her formal obligations and responsibilities lie – the 
child, parents, family, or a combination.  The idea of patient centered care focusing on the 
autonomy of the patient is not easy to directly apply to pediatric medicine and pediatricians 
appear to have many, sometimes even conflicting obligations.155  In order to best serve patients, 
doctors and nurses need to address issues with the patient or their family in a timely manner to 
give them adequate time to make decisions.  There are immense amounts of feelings, emotions, 
and outside impacts on family members, and extra time and care needs to be taken to deal with 
them all differently.  This is why within pediatrics, parents and physicians are many times 
thought of as co-fiduciaries, both having strong obligations to the child patient.156  There is a 
great disparity in most instances between what the pediatrician understands about the medical 
case and what the parents are able to understand.  As laypersons, parents do not have the 
expertise to promote the medical interests of their child and must defer to the evidence-based 
clinical judgments of pediatricians.   Pediatricians have many conflicting roles including listening 
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to the child, upholding the family unit, and supporting the parents, while first and foremost 
serving the child’s best interests.157  Pediatricians have an obligation to present all medically 
reasonable alternatives, specifically all options both possible and physically available with 
reliable evidence of clinical benefit and from there, parents are free to select any one of such 
medically reasonable alternatives.  Parents are not however ethically free to reject all medically 
reasonable alternatives, because doing so is no consistent with protecting and promoting the 
child’s health-related interests. Pediatricians have an obligation to protect and promote the 
health-related interests of the child while parents have a fiduciary obligation to promote and 
protect the non-health-related interests of the child.  Pediatricians should be willing to make 
strong recommendations and potentially greatly influence parental decision making.158  
Balancing the roles of physicians and parents is challenging, especially when incorporating the 
opinions of the mature minor, and becomes slightly more challenging when decisions are 
constrained by society.159  
Society as a whole has a stake in the overall health and wellness of children.  At one 
point, children were thought of from a legal standpoint as the property of their parents, however 
over time this has changed.  There has been a transition from the state not wanting to infringe on 
family life and allow parents to raise children as they see fit, to now advocating for the child’s 
interests and even overriding the parents in some instances.  In cases when parents or legal 
guardians fail to exercise appropriate parental responsibilities for their children, in many cases 
the state assumes legal custody of the child or appoints a guardian to make the decisions for 
them.160  States have the legal authority to step in when they believe that the minor patient would 
benefit or that the best interests of the child would be served with someone else as decision 
maker.161  In addition, legislation has established things parents can and cannot decide for their 
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children.  There are limitations of parental rights to refuse treatment for their children and to 
insist on treatment, such as instances when specific interventions are determined by the care 
team to be inappropriate or ineffective, or when the burdens and risks clearly outweigh the 
benefits.162  In these instances, physicians have an obligation to protect their young and 
vulnerable patients from measures that are not clinically indicated and the state can step in.163  
The role of society is not one that is involved on a daily basis for decision making however legal 
systems have stepped in to ensure the protection of the well-being of children and the legal 
dimensions of what is and is not allowed must be considered during the decision making process.  
There are many stakeholders in pediatric medicine and the opinions and conceptions of all 
parties must be balanced.  Although parents or guardians currently in the way legislation exists 
have the legal final  say and authority to make the child’s medical decisions in most instances, 
ethically, this is not sufficient for the best decision to be made and there is a need for an 
enhanced model that incorporates and acknowledges all parties.  
 
3.3.2.2. Decision Making Models Applied  
 Pediatric decision making is not an easy process with many individuals and stakeholders 
involved, including the minor patient with a varying degree of capacity. In order to properly 
balance all of these dimensions and elements, a model is needed to facilitate and guide the 
process.  Currently in pediatrics the best interests standard is utilized for children but before 
moving to discussions of that model it will be briefly addressed why the substituted judgment 
model does not apply to children since it is the ideal model utilized by surrogates within adult 
medicine.  Substituted judgment is not typically relevant to children because they have never had 
the capacity for decisions, which is the basis of this model.164  This standard for the model is 
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impossible to apply to children as it is formulated because the autonomy of an individual who 
never had autonomy cannot be upheld or executed on his or her behalf, nor have beliefs or values 
that have not been developed be applied to scenarios.165  Despite this, children have varying 
levels of capacity and experience, and can sometimes be involved to a certain degree with their 
care, so these experiences can potentially be taken into account when making decisions, even if 
they do not have full decision making capacity.  Parental decisions may or may not reflect the 
values of the child, as they are not required to be since the child has not had the opportunity to 
mature and is not an autonomous individual.166  The substituted judgment model can be a 
comforting tool for parents to feel better about decisions or think of things in a different way that 
may incorporate what they child believes by thinking their son or daughter may have wanted a 
particular intervention or removal of therapy.  Additionally, this model can help guide parents of 
older children who are unable to participate or share their thoughts and opinions.  Although not 
directly applicable, because this is the ideal model of surrogate decision making in adult 
medicine and children are found to have varying degrees of competence, it should be taken into 
consideration when reformulating a decision making model for children although obviously not 
used as the stand alone model for pediatric decision making.   
 Substituted judgment cannot be used as a comprehensive and applicable model for 
pediatric decision making, making the best interests model the next candidate.  The best interests 
standard is the typical model parents are asked to utilize in pediatrics, requiring that parents 
select the treatment for their child that is in their child’s best interests after considering all 
options and relevant information.167  During the deliberation process, parents are asked to weigh 
all potential benefits and burdens and select the option with the greatest net benefit for the child 
which additionally causes the least burden.  The standard is argued to give parents the guidance 
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they need when making choices for their children because they have personal discretion to judge 
what is in their child’s best interests but additionally have a duty to provide them with acceptable 
care.168  Under this standard, parents should use all available information to assess the child’s 
immediate and long term interests and should then select the option that maximizes the child’s 
overall or long-term benefits and minimizes burdens.169  The problem with this is that there are 
objective and subjective elements to these crucial assessments, and since parents are the legal 
decision makers the burden is placed on them without arguably enough support or ensuring 
understanding.170  
 The best interests model is increasingly used by judges, physicians, lawmakers, and 
teachers to make judgments for those lacking the capacity to do it themselves.171  This standard 
has been discussed frequently in medical, legal, and bioethics literature, and given different 
meanings by different authors, such as “requiring decision makers to do what is ideal”172 .  These 
formulations however are problematic because they make the best interest standard require 
something that is potentially impossible, and parents cannot have a duty to do the impossible 
therefore these explanations of the standard do not capture the “practical” meaning. In practice, 
the best interests standard is more of a guidance tool rather than an ideal, and even as a guidance 
tool it is lacking.173  As a guide, the principle does not require what is ideal, but what is 
reasonable.174  The best interests principle, even as a guidance principle, it is only supposed to be 
a regulative ideal, not a strict requirement.  Parents’ obligations toward their other children as 
well as their own legitimate self-interests can conflict with doing what maximizes the child’s 
well-being, and sometimes may take precedence.  It cannot be expected that parents ignore their 
own important interests to benefit their child, but they are supposed to be making the decision in 
the best interests of their child according to the definition of the best interests standard.175  The 
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model should not be thought of as requiring literal optimization of the child’s interests in all 
cases, but also suitable intervention principles will allow parents considerable leeway- tolerating 
departures from what would be best for the child.176  The standard interpretation of this model is 
that it requires the choice of what is reasonable given all of the information and options 
available.  It is however, unclear who evaluates and determines whether the choice is reasonable 
since the parents, physician, child, and even society have roles and a stake in the process and 
decision that is made.   
 In addition, the best interests model places too much responsibility and burden on the 
parents, who are already in an undesirable and extremely difficult position.  Parents may not 
always make good judgments about what is or is not in their child’s best interests for two 
reasons: (1) some find it difficult to accept the birth of a defective child so that they decline 
reasonable treatment, and (2) some find it too difficult to accept the death of a child so that they 
insist on unreasonable treatments.177  The best interests standard is argued to be vague and 
subjective because determining what is ideal or best is very difficult and in these cases 
individuals, specifically the parents or guardians, fall back on personal biases and experiences 
for formulate their conceptions of best and ideal.178  Parental distress upon discovery of infant’s 
problems is understandable and this distress increases as the future impact on their lives and 
potential entire family begins to set in.  Assessments of the best interests of the child are formally 
guarded by the parents, however the clinician is best placed to judge them on the basis of 
medical criteria.179 These conflicts make it necessary that the physician and parents work 
together to outline options, benefits, and burdens to enable the best decision to be made.  
 Overall, there is a great deal of controversy over how to make good treatment decisions 
for children.180  The best interests model does not acknowledge the many dimensions of pediatric 
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decision making, only explains that the parents must weigh the benefits and burdens and select 
the option that is best for their child, which is beneficial, however not sufficient for pediatric 
decision making.  In addition, this model does facilitate the participation of the child patient to 
the level that they are capable unless the physician and parents enable such interaction.  Despite 
claims that they are the best decision makers for children, parents are not in the ideal place to 
make medical decisions for their children due to outside impacts, emotions, and a lack of 
medical knowledge, among others.  Additionally, neither the substituted judgment nor the best 
interests model gives enough guidance or support to parents, even combined.  Both models have 
a lot to be gleaned from them that could arguably be incorporated into a new, enhanced model, 
however it is crucial that the enhanced model be developed for pediatric decision making to 
enable parents or guardians to make the optimal decisions for their child.  
 
3.4. Conclusion  
 Pediatric decision making is more different than adult decision making, however it is 
important to understand the concepts of both decision-making processes and models since 
pediatrics emerged from adult medicine.  The model that is most widely argued for and used in 
practice with pediatric decision making is the best interests model, however due to many 
limitations and issues, it is insufficient to guide and facilitate the proper coordination of all 
parties involved and help the parents on a level that they need.  Physicians have an obligation to 
look out for and protect the interests of their patient, the child, and according to the best interests 
model are asked to give parents enough information to determine what is in the medical best 
interests of the child.  They are additionally not supposed to coerce or be paternalistic in their 
guidance and discussions with parents, which is a fine balance for them to uphold.  From this 
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information, parents are given the daunting task of selecting the best treatment option for their 
sick child taking all other dimensions into consideration.  Society has an interest in protecting the 
lives of children and works to ensure that parents are making decisions that are in the child’s 
interests and do not put the child at risk while also not overstepping their boundaries.  Society 
has an important role because it have the ability to impact all decisions, however societal 
influences should not go too far and cannot restrict the autonomy and liberties of the patient, 
parents, or even physicians.  The final, and most challenging yet crucial role in the decision 
making process is the child patient, him or herself.  The child must be evaluated as a possible 
decision maker, even if that is simply to say they are unable to participate in a meaningful way, 
but things become grayer when the child is an adolescent of undetermined capacity.  Children of 
all ages need to feel that they have been listened to and taken seriously and additionally medical 
professionals have a duty to respect the child’s voice.181  Even when children are not found to be 
decisionally capable, they should still be listened to and involved in the process, despite the fact 
that they will not have the final say or legal stake in the decision.182  The voice of the child must 
be held in balance with the views of the other legitimate stakeholders in the decision making 
process. The goal  of the process should be to identify the decision that is in the best interests of 
the child, which can only be achieved through a new formulation of a decision making  model 
governed by practical ethical principles applied to pediatric medicine in a way  that enables the 
participation of the child.  
 There is a great need for an enhanced decision making model for children not only 
because the models of adult medicine do not apply nor are sufficient but also because, first and 
foremost, pediatric decision making is more complex than adult decision making due to the 
additional dimensions, individuals involved, and the vulnerable position of the patient as 
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incapable of being a decision maker.  The overall goal within pediatric medicine is for the 
patient, family, and caregivers to work together in a process of education and support enabling 
collaborative decision making.183  In order for this to occur and the best results to be achieved 
within pediatric medicine an enhanced decision making model is needed that acknowledges the 
capacity of the child, includes all relevant parties including the child to a level that they were 
found to be able to participate, and offers more guidance and support for parents while 
attempting to determine a course of action for their sick child. 
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Chapter 4 - Changing Field of Pediatrics and the Need for an Enhanced Model 
4.1. Introduction 
 The field of pediatric medicine is continuously changing and developing with new 
technologies and innovations.  These developments are made in hopes of curing illnesses and 
providing more effective therapies for devastating pediatric disorders and illnesses.  With these 
new interventions comes much promise for the future, but also many complex ethical dilemmas, 
numerous issues, and challenging decisions that must be made.  This chapter will specifically 
look at expansion within the areas of genetic screening, neurotechnologies, and clinical research 
in genetics and neuroscience.  New technologies have developed in each of these areas and have 
led to tremendously enhanced ethical issues and decisions to be made unaccommodated by the 
current models of decision making utilized within pediatric medicine.  Each of these areas has 
been the focus of a great deal of experimental research leading to the utilization, and potential 
expanded use, of many new therapies and technologies.  In the field of genetics, newborn 
screening panels have steadily expanded, depending on the location and many times including 
the identification of disorders without accessible or affective therapies.  Advancements in the 
area of whole genomic sequencing, including the ability to reduce cost and identify more 
disorders, leads to its utilization as a diagnostic tool and the potential use of it coupled with 
newborn screening in the future.  Within the field of neuroscience the development of diagnostic 
tools to view brain processes and areas of engagement have led to the diagnosis of many 
neuroaffective disorders and other conditions of the brain. Clinical research trials have been 
central to the development of new interventions throughout medicine, particularly within 
pediatrics and the areas of genetics and neuroscience. This chapter will look at the expansion of 
each of these fields, emphasizing the ethical issues that they create, including the challenging 
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decisions to be made, placing parents, medical providers, and the child patient in difficult 
positions.   
After reviewing the advancements that have been made in the areas of genetics, 
neurotechnologies, and clinical research, the second half of the chapter will explore the ethical 
challenges associated with them.  There are many ethical issues that these new interventions 
bring with them when applied to the field of pediatrics including issues of informed consent and 
assent, the creation and broadening of the therapeutic gap, great levels of uncertainty, privacy of 
information that is found about the patient, future implications for the child and his or her family, 
and the great potential for enhancements or modifications with these interventions.  Due to the 
evolving nature of these interventions and continued growth and expansion leading to the ability 
to know and treat more disorders and illnesses each day, these ethical issues are very challenging 
to address and continuously changing.   Overall, it will be argued that the issues associated with 
the new advancements in the areas of genetic screening, neurotechnology, and research with 
children make central components of decision making processes, including determinations of 
benefit and burden and the ability to give meaningful consent, extremely challenging, if not 
impossible in some circumstances.  Additionally, cases of mature minors make this even more 
troubling, necessitating that a new variation of the shared decision making model is created to 
facilitate decision making and enable parents to make the best decisions for their children.  
 
4.2. Emergence of New Technologies  
The challenge of parental decision making in pediatrics becomes increasingly complex as 
new technologies and interventions enter into the spectrum of care.  Pediatrics has always been a 
field of innovation and advancement due to heightened attention given to the care of and for 
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children however, within the past decade, tremendous progress has been made throughout the 
field.  This progress, specifically within several crucial areas, has saved and improved the lives 
of countless children, but additionally presents enhanced ethical issues to work through and 
difficult decisions that must be made.1  The fields of genetics, neuroscience, and clinical research 
are expanding at an exponential rate, with promises of enhanced therapies, earlier or more 
accurate diagnoses, better care, and inevitably an improved quality of life for sick children.  
Advancements in each of these areas make decisions challenging in all of pediatrics, but even 
more so with adolescents as their role is not clearly defined in the decision making process, nor 
is a there an easy way to calculate potential benefit and burden of both current and future 
interests of the child in both therapeutic and non-therapeutic interventions.  This section will 
develop the innovations and developments of the fields of genetic screening, neurotechnologies, 
and clinical research that have led to more complex ethical issues and decisions throughout the 
field, placing children, parents or caretakers, physicians and even society in difficult positions 
and charged with making very challenging decisions.  
 
4.2.1 Genetic Screening 
 The area of genetics has grown tremendously in the past few decades as a great deal of 
attention and focus has been placed on this field.2  There was a great deal of enthusiasm and 
excitement generated after the Human Genome Project and many gained strong beliefs that the 
role of genetics was to identify health risks, dispositions, and inevitably develop care and 
treatment options for many illnesses, such as cancer, diabetes, or heart disease.3  This project 
brought attention from the media, politicians, and the general public, leading to a great deal of 
attention and financial support leading to a great deal of growth and expansion of the field, that is 
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only increasing over time.4 The pace at which new genetic interventions are developed and 
implemented throughout the field of medicine is quickly expanding and not likely to decrease in 
the near future.5 With this great expansion come many therapies that are valuable but also those 
that are not and may lead to inaccurate diagnosis or misleading results.  Genetic screening has 
seen tremendous growth in the past decade and is only going to continue to grow in coming 
years.  Genetic screening tests are performed throughout the world, and on every baby born in 
the United States and many other countries.6  Screening is a public health initiative that can be 
used to survey an entire population for illnesses to identify those with a predisposition before 
they exhibit symptoms.7  It can additionally be used on a smaller scale for a subpopulation or 
even individual.  The intended purpose is to identify those who are suffering from or are likely to 
develop a specific disease or condition and are likely to benefit from each detection and 
intervention.8  Genetic screening for newborns began primarily with newborn screening in the 
1960s after a simple genetic test involving a few drops of blood was developed for PKU, a 
disorder that causes severe mental retardation if left untreated but can be easily regulated by 
diet.9  Shortly after this development, most states in the US passed laws mandating that the test 
be performed on all newborns.10  It was decided that the burdens of the bloodspot were 
outweighed by the positive impacts that could come from the identification of the child carrying 
the genetic disposition for PKU.  Currently about 200 cases of PKU are diagnosed each year 
through newborn screening and education is provided to the family on how to regulate the 
disease and prevent side effects.11  The utilization of genetic testing for PKU is a successful 
intervention as there is something that can be immediately done for the child to lessen and 
ideally prevent symptoms of the disease.  Over time though, and with the development of tandem 
mass spectrometry (MS/MS), newborn screening has expanded to over thirty disorders, all of 
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which are not as predictable or treatable.12  In the past, tandem mass spectrometry was time-
consuming and expensive, making it impractical for newborn screening with unpredictable 
results.  But after the automation and advancements of MS/MS, it became possible to use the 
increasingly sensitive genetic microarray in newborn screening on a larger scale, specifically 
with the entire population of newborns.13  MS/MS can be utilized to screen infants for many 
disorders without needing more blood collected than for the initial PKU newborn screening test, 
leading to the rapid expansion of newborn screening.14  Due to the effectiveness and no 
additional blood needed than the existing test, MS/MS was added to newborn screening panels 
and led to screening processes that were quick, accurate, and relatively inexpensive.  MS/MS 
makes it possible to test for many more disorders though, leading the issue to then become what 
disorders are tested for as part of the panel.  Depending on the state, newborns are screened for 
anywhere from 29-54 conditions.15  In most states in the US, laws mandate newborn screening 
and of the 4 million newborns screened each year, 5,000 are found to have heritable disorders.16  
Almost all babies born in the United States undergo screening immediately after birth to identify 
genetic defects and dispositions that could cause serious illnesses if left untreated and all but 6 
states charge for these tests.17  These disorders are included in order to identify the diseases as 
soon as possible so that treatment could potentially be given even before symptoms present or 
parents could be aware, ready, and able to give a therapy as soon as symptoms onset.18  There are 
however, many disorders that are screened for that are not as treatable or easily diagnosed as 
others, making the expansion of the panel complicated.  
Beyond screening at birth, genetic testing is available for older children and quickly 
becoming an important diagnostic tool in medicine.19  It has become common for adolescents to 
participate in some kind of screening and there have even been high schools who have screened 
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for disorders such as Tay Sachs disease.20  A number of different approaches to broadening 
newborn screening beyond tandem mass spectrometry, such as proteomics, microarrays with 
bead technology and nanotechnology approaches, pulse oximetry, and DNA-based technology, 
are in various stages of development, making it likely that the number of disorders screened for 
will only increase as will the use cases for them throughout society.21 Additionally, advances in 
whole genome sequencing (WGS), including decreasing cost, heightened accuracy, and more 
predispositions for diseases that can be accurately identified, it is possible that this process will 
be added to or done in conjunction with screenings performed at birth.22  It is additionally 
possibly that WGS could be performed at the request of parent or included in other screening 
initiatives, as it is already beginning to be utilized in older children for diagnostic purposes.  
WGS has the potential to expand upon the positive outcomes of other genetic screening, however 
with these benefits come enhanced ethical concerns.23   As WGS steadily expands, so does the 
list of disorders that can be tested for, many of which have limited to no therapies available, do 
not develop until adulthood, or have uncertain clinical significance.24  One of the biggest 
challenges is that sequencing is not full proof nor does it lead to certainty; the identification of a 
disease causing genotype does not guarantee a child will develop the disorder, predict when it 
will happen, or give details about the extent of the disorder.25  In the near future WGS will 
become both financially accessible and scientifically feasible throughout medicine with the 
potential for it to expand to society in different ways, such as large scale screenings, leading to 
many ethics issues.  It will be difficult to determine what should be done with the results from 
the genetic sequencing including who should have access, how much they should have access to, 
and where the information will be stored to ensure privacy.26  Whole genomic sequencing, as 
well as the other expanding technologies and interventions of genetics, have tremendous 
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implications for improved quality of life and the early detection of many disorders, however the 
associated ethical issues and problems examined in the second half of this chapter must be dealt 
with in order for sequencing to positively impact society.27 
 When newborn screening initially began, and until very recently, there was a consensus 
that screening should be guided by inclusion of disorders that can be effectively diagnosed and 
treated relatively close to the time of the screening.28  In light of this, both the American Society 
of Human Genetics and The American Academy of Pediatrics believe that testing for disorders 
without therapies should be limited.29  There are unclear and limited benefits to testing for 
disorders that are not treatable and additionally those with inaccessible therapies or unclear 
diagnosis results.  Despite these recommendations, there are arguable benefits other than therapy, 
such as planning for the future or identifying subjects for research, making it unclear if it is in the 
child’s interests to be screened or not.30  Many parents argue they have a right to know, and that 
the knowledge from the test provides them with benefits.31  Deciding what should and should not 
be screened for becomes a much bigger issue with the decreasing costs of whole genomic 
sequencing, the growing number of diseases that can be identified, and the increased use of 
screening not only at birth but also later in life.32  Genetic testing is becoming an important 
diagnostic and therapeutic tool in medicine, making discussions of determining benefit and 
burden crucial.33  In the future there is likely to be a large array of DNA-based tests to diagnose 
genetic disorders and identify predispositions to genetically influenced disorders.34  Whole 
genomic sequencing will greatly expand the therapeutic gap, identifying children with disorders 
lacking therapies, those that do not develop until adulthood, or those with very misunderstood 
clinical significance.  As these panels expand and technology progresses, health services, public 
policy and oversight will play a crucial role in establishing boundaries and informing decision 
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makers about genomic interventions.35   When a mutation is identified it is unknown whether the 
child will develop the disorder, it is just a possibility which is both confusing and misleading to 
patients and families, necessitating guidance and oversight from many groups.  The expansion of 
the field of genetic screening has created many new and enhanced ethical issues that parents and 
decision makers for children must deal with and work through in order to make good decisions 
for the child patient.  As science expands quickly in this field, there is a great need for a way for 
parents, physicians, and children to work together to determine what they should or should not 
screen for in their children.  
 
4.2.2 Neurotechnologies 
 Neuroscience is the study of the brain and nervous system, encompassing many aspects, 
from molecular and cellular biology, to psychology and behavior.36  Neuroscience has led to 
many innovations in clinical medicine that have not only therapeutic but also non-therapeutic 
applications, all with ethical implications.37  In the last decade tremendous technological 
advancements have been made in understanding basic brain and behavior relationships, leading 
to new possibilities and opportunities to diagnose or even predict, treat, and potentially enhance 
capacities.38  Many believe that the twenty-first century will be viewed by later generations as 
the century of neuroscience, leading to tremendous breakthroughs for the medical world as well 
as society in general.39  These interventions enable physicians and patients to better understand 
how the brain impacts the way they interact with the world and even begin to diagnose and treat 
disorders or conditions of the brain.  Some of the biggest yet controversial developments of 
neuroscience are functional neuroimaging, brain mapping, psychopharmacology, and 
enhancement opportunities with the potential to impact behavior, personality, and 
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consciousness.40  Many doctors believe that they can analyze the development of a child’s brain 
and track possible psychological or developmental disorders after a simple five-minute scan.41  
This would enable physicians to diagnose the child, however there is also the possibility that it is 
misinterpreted or overanalyzed since not all brains are identical.  Researchers are beginning to 
identify brain processes that are related to experiences and concepts such as free will, agency, 
moral judgment, self and personality.42  They are able to review activation or activity of the brain 
and different areas of the brain and determine emotions, how people feel, and even which areas 
of the brain are necessary for certain functions.  This is especially helpful in the monitoring and 
treating of patients with psychiatric and developmental disorders. Additionally these tools can be 
utilized to create targeted medical approaches based on the specific patient and his or her 
disorder.   
Another area of development is that of functional MRIs.43 A functional MRI also offers 
ways to analyze how different parts of the brain work together functionally and can then be 
applied to patients who lack certain abilities or have deficits.44  By comparing data with 
standardized models of how the brain functions or how a specific disease develops a variety of 
new clinical insights becomes available and it can be seen how the child’s brain is out of sync 
with the normal developmental curve.45  This approach could enable treatment before any onset 
of symptoms and help physicians track the results of clinical trials of new therapies, but for the 
time being, the focus is on understanding the brain and being able to relate behavior to brain 
activity.  Pediatric brain scans are not an extremely large practice at this time, but there is a great 
possibility that this will be one of the new interventions more commonly used to care for 
children, along with genetic screenings, to understand, diagnose, and inevitably treat.46  New 
techniques for monitoring and manipulating brain functions are developing rapidly but it is not 
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clear how they should be used together in the care of children.47  It is currently not known how 
all of the different systems of the brain interact, or what a particular brain abnormality can 
predict about an individual, and it is further unknown how intervening in these systems can 
affect the beliefs, desires, intentions and emotions that constitute the human mind.48  It is 
difficult to assess and diagnose individuals with disorders of the brain and even more challenging 
to use new therapies to treat them.  New technologies have increased the burden on the physician 
to assess, diagnose, treat, and in many instances obtain informed consent.  Additionally, due to 
uncertainties, careful consideration must be given, precautions must be taken, and in some 
instances, doctors may need to provide treatment when inappropriately demanded or if it is of 
uncertain benefit.49  When dealing with the brain, there are many issues that arise immediately, 
even before the introduction of technologies and therapies due to societal views or actual 
vulnerabilities.  Many people have personal ideologies and conceptions in regard to the brain, 
including those of the self, free will, personal choice, and even personality and consciousness, 
and when something challenges that or even presents new information, it raises concern and the 
need for extra considerations.50 Technological advancements of neuroscience, just as those of 
other fields of medicine, bring with them both new possibilities and issues to address.51   
 The application of neurotechnologies to children creates even more ethical issues and 
dilemmas as they are an extremely vulnerable population. It is one thing to allow adults to take 
risks, participate in new treatments or therapies, and even to choose controversial therapies based 
on respect for his or her autonomy, but a completely different thing for parents or guardians to 
make those decisions for children.52  Brain scans and other new technologies can be utilized for 
children with both therapeutic and non-therapeutic benefits, but it is not clear if parents can make 
such choices for their child, and if they can it is not evident how it should be made.53  There is 
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the possibility that parents could even request enhancements for their children but with that come 
even more ethical dilemmas and issues ranging from justice to the rights of the child. There is a 
great need for the identification of the key ethical issues and the formulation of regulations, 
policies, and guidelines for all those involved with the advancement of neuroscience to enable 
the benefits of the technology to be utilized.  Neuroscience has great potential to treat disorders 
of the brain, many of which impact children tremendously.  Many neurodevelopmental disorders 
that affect early brain development are misunderstood.54  Neurodevelopmental disorders have 
genetic as well as environmental influences and can place a large burden on families, patients 
themselves, and society on the whole.  A lack of effective therapies is a major problems but 
neuroscience has begun developing new techniques and methods for assessment and diagnosis, 
treatment, and potentially even fixing some of them, however it is still in the early stages.55  
There is a lack of evidence about what neurological interventions can do, and even less about 
what it should be doing.  With all of the developments of the brain and neuroscience it becomes 
crucial to look at these issues and more importantly define a system for how decisions should be 
made and outline the role of all involved in pediatrics. Children with neurological disorders are 
in a very difficult and vulnerable position and one of the biggest issues that come with the 
advancements of neuroscience is how decisions of care should be made for the child.56  The 
child, who is the patient, cannot make the decision for him or herself, placing a large burden on 
both the parents and physician complicated by the uncertainties and new technologies of 
neuroscience. Disorders of the brain in children can be extremely burdensome to not only the 
child but his or her parents and entire family, adding additional dimensions and ethical issues.57  
There are many issues that arise with neurological and developmental disorders that impact 
decision making, which will be looked at in more depth in the second half of this chapter.  
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4.2.3 Clinical Research 
 Clinical research has been the cornerstone to advancements within medicine enabling the 
creation of new therapies, the application or modification of those therapies for new populations, 
and the use of pharmacological interventions created for one condition to be accurately 
developed and applied to others.58  Research studies are crucial to the expansion of the field of 
medicine and development of new technologies and interventions, but is also full of ethical 
issues and troubling dimensions, especially when applied to children and pediatric populations.59  
Research with children is potentially the most troubling area of development for the current 
decision making models as it encompasses the issues of both genetics and neuroscience, 
highlights the vulnerable status of children, makes it possible that they will be exploited, and 
makes issues of therapeutic and non-therapeutic interventions immediately more troubling.60  
There are many legal and ethical issues associated with vulnerable populations such as children, 
especially those with genetic, neurological, or developmental abnormalities making conducting 
research challenging.61  By definition, clinical research trials involve the “trial” of a new therapy, 
typically with only a selection of the enrolled subjects receiving the therapy.62  Additionally, due 
to the many unknowns, it is not even clear if it is beneficial to be receiving the therapy, or to be 
part of the control.  Even in studies without a control group receiving a placebo where all 
participants engage in the new therapy, the levels of uncertainty of the therapy are great and the 
roles of all involved are not clear, nor is there a way for decisions to be facilitated for the child to 
participate in the research study.63  New technologies create the possibility for parents to enroll 
their children in research trials both with and without therapeutic benefits utilizing the new 
technologies of genetics and neurology, but it is not clear if they can make such a choice for their 
child, and if they can, it is not understood how they should decide.64  There are many issues with 
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pediatric research, but the largest issues that will be elaborated is the fact that children are 
vulnerable and need to both be protected and advocated for so they are appropriately included in 
research but not exploited or taken advantage of.65  
 The current research model does not consistently protect children from harmful and 
useless research nor promote their participation and interests overall; research with children must 
protect their vulnerable status while ensuring that they are not exploited.66 Children are both part 
of a vulnerable population that needs certain levels of protection from research risks and 
“therapeutic orphans” who were at one time denied access to the benefits of research.67  In the 
past children have been exploited as research subjects, however over time, as they gained a role 
in society, this changed and they became the central part of society and the family that they are 
today, viewed as vulnerable and in need of protections.68  Until recently, this desire to protect 
children led to their exclusion from most, if not all medical research in order to not exploit their 
vulnerable status and harm them.  This created many problems for pediatric care, specifically the 
lack of personalized therapies and treatments developed for and tested on children, leading to 
regulations in the United States promoting the inclusion of children in clinical research.69  The 
development of lifesaving cures and treatments for childhood diseases and illnesses depends on 
the advancement of pediatric research, necessitating their inclusion in these processes.70  
Translating knowledge gained from scientific advances in biology, genetics, and neuroscience 
into treatments for children is possible only through research and research trials to prove efficacy 
and overall value as well as learn more to enhance the therapy or intervention.71  Just as with all 
areas of pediatric medicine, pediatric research must be handled in a different way than adult 
research; the overall needs of children differ from those of adults, but both are entitled to a 
healthcare system that supports a healthy and productive life, making further research with 
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children necessary.72  Children are developing and changing at a much more complex rate than 
adults, and elements that would not be issues for adults may be for children, and vice versa; 
adults and children cannot be medically lumped together and treated in the same manner 
necessitating pediatric research.73 
 Research methods must take the exceptional vulnerability of children into consideration 
in order to avoid exploitation and abuse.  During the Nazi regime children were used as guinea 
pigs for research and because of this horrible experience, the Nuremberg code addresses children 
and appears to suggest an absolute prohibition against pediatric research emphasizing that the 
voluntary consent of the subject is essential and that those who cannot legally give consent 
should be excluded.74  In the 1970s, the United States developed regulations that allowed 
advances and the participation of children in research while protecting them from unnecessary 
and uncompensated risks and discomfort.75  Current regulations are in place to provide additional 
protections to children in pediatric research, however this does not mean that there will not be 
negative outcomes as these are inevitable in all situations when dealing with an unknown.76  
Risks cannot be eliminated from research due to the inherent nature of medical research, 
however clinical researchers must be learn from mistakes to prevent future occurrences of abuse 
or harm and maximize benefits.  With research, benefits cannot always be the “best interests” of 
the child because sometimes the child does not stand much of a chance of receiving a benefit, but 
other future children do.77  Additionally, there are other factors that come into play in the 
decision making process including altruism, compensation to parents or child, the maintenance 
of hope, or even confusion coming from the therapeutic misconception that anything offered will 
be of benefit.78  Informed consent, as a crucial component to pediatric research, is the 
combination of parental permission and assent of the child, but also must fall within the 
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allowable limits of society and should additionally involve the physician in a large role helping 
to navigate through these many dimensions.79 It must be clear what the parents or guardians are 
consenting to, the must demonstrate actual understanding, and the child him or herself must be 
involved if possible.  All of these issues will be expanded in the following sections, and 
answered with the enhancements offered to the shard decision making model in chapter 5.  
 There is a need for balance between protecting children and preventing or reducing harms 
and respecting and involving them and listening and learning from them, to not silence and 
ignore them.80  Overall there are many ethical issues with pediatric research including consent, 
current and future autonomy of the child, comprehension of the child or family, vulnerability, 
and possible exploitation.81  Children require additional safety measures due to their limited 
capacity to give informed consent and vulnerable status, but well-designed and well-regulated 
research with children is needed to improve children’s health, and pediatric ethics can work with 
doctors and researchers to help ensure that this happens.82  Children are in a unique position in 
that they must be protected while also advocated for so they are appropriately and meaningfully 
included in not just research, but also decision making processed to select to enter into a study so 
the child is not exploited or taken advantage of.  The advancements in neuroscience and genetics 
have great potential but also a tremendous amount of unknown information and uncertainties 
surrounding impacts and outcomes, leading to the need to continue research with children but 
also to develop a way to address the many enhanced ethical issues that arise, including consent 
and assent to the trial, unclear benefits, burdens, and outcomes, privacy of information, and 
future implications for the child and his or her family.83  These issues, and others, will be looked 
at in depth in the following sections.    
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4.3. Enhanced Ethical Issues & Challenging Decisions  
 Decision making is one of the most complicated issues throughout all areas of pediatric 
medicine, and it becomes even more complex in light of the advancements in genetics, 
neuroscience, and clinical research.  Due to these advancements there are complex decisions for 
parents to make, a complicated role for the child, a challenging demand of the physician to 
present complicated and unclear information, and the increasingly important role of society as 
these technologies bridge into areas that they must address and make decisions to either allow, 
prevent, or regulate and restrict.  This chapter will elaborate the specific ethical issues that 
accompany these new technological breakthroughs and advancements, focusing on those that are 
troubling for the current decision making models and make enhancements necessary.  The issues 
that will be developed are informed consent and assent, the growing therapeutic gap, increasing 
levels of uncertainty, privacy of information and future implications for the child and his or her 
family, and the potential for enhancements or modifications. All of these issues make decision 
making challenging and pose an increasing numbers of problems for the current decision making 
models in pediatrics, creating issues for parents and leaving them without a sufficient way to 
work through them and make the best decision for the child.  Throughout the areas of genetics, 
neuroscience, and clinical research many advancements have been made, however there is a need 
for a modified version of the shared decision making model that accommodates and addresses 
the enhanced ethical issues that come with those developments and those that will continue to 
develop with time.  
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4.3.1 Informed Consent and Assent 
Informed consent is a complicated aspect of medicine with adults and children.84  There are 
two basic components to informed consent, the disclosure of information by the physician to the 
patient and the decision that the patient makes.85 Patients must have enough information to make 
educated and informed decisions that are meaningful to them.  The concept of informed consent 
is grounded in respect for persons and enabling individuals to be in control of and make choices 
about what happens to them.86  Informed consent is crucial to decision making processes in the 
medical world as treatments cannot be selected without it, unless it is an emergency situation.  
There are three main criteria to informed consent being valid specifically that the person giving 
consent is competent to make the specific decision, that the patient understands the information 
and is able to relate the details to their own life, goals, and values, and additionally they must 
participate freely and without coercion from others.87  These components are very important to 
decision making processes and inevitably informed consent.  Patients must not only be able to 
comprehend the options and potential courses of action, but work with the physician to 
understand them in relation to their own lives and goals to make a decision that is meaningful to 
them. With children, this becomes difficult because the child is not the legal decision maker and 
his or her parents are making decisions that should be guided by the child’s current and future 
interests as well as medical facts.88  Informed consent is challenging with children in general and 
even more complicated by the new technologies.  
The role of the child is typically incorporated into decision making processes through an 
idea of assent, since they are not autonomous and able to give formal informed consent for 
themselves. Within pediatrics, parents or guardians are the legal decision makers for their 
children.89  Children, however, are encouraged to participate in decision making processes 
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through assent.  There are many issues with assent, including that there is not an entirely clear 
definition of assent, nor way to incorporate the child’s assent into decision making processes, but 
there are some standard components.90  Assent, at a minimum should include (1) helping the 
child achieve a developmentally appropriate understanding of his or her condition, (2) explaining 
to the child what he or she can expect from the different options, (3) an assessment of the child’s 
understanding of the situation overall, including emotional responses and reactions to stress or 
pressure, (4) the child’s opinion and willingness to accept proposed options or therapy.91  It is 
crucial that the child is incorporated in a meaningful way and that they understand what is going 
on before being able to actually give assent.  Assent is most common within research trials, in 
order to ensure that they child is aware of the details of the study and incorporated into the 
decision making process, however it is not entirely clear what assent actually means.92  Many 
times, the responses of parents and children will be different, and it is not clear how these cases 
are or should be handled.93  In practice, parents can override a child’s assent, calling into 
question the weight that the assent of the child carries. If the child is easily overruled, assent does 
not serve a purpose, but if the child’s assent prevents them from entering into a research trial, 
thereby overruling their parent’s consent, which calls into question if parents are actually giving 
consent.94 Inevitably the parents carry the responsibility to make the final decision, leading to 
them being the focus and many times, overlooking the child in the decision making process and 
failing to ensure that children understand the research protocol and overall process.95  Children 
can and should be involved in deliberation processes, but the final decision is to their parents. In 
light of this, it is complicated to require both the consent of the parents and assent of the child.96 
If they agree, it acknowledges the child and incorporates them into the process, however if they 
do not, and are overruled, it undermines their role, potentially causing more harm than good.  
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Similar to informed consent, the emphasis in assent processes with the child patient should 
be on sharing values, information, and opinions openly to ideally make a joint decision.97 
Institutional Review Boards, the body guiding and regulating research processes, individually 
have policies for including and adding the assent of the child, but there are very different 
definitions of assent are prevalent among different.98  In a study by Kimberly et al, it was found 
that there was tremendous variation in process and tools used to document assent of the child 
among IRBs.99 Many IRBs were found to have up to three forms: one for consent or permission 
from the parents, another for the assent of the child in accord with their development level, and a 
consent form for emancipated minors or young adults. The Belmont report and the American 
Academy of Pediatrics (AAP) Committee on Bioethics have both outlined that researchers 
should ensure that all research subjects, adult and child, comprehend the information about their 
research participation, however federal regulations have not made this a requirement.100  
Although sometimes assent forms are used within research, they cannot replace the central 
component of assent, which is the relationship and process. Just as informed consent is not only 
about the decision made, assent is not only about the end result that is the child’s assent or 
dissent to the proposed therapy. In order for consent processes to appropriately incorporate the 
child, it is argued that a formulation of parental permission and patient or child assent. The 
American Academy of Pediatrics argues that in most cases, physicians have an ethical and legal 
obligation to obtain consent, which is primarily made of parental permission, before a medical 
intervention is selected for a child.101  They further argue that the physician should solicit the 
child patient’s assent when appropriate and direct consent from the child if he or she is of 
decision making capacity, even though this is not always assessed, in addition to when otherwise 
directed by law.102  Federal regulations require that, whenever possible, children affirmatively 
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agree to participate in research, specifically that they give “assent,” before enrolling in research , 
however due to the fact that this regulation is only required “whenever possible,” it does not 
happen in all instances.103 The assent component is a challenging recommendation though 
because it is unclear how to handle cases where there is disagreement between the child and 
either physician or parents.104  It is a good idea for assent to be added to processes when the child 
has been found to have enough decision making capacity to be involved in a specific instance, 
but conflicting opinions must be dealt with in order to not cause harm to the child or overall 
consent process.105 The concept of assent is possibly harmful, placing children, parents, and the 
physicians in challenging positions to incorporate dissent. It is important to note that no one 
should solicit a child’s opinion or views without intending to weigh them seriously into the 
process and overall decision and in instances where they do not have an option, they should be 
informed of this so they are not lied to or deceived.106  As children develop decision making 
capacities they should gradually become the primary decision makers and guide their 
healthcare.107 A child patient’s refusal to assent should carry weight, especially when the 
proposed intervention is not essential to his or her welfare or could potentially be deferred 
without substantial risk to the child.108 It is important that the child be incorporated in a 
meaningful way into decision making processes, and the idea of assent, in theory, does this, 
however due to its conflicting definition and different applications throughout the practice, not to 
mention the fact that it is almost never used outside of research, leads to the need for the role of 
the child to be revisited.  
Issues of consent and assent are prevalent throughout the field of pediatrics, but they 
become more difficult with emerging technologies leading to complex information to 
comprehend, barriers to communication and understanding, and unclear roles for all involved in 
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the process, primarily the child him or herself, overall complicating decision making.109  The 
legal status of the child in society and their developmental status make consent challenging 
throughout pediatric medicine, as parents are looked to as the legal decision makers in most 
cases.110  However, new therapies in the areas of genetics and neuroscience, and the growing  
number of pediatric research trials, make these issues more pressing and convoluted.111  Issues of 
who should be involved in the decision making process and how they should make decisions 
become much more challenging to determine and balance with the additions of complex 
information, unclear benefits, and the assent or refusal of the adolescent child.112  As children 
approach adulthood they have different levels of capacity and decision making abilities but must 
be included in consent processes to the appropriate degree.  It is relatively straightforward that 
parents are the decision makers for young children under the age of 5, especially when it is 
evident which option is in the child’s best interests, however this role becomes more difficult to 
justify and solely rely on when the child is an adolescent.  Adolescents are in a challenging 
position with varying levels of decision making capacity as they approach adulthood and gain 
control over their lives.  Additionally, many of the new therapies have varying degrees of 
uncertainty and benefits to the child.  With older children, assent becomes important to care and 
decision making processes.  Similar to decision making capacity, the ability of the child to give 
assent should be evaluated on a scale after evaluating the child’s capacities and abilities 
including both maturity and understanding in comparison to the decision to be made.113  The 
assent of children with more maturity, life experiences, and overall levels of comprehension of 
the specific situation and medical options should be given more weight in the decision making 
process.  
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Consent and assent become even more complicated with pediatric research trials in 
genetics or neuroscience.  The role of the parent is troubling for older children in all areas of 
pediatric medicine, but even more so as which much research there may or may not be 
therapeutic benefits for the child.114  For research, it is not clear if the consent of the parents 
carry the same weight as in other areas of pediatric medicine, as the assent of the child is highly 
sought after in research.115  Although children do not have autonomy or the legal right to make 
their own decisions, they are developing the necessary capacities for making medical decisions, 
placing adolescents in a unique and undefined place.116  Their explicit role in consent is not clear 
and despite the many benefits of including them, specifically validating them as individuals and 
recognizing their agency, there is not a standard way to do so.117 The child cannot give formal 
consent, however if the focus shifts from autonomy and consent to that of respect for persons and 
the best interests of the child, formal consent for research should be achieved through a 
combination of parental permission and assent of the child.118  It is typically strongly 
recommended that the assent of the child be collected before entering them into a research study, 
but this is not absolute.  In therapeutic clinical trials, the permission of the parents carries the 
greatest importance, however in those that are non-therapeutic with minimal benefit to the child, 
the assent should be considered more heavily and arguably even in cases of young children.  
Barfield and Church argue that in older adolescents, assent should carry the same weight as 
informed consent, even though parental permission is still required, acknowledging the self 
determination of the child and right to direct their lives.119  New therapies in the areas of genetics 
and neurology are exceptionally troubling for this as these decisions carry much more 
complexities, uncertainties, and possibilities for impacts lasting the duration of the child’s life. 
All of these issues, which will be developed throughout the rest of this chapter, make it crucial 
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that there is a way to evaluate and incorporate the child patient when possible and his or her 
assent in addition to the formal consent and permission of the parents.  
As the well accepted decision maker for children, parents have many challenges and 
barriers to meaningful consent for new therapies and interventions beyond the involvement of 
the child him or herself in the process.120  Parents are emotionally involved and connected to the 
situation, many times clouding their judgment or ability to fully assess a situation.  121 Within the 
fields of genetics and neuroscience, many therapies are hard to comprehend and determine when 
to use, both for parents and children, as there are many unknown elements to all involved, many 
times including providers.122  These uncertainties will be further developed in a later section, but 
without full comprehension of the therapy, the possible outcomes, and future implications 
informed consent and assent are very challenging, if not impossible.  Outside of unknown 
elements, new interventions in the fields of genetics and neuroscience are difficult to 
comprehend due to the complexity of the information.  It is up to the physician to explain all 
options and likely outcomes in a way that is comprehendible by the parents, but this is not 
always what happens.  Studies show that parents are reluctant to ask for help or an additional 
explanation, and many times make decisions based when they do not understand everything, or 
in many cases, let providers guide care decisions.123  Most parents are typically not of a medical 
background, many times placing a large educational and language barrier between the medical 
team and parents.  Low health literacy, culture, ethnicity, socio-economic status, and overall 
education levels greatly impact decision making processes for parents and their overall role in 
the process with physicians and their children.124  Low health literacy was found by Yin et al, 
2012  to lead to difficulties in comprehension and processing of basic health information, needed 
for appropriate decision making, with parents having difficulties in many areas including 
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reading, listening and engaging, and analyzing information, leading to dependence on providers 
and the medical team.125  In a study by Simon et al it was found that when English speaking 
physicians presented details to non or limited English speaking parents they left out important 
details and information such as the concept of randomization or even the right to withdraw from 
the study.126  This information is extremely relevant and needed by parents to make the best 
decisions for their children, and there must be a way to not only ensure the information is 
conveyed and delivered to parents, but also that they comprehend the details in a way that is 
meaningful and enough for them to give proper consent.127  
Research poses another complexity for parental consent and comprehension due to the 
therapeutic misconception.128  The therapeutic misconception refers to the problem created when 
providers offer therapy to patients, that may or may not have benefit to them, and the patient 
perceives such a benefit based solely on the fact that the provider offered them the intervention.  
In research, in addition to the complex treatment options and unique terms to research, such as 
randomization of placebo, many times parents assume that there is therapeutic benefit to be 
gained from the study.129  New medical interventions are dependent upon clinical research trials, 
making them necessary for the advancement of medicine, making stringent informed consent 
processes needed.130  Comprehension barriers of parents many times lead to great 
misunderstandings when enrolling children in research trials and there is disconnect between 
what parents understand or expect and reality.131  A study by P. Applebaum et al. found that 24% 
of subjects believed the study had no risks or major disadvantages, despite singing in depth 
consent documents explicitly outlining the risks and potential disadvantages.132  Parents must 
fully comprehend what they are signing their children up for as the benefits cannot always be 
based on the best interests of the child because many times because sometimes the child does not 
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have great potential for benefit.133  Informed consent for pediatric research must be a 
combination of parental permission and assent of the child, where the assent or possible refusal is 
worked into the process.134  Issues of consent and assent are challenging throughout pediatrics 
and tremendously complicated by new technologies, requiring a facilitated decision making 
model that accommodates all aspects of consent.  
 
4.3.2 Therapeutic Gap  
 The therapeutic gap is another major issue associated with the new technologies 
emerging within the fields of genetics and neuroscience.  The therapeutic gap refers to a gap 
created when disorders are identified however there are not therapies, treatments, or available 
options for the disorder.  135  Advancements in the areas of genetics and neuroscience have 
greatly widened this gap, making it possible and in many cases common to identify disorders that 
are not fully understood and many times lack proven or accepted treatments.  This gap is 
evidence of strong growth in the fields and progress being made, however it places physicians, 
researchers, and possibly parents in challenging positons. The therapeutic gap connects ideas of 
fate, destiny, and suffering with the predictive power of genetics, giving great hope for the 
future, but additionally creating gaps that place parents in challenging positions.136  Within the 
field of genetics, whole genomic sequencing will make it possible to screen for many diseases 
and identify risk factors for multi-genetic diseases, carrier status for many autosomal recessive 
conditions, adult-onset conditions, or those with uncertain clinical significance.137  This creates a 
large gap in what can be identified and what can effectively be treated.  Another field that has 
seen tremendous growth from the expansive genetic screening is that of neuroscience and 
neurology.  Currently, genetic screening is used to identify many neurodevelopmental disorders, 
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but when they screen for the neurological disorder, they are able to identify other aspects of the 
child’s genome, many of which fall within the therapeutic gap and are not treatable.138  Genetic 
tests are becoming more expansive, accurate, and affordable, leading to the potential that they 
are used on a much more regular and widespread level, possibly venturing into unclear areas.  
Just as with newborn screening, the possibility exists that disorders will be added to a genetic 
panel due to lobbyists, patient advocacy groups, or even the sole reason of being able to that are 
not necessarily ethically permissible with effective and readily available therapies,.139  Outside of 
genetic tests for neurological disorders, other advancements in the field of neuroscience include 
functional neuroimaging, brain mapping, and psychopharmacology, all of which have 
tremendously increased the therapeutic gap.140  These technological interventions shed light on 
many personal and affective disorders of the brain which are very different than typical diseases 
and disorders in that they carry with them many stigmas and are even viewed by some as 
personality traits.141  The findings of neurotechnologies such as brain scans and functional MRIs 
can be associated with psychological and social disorders, labeling children with conditions such 
as autism, ADHD, schizophrenia, and bi-polar disorder, which can have great implications for 
the future and unclear therapeutic benefit for the child.  These issues are magnified by the 
uncertainty and diversity surrounding these interventions, and the inability to establish consistent 
thresholds for “positive” screens.142 A genetic predisposition does not equal a diagnosis, however 
in cases of personality or brain disorders, there is a fine line to walk due to society and future 
implications.143  Many of these conditions carry with them social stigmas and could hinder the 
child’s future by labeling them with them, however by identifying it at an early age the child 
would have a better chance at treatment and the ability to take care of the disease and lessen the 
impacts.   
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The World Health Organization argues that screening for diseases should be based on 
stringent criteria in order to do what is best for the child and in his or her best interests.144 WHO 
argues that in order to include something in a panel or to ethically allow for a disorder to be 
screened for, there must be an accurate diagnostic process, specifically the findings are 
meaningful and understood, and additionally adequate and accessible treatment must exist for the 
disorder.  The American Academy of Pediatrics agrees with WHO emphasizing that conditions 
should be screened for when there is an effective therapy that is available to all who are screened 
close to the time when they are screened.145  For example, if a disorder cannot be treated until a 
patient is in his or her teens, there would be no reason to screen the child as a newborn.  
Additionally, if a treatment exists but it is not available to the general public and is too 
expensive, there should not be a screening program for this nor should a standard panel include 
this disorder.  It is important that clinicians only run tests if results could change care and clinical 
management, not just to test and be able to diagnose the child. Despite these recommendations, 
many of the currently recommended illnesses that are regularly screened for as part of newborn 
panels are poorly understood, untreatable, or lack effective therapies. 146  If there is not an 
immediate benefit to the child, ethical issues arise and the use of the intervention is not 
straightforward or clear.    
There are arguably other benefits to knowing than treatment including for the family to 
know and prepare themselves, or even for society at large for planning or budget purposes or to 
gain more knowledge of diseases and inevitably increase the ability to treat them.147  It is argued 
that by knowing if an individual has a disease, even if untreatable, there are benefits including 
psychosocial and research benefits to other recipients, such as family members or society as a 
whole, and the ability of the family to plan for the future, even if it is uncertain and not 
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definite.148  Tarini and Goldenberg discuss these other benefits in relation to newborn screening, 
and argue that if a therapy does not exist the specific test should not be added to the screening 
panel.149  Outside of newborn screening in light of the expanding technologies, this idea becomes 
even more crucial because even if not mandated by society, as newborn screening is, it is not 
clear how providers should offer tests and handle requests by parents or how parents should 
decide what to learn about their child.  Bennet asked several physicians to elaborate the negative 
impacts of expended screening and the ACMG’s recommendations, and all elaborated some of 
the outcomes of recommended testing for rare disorders or those with unclear clinical 
significance including the therapeutic gap, false positives, and elements of uncertainty or future 
implications, both of which will be looked at in following sections.150  
The therapeutic gap has always been an issue of medicine, as the first steps to the 
development of a therapy or treatment for a disorder is the identification and then studying of the 
disease, however these new technologies bring forth new identifiable diseases exponentially 
faster than in the past. New conditions or predispositions are identified on a regular basis, not 
always while looking for them, many come up while researching or elaborating on established 
research and disorders.151 In addition to lacking therapies, many of the newly identifiable 
disorders are not definitive, and a diagnosis, or finding that the patient has a genetic disposition 
or abnormal brain scan, has very unclear meaning; the patient could develop the disorder, but he 
or she also could never show symptoms or manifest the disease.  Without being able to 
accurately determine if a patient will develop a disorder, even if a therapy exists it is unclear if it 
should be tested for and additionally if it is, when you would utilize the intervention.  The gap 
between what is known and what is not is a large issue prevalent throughout genetics, 
neuroscience, and clinical research trials, only to be made larger and more serious in the coming 
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years.152  The therapeutic gap will ideally get smaller, however it does not appear to happen any 
time soon since even if therapies are found for the genetic or neurological disorders currently 
identifiable, there are growing numbers each day, making this a huge issue throughout the areas 
of genetics, neuroscience, and clinical research.  
 
4.3.3 Uncertainty  
Uncertainty is prevalent to a certain degree throughout medicine, however it is a much 
bigger issue with new technologies as they do not have established histories and foreseeable 
outcomes in all instances.  With the new therapies available on a regular basis it is unclear what 
the actual benefits of intervention currently are, will be, or even could be due to many unknown 
elements.153 The new interventions throughout the fields of genetics, neuroscience, and clinical 
research are surrounded with a great amount of uncertainty.  Physicians do not know what they 
will find before performing each intervention, they do not definitively know what diagnosis or 
the identification of an abnormality means in all cases, and they do not know what the outcomes 
will be for individual children. Some of the therapies have much more established histories and 
physicians are able to have more concrete reasoning for the selection of a therapy and better help 
parents weight benefit and burden, however with some, specifically within research, there are 
many components that the researcher or clinician has no way of knowing.  Advancements and 
new interventions, by definition, are filled with more uncertainty than other areas of treatment in 
medicine, and the areas of genetics, neuroscience, and clinical research are several of the areas 
where this is prevalent.  
 Advances in genetics have led to the ability to test for and identify predispositions for 
many more disorders than therapies exist, creating the therapeutic gap and great levels of 
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uncertainty.154  It is unclear if it is in the child’s best interests to identify conditions that cannot 
be treated based on the fact that a therapy does not exist, but also because much uncertainty and 
unknowns come with these identifications.155  The identification of a mutation does not 
guarantee that the gene or disorder will manifest at any point or even if it will, the test results do 
not allude to when the disease will develop or begin, placing parents, providers, and children in 
challenging positions.  It is difficult to determine the likelihood that a child will develop a certain 
illness and identify what a “positive” result is or means.  Some tests do not have a definitive yes 
or not but rather a probability of developing the disease and in these cases, a certain probability 
is associated with a positive result.  It is challenging to determine what to tell parents when a 
probability is identified since parents all weigh importance and significance differently and the 
results may or may carry significance to them.156  A positive result does not even mean that the 
child has the gene or condition as false positives are common, and depending on the disorder 
being screened for, the definition of positive is not always meaningful, complicating the 
communication of these findings to parents.  False positives lead to parental stresses, impact the 
parent-child relationship, and can lead to perceptions of the child’s health impacting their whole 
lives.157 Levels of uncertainty surrounding genetics lead to a great need for a formulation of 
decision making that enables physicians to feel empowered to communicate the necessary 
information to parents but also ensures that parents understand and involve the child when 
possible since these findings have implications for the future.  
There is additionally great levels of uncertainty surrounding neurotechnological 
interventions. Researchers within neuroscience are beginning to identify brain processes that are 
related to behavior, experiences, and concepts such as free will, agency, moral judgment, self 
and personality and ways to read and interpret them.158  However when venturing into these new 
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areas, there is not an established “normal” to compare to nor are every two individuals the same 
in response, making these reading challenging and filled with unknown elements.  New 
techniques for monitoring and manipulating brain functions are developing rapidly but it is not 
clear how these interventions should be used together and when they can be presented to or used 
with patients.159  It is currently not known how all of the many systems of the brain interact or 
what a particular brain abnormality may be able to identify or predict about an individual. 160 It is 
further unknown how intervening in the systems of the brain can affect the beliefs, desires, 
intentions and emotions that constitute the human mind and elements that many believe, make 
the patient who he or she is.  There is a great need for more evidence on what neurological 
interventions can do and should be doing for patients.161  When an abnormality is identified in a 
brain scan, for instance, its significance is not entirely understood at this point other than to label 
it “abnormal” as with the newborn screening test for Krabbe disease, where a diagnosis of “likely 
to develop” does not carry much weight.162  In order to see the benefits and be able to use these 
interventions, there is a need for more research and understandings of the brain.  
Assessment and the determination that the intervention is necessary is another uncertainty 
that comes with these technological advancements.  A major issue of the new technologies that 
overlaps with the concept of children being vulnerable, is whether or not the interventions may 
be classified as “medically necessary.”  The potential risk and benefit of new technologies as 
well as the potential for exploitation is much greater in pediatric medicine, which is why many 
physicians only use them when they are found to be medically necessary.163 For example, an 
MRI scan has risks associated with sedation, which is necessary with children to keep the child 
still long enough, which outweighs the potential benefits in many cases, however not in all cases.  
An MRI might be more easily selected with adult patients because of the lower risks, but with 
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children this heightened risk must be taken into consideration.  It is difficult for physicians to 
ascertain whether or not an intervention is medically necessary though, and if it carries great 
possibilities with it, excluding the pediatric patient because it may exploit them is just as 
damaging to the child.  The imaging of children with neurobehavioral and psychiatric disorders 
may help to identify subtypes of the disorders that were established by behavioral criteria, 
however they may not directly guide treatment for the specific child and may introduce undue 
risk associated with sedation use to vulnerable populations.  Data collected from such studies 
may contribute much to our understanding of developmental processes yet it is debatable 
whether imaging of children where it is not ‘‘medically necessary” is justified, and again, 
something that parents or physicians can and should be doing or offering for children. These 
neuroimaging studies have provided valuable information about the biological nature of many 
different neurological disorders, but it was noted that they have not directly contributed to the 
medical treatment of the individuals participating.  This leaves many questions of whether or not 
these interventions are medically necessary or justifiable.  Pediatric neuroimaging offers an 
unprecedented opportunity to examine the complexities of development and holds immense 
potential for helping to treat both neurological and developmental problems.  However with 
those benefits are many risks, uncertainties, and the potential for misuse of information.   
Other issues of uncertainty include incidental findings and the always troubling issue of 
informed consent that is made very challenging when information is not clear.  Incidental 
findings from both genetic and neurological interventions are a great concern that must be 
addressed.164  For instance, if a brain scan is done to determine if a child has ADHD and it is 
found that they do not, but another area of their brain looks “abnormal” it is unclear how this will 
be handled or what type of diagnosis will be given to parents, or if the physician should order 
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further tests to determine if there actually is another problem. These issues are prevalent 
throughout the new technologies discussed necessitating guidance and structure in the decision 
making processes to select what should and should not be tested for or reviewed.  Additionally, 
informed consent, which is troubling throughout medicine, becomes especially complicated 
without levels of certainty. Without complete understanding, meaningful consent is very 
difficult, if not impossible. With regard to these new technologies, more research and 
information is needed to determine what the therapies do and how the information that they 
collect can and should be used in a meaningful way. There are many impacts, some of which are 
unforeseeable and in the future, which is the issue that will be looked at next.  It is unclear how 
knowing that a child has a significant chance of developing something that is untreatable and not 
preventable will impact the child, their family, or society in general.  In addition, it is not evident 
how to determine when a child has a “significant” chance.  It would be unfair to not allow 
children to benefit from the developments of neuroscience and genetics, however because of this 
status more protections and measures must be taken to make sure they are not being exploited 
and things are done that are truly in their best interests and overall benefit.  These technological 
breakthroughs have tremendous possibility to enhance the lives of children and their families, 
however with those come many new issues and considerations, all which must become part of 
the decision making process.  The concerns and dilemmas are real, complex, and numerous, 
however with the right precautions and steps, they appear to be manageable and the negative 
impacts should be able to be minimized.165  These new issues and considerations make an 
enhanced shared decision making model extremely important and necessary for the best 
outcomes for children.  
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4.3.4 Privacy of Information and Future Implications  
There are many issues that need to be resolved throughout the areas of genetics, 
neuroscience, and clinical research that have future implications before genomics and 
neurotechnologies can be appropriately translated into clinical practice and care including the 
privacy of the child, family, and results, and larger ethical issues surrounding future implications 
for the child.166 In the last decade tremendous technological advancements have been made, 
leading to new possibilities and opportunities to diagnose or even predict, treat, and potentially 
enhance capacities.167  These new technologies may make financial sense and lead to good 
medical outcomes in many instances, however there is the potential for the misuse, overuse, or 
even incorrect use of the information generated.  Many of the disorders tested for are relatively 
common and have a substantial impact on both the individuals who have them and those who 
interact with them, and improved treatment could have significant benefits for all involved.168  
The use of new technologies with pediatric patients is accompanied by all the ethical dilemmas 
associated with their utilization with adults, magnified exponentially, like other therapies of adult 
medicine applied to pediatrics.169  There are many future implications for the information 
discovered with the technological interventions that impacts both the child and family making it 
necessary that privacy and security are top priorities in order to protect the information of 
patients.170  With newborn screening, because the tests are conducted by the state, positive test 
results are shared between the state health department, hospitals, parents, and patient’s 
provider.171  It is not well known where all of the genomic information that is collected is stored 
or what can be done with it in the future, if anything, and if the patient’s permission would be 
needed if the specimen has been unidentified.  Great concern arose in the 1990s about what was 
being done with the bloodspots that were taken at birth, including concerns of storage, access, 
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and research or tests performed on them. 172    These issues become even larger with whole 
genomic sequencing and the ability to test for more diseases and disorders, and DNA tests which 
seemingly eliminate the privacy of the sample. There is unclear ownership over the sample, 
specifically if it is not labeled, can the state do what they want with it, or should it be labeled and 
then parents and or the child request its utilization or destruction.173  Clinical research could 
benefit from the unidentified research and testing on the blood samples to be able to have a 
clearer medical picture for the future and enable societal planning, but even unlabeled due to 
DNA tests, it is not really possible to “de-identify” a genetic sample. Clear processes were not 
established in the beginning of newborn screening practices, and they are regulated by each state, 
however there must be a more consistent approach or recommendation in light of the expanding 
technologies broadening the spectrum of things that can be screened for and what could be done 
with the sample.  
In addition to the storage and utilization of genetic information, other issues of privacy 
are troubling throughout the areas of genetics and neuroscience.174  Conditions that previously 
were understood through fate, destiny, or even environment and lifestyle choices may now be 
explained using genetics or medicine, which is troubling and even alarming to come 
individuals.175  Children may be labeled, treated differently, denied benefits such as enrollment 
into competitive schools, a job, or medical insurance for presumed pre-existing illness, and even 
subjected to low self-esteem or additional stress based on things that have been identified before 
there are genuine symptoms or proof of the illness.176  There is a very real possibility that the 
information will become a means of “describing” the child, which makes the issue of privacy of 
the information tremendously crucial and problematic.177  If the benefits of testing for disorders 
without therapies inevitably do outweigh the harms, leading to standardized testing for disorders 
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that are untreatable at the time of the test, this issue becomes very important.  Children could be 
identified to have a predisposition for a disorder that is untreatable, enabled to take lifestyle 
precautions to lessen the chances that it will develop, but then still be labeled as “pre-disposed” 
for that illness, or even thought by some to actually have the disorder, impacting the child 
throughout his or her life in ways that have not been fully understood. Another area that falls 
within future implications is the issue of how to handle incidental findings of both neurological 
tests or genetic screenings.178  There is currently not a mechanism in place for consistent follow 
up or provider education of families, creating the problem of identifying an abnormality, and 
then not doing anything about it, leading to issues down the road for the family and child.179  
New technologies and both the opportunities and implications of these technologies is a 
tremendous issue that impacts the roles of parents and physicians and emphasizes the need for a 
shared role.  Overall, it is crucial that information is evaluated in terms of both current and future 
outcomes.180  There is a great need for caution as progress is made and arguments are taken on to 
expand panels and test for disorders of the brain without clear diagnosis attached because 
inevitably, more harm can be done to the child’s future than benefit.  
An additional problem that is magnified with the addition of new technologies impacting 
the future of the child is the over-interpretation or misrepresentation of results.181  Once 
physicians have brain scans or the results of a genetic sequence, it is quite possible to read too 
much out of them, and over-interpret the findings.182  Since all children develop differently and 
at different paces it is hard to define “normal” and develop standards, so it is unclear what an 
“abnormal” result that is not linked to a specific disease or disorder means for the child or 
family.  Additionally, since it is unlikely that any two results will be identical, if the physician or 
parents think something is wrong with the child there may be bias associated with how the 
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results are read and then judgments are made from there.  If there is not an accepted “normal” 
there is the potential that physicians will begin to look for something that is wrong.  Another area 
that falls within future implications is the issue of how to handle incidental findings of 
neurological tests or genetic screenings.183  Overall, it is crucial that information is evaluated in 
terms of both current and future outcomes.184  Additionally, some findings may simply show that 
the child has an increased risk for an underlying disorder, not that they currently have the 
condition or even that they certainly will develop it, but once you have the information that they 
may, that has the possibility of being attached to the child.185  A child may be labeled, treated 
differently, denied benefits such as enrollment into competitive schools or medical insurance for 
presumed pre-existing illness, and even subjected to low self-esteem or additional stress.  There 
is a very real possibility that the information from the scan will become a means of describing 
the child, which can have lasting impacts on many aspects of a child’s life and future.186  
 
4.3.5 Enhancements 
 New technological advancements in the fields of genetics and neuroscience have greatly 
changed the face of pediatric medicine, making it possible to identify and potentially treat many 
disorders or conditions that were previously impossible.  With these advancements come much 
promise and hope for the future in both of these fields, but also much territory that has rarely if 
ever been entered into before, including those of enhancement.187   Decision making is extremely 
complex in light of the continuously developing options and studies that bring with them social 
policy implications, including cognition, violence, and the genetic influences on the structure and 
function of the brain.188  With the ability to identify impacts on these concepts, both genetic or 
neurological, there is more potential to enhance and make modifications.  However, just because 
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it is possible to modify or enhance capacities and abilities, it does not mean that these 
interventions should be taken or done, especially with children.  It is currently not clear what 
adults can request for themselves, including enhancing mood, reducing appetite, or even helping 
with sleep.189  Many of these “enhancements” are considered general parts of society and life for 
adults, however it is unclear how to apply them to children. Children with disorders in these 
areas may benefit from some of these interventions, however adults use them without a specific 
diagnosis or disorder, and it is not clear if parents can use them with children.  Most would agree 
that in most cases, without a diagnosis or intervention from a provider, parents should not be able 
to use these pharmacological enhancements with their children.190  However, the developments 
in the fields of genetics and neuroscience make these issues much more pressing, as they bridge 
into areas that are much more grey, such as memory and cognitive enhancements, making it 
crucial to look at how decisions are made for the utilization of enhancements with children. 
Developments in genetic screenings give hope that it will be possible to identify a spectrum of 
heritable disorders and conditions, both treatable and not, but this only adds to the complexities 
that parents must go through when making decisions for their children.  The identification of 
more diseases not only leads to issues of uncertainty and an expanding therapeutic gap, but also 
the potential for enhancements and modifications requested by parents, society, or even by 
providers in the medical best interests of the child, making it crucial that there is a way for all 
stakeholders to make decisions that will benefit the child.    
There is much hope for the future including the treatment and possible cure of these 
identified disorders as more is learned and understood about them through research and the 
utilization of the therapies with patients.  Many things are possible today that were not even 
thought of a decade ago emphasizing the exponential rate of growth that has occurred recently.  
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Within the field of neuroscience, recent fMRI studies have shown the potential to read into 
processes of the brain connected to thought and behavior with diverse medical benefits.191  Issues 
arise further with ideas of cognitive enhancement, psychopharmacological interventions and 
enhancements for memory or mood, and even the prediction of disease.192  Additionally, new 
technologies bring hope for the ability to diagnose disorders such as ADHD and autism.  With 
regard to genetics, it may be possible to modify a genetic mutation, both with therapeutic and 
non-therapeutic benefits, creating the possibility that parents may want to request changes or 
modifications for their children after seeing results.  Though not definitive at this time, many 
believe that this is where these technologies are going, which additionally pose questions and 
issues of possible enhancements.  There are many opportunities for enhancement and it is 
possible that the rights of the parents and child potentially conflict with each other and 
additionally ideas of society.193  Parents could request enhancements for their children, beyond a 
level of “normal,” but with that come many ethical dilemmas and issues ranging from justice and 
access to the current and future rights of the child.194  This leads to problems in defining ideas of 
normal, which could be more abstract, defined by science or lead to more stringent public 
screening initiatives to definitively elaborate the concept of normality.  Developmental stages of 
children make assessments of normality very challenging for children because each child of a 
specific age does not have the same capacities or results of these interventions.  Even if it is 
possible to define a conception of normal, it is not clear if the parents should be able to enhance 
their child above normal, which would lead to those who have access to more resources and 
means having the more “enhanced” children, creating an even bigger social gap.  Additionally, it 
will come into question whether or not society could require parents to enhance their children to 
a normal level, if a way were found to do so that was accurate and financially feasible.195  It is 
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unclear where to stop testing, or what constraints to put on the utilization of the information 
found.   Lines must be drawn surrounding enhancement, including when physicians and society 
can refuse parental requests and when they should potentially suggest them for therapeutic 
reasons.196  There are many promising aspects of both genetics and neuroscience, however when 
they are applied to children the stakes become higher, and determining benefits and burdens 
become very challenging, especially in light of enhancement.  These issues lead to the likely 
utilization of policy oversight to ensure that access to the therapy is available when needed, 
patients are not subjected to unjust screening or interventions, and privacy is respected with 
regard to the information.197  Additionally policies should help formulate what parents can and 
cannot request for their children with regard to enhancements to ensure that the child is not put at 
risk.  Once so much personal information is easily gained of children it is difficult to determine 
where it will go or what it will be used for, making the decisions to obtain this information 
extremely important.   
 
4.4 Conclusion  
 Pediatric medicine is a complicated field filled with great innovation, many invested 
stakeholders, and overall, many difficult decisions.  Throughout the past few decades, 
tremendous advancements have been made in the areas of genetics, neuroscience, and clinical 
research with children, leading to better care and therapy options for children now, and promise 
for even more in the future.  Within the field of genetics, whole genomic sequencing and other 
genetic assays have made it possible to test for numerous conditions, both for the identification 
of or the pre-disposition of genetic disorders, many of which are not treatable.  Despite this, there 
are many conditions that can both be identified and are able to be treated, or possibly improved 
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with choices that the child could make throughout his or her life, giving argument for some level 
of testing.  Additionally there are some disorders, such as several neurological conditions, that 
can be identified and diagnosed through genetic screening.  There is great potential with these 
developments, however many ethical issues as well that must be addressed. Within the area of 
neuroscience, new technologies looking at brain and behavior relationships and overall function 
leading to new possibilities and opportunities to diagnose or even predict, treat, and potentially 
enhance capacities.  Some of the most controversial new technologies and developments of 
neuroscience include functional neuroimaging, brain mapping, and psychopharmacology, all 
with the potential to impact behavior, personality, and consciousness by looking at how the brain 
interacts with the rest of the body and environment. There is not enough evidence about the 
impacts or affects that both neurological interventions or genetics screenings can do and even 
less about what they should be doing or used for.  The final area of expansion discussed was 
clinical research especially in connection to genetics and neuroscience.  This research is 
combined with all of the ethical issues of the areas themselves, more complicated by the fact that 
it is research and the outcomes are even more unclear and issues of informed consent and 
comprehension become even more complicated and challenging. With all of the developments of 
genetics and neuroscience it becomes crucial to look at these issues and more importantly define 
a model for how decisions should be made and outline the role of all involved in pediatrics. 
 Throughout pediatrics, parents and physicians work together to make decisions each day, 
however the additional dimensions and issues brought with the technological advancements in 
the fields of genetics and neuroscience complicate these decisions.  They additionally emphasize 
the need of the child to have a role in the process, since many of the ethical issues have impacts 
that will last for the duration of the child’s life and could constrain or form the child’s future.  
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The increasing number of research trials, while are necessary for the continued expansion of 
pediatric medicine, bring tremendous ethical issues and decisions that parents, as the guardians 
and decisions makers of their children, must make, alongside physicians and researchers who 
must balance the need for research trials with the interests of the child.  All of this happens 
within the constraints of societal regulations that both advocate for and attempt to protect the 
interests of the child, who has an undefined role in the process.  The undefined role of the child, 
primarily adolescents approaching adulthood and gaining decision making capacities, combined 
with these new technologies make the need for them to have a role in the decision making 
process crucial as these bring with them issues that can impact the child for the duration of his or 
her life.  Issues of informed consent from the parents, the assent or potential refusal of the child, 
the identification and potential screening of diseases without therapies, privacy of and access to 
information found or genetic information collected, future implications for the child, and 
potential enhancements all add dimensions to care and place tremendous burdens on all involved 
in decision making processes.  These additional burdens are currently not accommodated by the 
models of decision making utilized by parents and providers.  In addition, the current models do 
not facilitate the involvement of the child in these decision making processes that will impact 
their whole lives, necessitating modifications of the shared decision making model that both 
facilitate a role for the child and additionally accommodate the enhanced ethical issues.  
Throughout pediatric medicine a shared model of decision making is recommended, however 
due to the heightened ethical issues and dilemmas that arise within the areas of genetics, 
neuroscience, and research with children, it becomes crucial that stakeholders not only work 
together, but that they do so in a way that upholds obligations to the child and includes him or 
her in a meaningful way.  Overall, there is a need for a modified shared decision making model 
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that accommodates the enhanced ethical issues of the emerging technologies and all of the 
stakeholders appropriately in order to facilitate not only the decisions currently being made, but 
also decision that will be associated with new developments and technologies.  
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Chapter 5 - Enhanced Decision Making Model 
5.1. Introduction  
 The expanding technologies of genetics, neuroscience, and clinical research bring with 
them increasing amounts of ethical issues necessitating a new and enhanced way for decisions to 
be made within pediatric medicine.  Currently in pediatrics, decision making is done through a 
shared process involving parents and physicians, primarily guided by the best interests standard.  
The best interest standard does not accommodate the many different ethical issues associated 
with the new technologies, including great levels of uncertainty, nor does the shared model, as it 
is, offer enough structure, support, or guidance to parents as the legal decision makers for their 
children.  There are many dimensions to making decisions for another, specifically one’s own 
child, and there is not a model that supports those many facets and barriers to decision making.  
As the legal decision makers for their children, parents are not the only individuals involved in 
their care or making decisions about treatment; physicians, society, and the child him or herself 
must play a role in the process, which the shared decision making model does not explicitly 
elaborate as it currently exists.  Decisions should be made through a shared process over a course 
of time, not one specific instance or interaction. However, the lack of a consistent definition of 
shared decision making and a shared model that is specific to pediatrics makes a modification 
necessary.  There is not a consistent definition of shared decision making as there are other 
decision making models, such as substituted judgment and the best interests models of surrogate 
decision making, other than that it is a shared process, which does not provide structure or 
guidance and elaborate the roles of those who are sharing in making the decisions.  There are 
different applications of shared decision making utilized throughout pediatrics, which leads to 
 169 
 
the need for an enhanced, more defined model that is developed specifically for pediatric 
medicine that accommodates the overarching and guiding principles of pediatrics.  This 
enhanced model will elaborate who should be involved in the process and what their roles should 
be depending on the situation to ensure that the best decisions are made and the interests, both 
current and future, of the child are kept as the central goal.  
 In order to develop a model of shared decision making specific to pediatric medicine, the 
guiding principles of pediatrics will first be elaborated.  The four overarching ethical principles 
of medicine will be applied to the field of pediatric medicine as well as the goals of pediatrics 
that this enhanced model will aim to achieve and accomodate.  After the principles have been 
applied to children and the goals of pediatric medicine developed, the new shared model will be 
elaborated first looking at the current concepts and definitions of decision making in general, 
shared decision making, and how parents make decisions for their children.  During this analysis 
the components and key pieces of information that parents find important or burdensome during 
the process will be elaborated and discussed to ensure that the new model adequately provides 
support to parents in the areas that are needed.  Then the actual enhancements of shared decision 
making will be elaborated, specifically looking at the evaluation of the child so he or she can be 
incorporated into the process in a meaningful way, the classification of the treatment decision, 
the proposed roles of parents and physicians, and potential outside impacts on the process.  The 
final component of the enhanced shared model is that of tools to enhance the decision making 
model that can be used in practice to facilitate the enhanced model and some possible areas for 
improvement, growth, and research in the future.  There is great need for a new, enhanced shared 
decision making model to accommodate the growing and changing field of pediatric medicine 
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specifically designed for children and out of the field of pediatrics that accommodates the many 
unique and challenging issues presented by emerging technologies.  
 
5.2. Ethical Principles of Medicine Applied to Pediatrics  
Ethical principles guide care and duties throughout the field of medicine.  It is important 
that the goals of medicine be in line with the values and principles of the specialty and 
population that it serves, making it crucial that pediatric medicine has a set of unique goals 
compared to adult medicine.1  Adult and pediatric patients are not the same and cannot be treated 
in the same way, however there is overlap in general goals, duties of parties involved in medical 
care.  The fields of adult and pediatric medicine share many baseline goals including the 
prevention of disease, promotion of overall health, the relief of pain and suffering, care or cure of 
disease, the avoidance of premature death, and the inevitable pursuit of a peaceful death.2  Not 
all maladies or illnesses can be cured, so many times just the care and treatment should be the 
goal.3  Within adult medicine, the guiding principles are used to uphold and guide medical care. 
The principles utilized throughout medicine to guide the duties of a physician and overall guide 
care are beneficence, non-maleficence, autonomy, and justice, and can and should be used within 
pediatrics to help achieve the same baseline goals of adult medicine.  These principles do not 
apply to children in the same way that they do to adults nor yield the same goals, but it is 
important that they are evaluated in light of the differences of pediatric patients and they are 
applied in a way that is meaningful to them.4  These guiding principles are direct and action 
guiding, and can be used to identify appropriate goals for pediatric medicine that can then be 
incorporated into an enhanced shared decision making model.5 In order to accurately represent 
the goals of pediatrics, the ethical principles of medicine will be applied to and evaluated in light 
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of the differences and unique elements of pediatric medicine.  This section will first review the 
principles of adult medicine, specifically concepts of beneficence, non-maleficence, autonomy, 
and justice and discuss how they can and should be applied to pediatric patients.  Following that, 
the goals of pediatric medicine will be discussed with a final section focusing on the promotion 
of the future and current interests of the child, as a central ethical principle that will be leveraged 
as part of the enhanced shared decision making model.  Decisions made for children should be 
guided by principles and goals specific to them in order to best facilitate decision making 
processes.    
 
5.2.1 Beneficence and Non-Maleficence 
 Beneficence and non-maleficence are two of the central principles of medicine, guiding 
care and the actions of physicians and medical practitioners throughout the field of medicine.  
Beneficence refers to promoting the interests of the patient and protecting him or her from harm 
when possible.6  When applied to medicine, this leads physicians to suggest therapies that are in 
the best interests of the patient and would overall cause the least harm when all benefits and 
burdens have been weighed.  This guiding principle is prevalent throughout pediatric medicine 
and in line with the best interests model, asking physicians to advocate for the best option.  There 
is not an obligation associated with this principle, specifically to uphold it requires the promotion 
of the good and overall interests of the patient, not necessarily doing what is in their best 
interests in all cases.  Non-maleficence on the other hand means to not cause harm to patients, 
and unlike beneficence, this principle does impose an obligation.7  Obligations not to harm are 
often interpreted as being stricter than those to help since they are more easily measured and the 
overall importance of avoiding harm. Despite the importance and obligation not to cause harm, 
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sometimes harm can be justified by potential benefits or good that can come in light of the 
burden or harm. 8 Overall it is about the overall net or benefit and burden, not the occurrence of a 
specific harm.  For instance just because a certain therapy or intervention causes a harm does not 
mean it should be avoided at all costs, these harms just must be weighed against the benefits.  
The principle of non-maleficence does not require the initiation or continuance of medical 
treatment without considering the patient’s pain, suffering, and discomfort.  Beneficence requires 
action, whereas non-maleficence focuses more on refraining from actions, specifically those 
actions or interventions that cause harm.9  Beneficence provides the primary goal of medicine 
rather than the obligation to do what is in the patient’s best interests; “best” is not a requirement, 
but a goal, ideal, and overall commitment.10  It represents a goal and responsibility of the 
physician, and central component of medicine being to do good and provide the best care. It does 
not require that the patient receive the best care in the world or access to any and all therapies 
that could lead to a good outcome, but that they receive the best medical care that their medical 
team and providers can provide, and that the team places the patient’s interests above their 
own.11  Beneficence and non-maleficence are overall guiding principles that physicians strive for 
and in and of themselves, explain a great deal about the medical field and its basic goals.  
The principles of beneficence and non-maleficence can be applied to the field of 
pediatrics in a similar way as in adult medicine and can be used as central, guiding principles.  
One major difference however is that increased attention must be given to the opinion of the 
child and the concept of “best.”   Specifically, conceptions of what is good and best for the child 
must take into the child’s own views and opinions, not only those of the parents, guardians, or 
physician.  Competent adults are able to make their own assessments about what is good and 
beneficial, whereas children cannot always make those assessments.  Even in instances where 
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they can participate in benefit and burden assessments and overall decision making processes, 
they are not the legal, final decision maker, so beneficence and non-maleficence cannot be 
applied to children as it can adults.12   A possible interpretation of the application of beneficence 
and non-maleficence to children would be that decisions should be made in the child’s interests, 
attempting to eliminate the subjective and ambiguous “best” from the determination. However, 
in many cases, the interests of the parents or whole family may be included in assessments, not 
only those of the child, which complicated this process and analysis.13  Beneficence is commonly 
construed as incorporating the patient’s autonomous wishes into care because “best” for a 
specific patient is typically closely linked to a his or her preferences and beliefs.  The concept of 
best is important to determine for each patient and it is much more challenging to apply to 
children, as non-autonomous decision makers, than it is to adults with the legal ability to select 
and refuse therapies, making their own autonomous wishes and beliefs of best known.  
Beneficence can sometimes make the principle of respect for autonomy challenging, especially 
when the principles are contradictory and patients want to do something that is not in their best 
interests, however physicians should still advocate for the best option.14 The promotion of 
beneficent and good acts while preventing harms is not absolute; in some instances physicians 
are not morally obligated to do so.15  These principles are additionally challenging in that 
sometimes there is no good option, or one without any harms, however to “do no harm” means to 
have a balance of benefit or good over the harms caused.16  Beneficence assumes an obligation to 
weigh and balance benefits against harms, benefits against alternative benefits, and harms against 
alternative harms, which must be included in the goals of pediatrics and additional held as central 
components to a decision making model. The goals of pediatrics should include ideas created 
from the principles of beneficence and non-maleficence. Promoting the good and overall benefits 
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for the child and preventing harm and risk, specifically protecting the current and future interests 
of the child, is very important to shared decision making, and will be a key component in the 
enhanced model.  
 
5.2.2 Autonomy and Justice  
 Autonomy and justice are the two other guiding principles of medicine that impact and 
guide decision making and must be incorporated into the enhanced shared model.  Principles of 
autonomy and justice must be applied to children in a unique way since they are not, by 
definition, autonomous individuals.  The principle of autonomy is central to adult medicine and 
decision making, and is used to justify and as the basis for processes of informed consent, 
enabling adults to make their own medical decisions in light of their own values and beliefs. To 
respect a patient’s autonomy is to acknowledge their right as a person to hold views, make 
choices, and take actions based on their personal beliefs and value system.17  Respecting the 
autonomy of the patient means supporting and facilitating the patient’s exercise of self-
determination in decision making, overall allowing him or her to weigh benefits and burdens in 
light of personal values and beliefs and make a decision that aligns with them.18  Specifically, to 
respect a patient’s autonomy requires more than non-interference with them, it involves 
acknowledging them as decision makers and then enabling them to act autonomously.  
  In adult medicine, the patient’s preferences guide decision making processes, enabling 
the autonomous patient to choose what is most beneficial to him or her, but in pediatrics, parents 
are tasked with weighing benefits and burdens and making choices for their child who is the 
patient.  Selecting the best therapy and weighing all of the benefits and burdens is especially 
challenging within pediatric medicine and many times, parental preferences may or may not 
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reflect those of the child, nor do parents always take into account the patient’s values or beliefs 
which may or may not have had the opportunity to mature.19  This calls into question the 
utilization of autonomy as a guiding principle within the field of pediatrics, since by definition, 
children lack complete autonomy.  Autonomy, defined as an individual acting freely in 
accordance with a self-chosen plan, cannot be seamlessly applied to children, because by 
definition children do not have full autonomy.  They are however, in the process of developing 
autonomy, and fall somewhere along the spectrum with varying levels.20  Some argue that 
parents can exercise the autonomy of the non-autonomous child, as a surrogate would in adult 
medicine, however it is first, not clear that that is where the authority of a surrogate is based, and 
additionally, unlikely that parents could exercise the not yet developed autonomy of their child.21  
Beauchamp and Childress argue that holding respect for autonomy above all other principles is 
not defensible within the field of medicine, and argue that autonomy and respect for autonomy 
should be a principle that is taken into consideration along with the other guiding principles.22  
This is important to consider and acknowledge as this is one of the only principles that does not 
directly apply to children.  It can and will be looked at in relation to the child’s development of 
decision making capacity and overall growth towards being an autonomous individual, however 
this principle should not be considered more important than the other guiding principles even 
though it is viewed that way many times within adult medicine.  The principle of autonomy is 
based in “respect for autonomy” rather than the exercise of autonomy, so it is possible that 
parents are selected as the most appropriate individuals to make decisions that would respect the 
child’s future autonomy.  This would not ask them to apply the child’s not yet developed values 
and beliefs, but rather, act in his or her best interests.  This is why, for pediatric medicine, a 
reformulation of the concept of autonomy will be argued for and a fundamental goal will be 
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addressed in the following section that respects the autonomy of the family and the future 
autonomy of the child, while promoting the interests of the child.  
Justice is another principle of medicine, although it has been argued to not be as 
meaningful or important as the others.  With regard to justice, children deserve to be treated 
justly as members of society and to be granted access to healthcare and resources.23  For this 
dissertation a communitarian concept of justice will be used to appropriately incorporate the 
impacts of society on the child and family.  A communitarian conception of justice emphasizes 
that the community has responsibilities to individuals, and vice versa, with both communities 
and individuals sharing and working towards common conceptions of a good life and justice.24  
The principle of justice must be reformulated within pediatrics as frequently society addresses 
justice for children.  For instance, society limits the rights of parents to refuse lifesaving 
interventions for their children, such as blood transfusions, or actions that put the child’s life in 
extreme danger.25  Society has an obligation and duty to protect children and overall promote 
their interests.  There are however conflicting court rulings making judgments of what parents 
can and cannot decide for their children, which will be fully addressed in the section on justified 
impacts on pediatric decision making.  Society attempts to balance allowing parents to make 
decisions for their children, as the legal decision maker and closest person to the child, but also 
ensure they are not placed in unnecessary harm.  
Another component of justice that should be addressed is that of just access to resources 
within the field of medicine.  The reason that justice is often excluded from discussions of 
guiding principles of medicine is that it can be held in conflict with the aspects of medicine that 
most are comfortable with and idealize, including love, mercy, compassion, and humanity.26 In 
spite of this, and the arguments made that medicine is only about serving patients and promoting 
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“the good,” there is no place in the world where a society is rich enough to provide all medical 
care needed or desired for all patients.  Throughout the field of medicine, decisions must be 
made every day about who has access to what resources. Decisions to utilize resources range 
from a specific intervention, have a longer stay at a hospital, and even benefit from the 
physician’s time.  The face of medicine has greatly changed and people have access to less care 
overall with insurance companies and medical institutions making cuts and utilizing cost saving 
strategies.27  These cuts and cost savings lead to the importance of justice within the medical 
world.  From a standpoint of justice, what matters is who gets what, not that distribution and 
regulation exist.28 To meet the standard of justice within medicine, the distribution of scarce 
resources should be both equitable and efficient with an overall goal of the most medical care for 
the cost. Additionally, specific to new technologies, there must be regulation and oversight to 
limit what is covered and what access individuals have to these new, typically expensive and not 
fully understood treatments.29 Justice has a secure place within medicine at this point to ensure 
that the patient gets a fair share, but not more, of the medical resources and that the social system 
gets its money’s worth.30 Justice is not the part of medicine that most in the field like to talk 
about, and many times they speak of the way things used to be, when in reality, justice is a 
central principle in medicine that must be taken into account into a shared decision making 
model. Overall concepts of justice and respect for autonomy can be applied to children, 
especially adolescents, in a meaningful way that ensures them access to a decent minimum of 
healthcare and overall improved equality.31   
 
5.2.3 Goals of Pediatric Medicine  
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 Providing medical care for children is not the same as treating adults, therefore the goals 
of pediatrics should be framed differently than those in adult medicine.32  The principles of 
medicine, beneficence, non-maleficence, autonomy, and justice, have been looked at in light of 
pediatric medicine and some of the different dimensions highlighted, specifically emphasizing 
the components that should be taken into account in both the formulation of the goals of 
pediatrics and the enhanced shared model.  The goals of pediatrics are different than adult 
medicine because within pediatrics, the child patient relies almost completely on adults.  
Specifically, the child relied on his or her parents, medical professionals, and society to define 
what is right and good for them, emphasizing the importance of all involved.33  A partnership 
exists between healthcare professionals, children, and families, emphasizing the need for shared 
objectives all with the child placed at the center.34  It is not evident that parents are always in the 
ideal position to make decisions for their children as they can have conflicting interests and 
typically heightened emotions.35  The goals of pediatrics are not only about the parents, as 
decision makers, the child patient, or the physician, but the relationship that they all must have 
together to advocate for and work to achieve the best interests of the child.  In order to 
adequately incorporate beneficence and non-maleficence into pediatrics, all relevant stakeholders 
must work together to not only promote the overall interests of the child, but also to protect the 
child from harm.36  They must both advocate for the child’s best interests, and do what achieves 
the most good, while additionally focusing on not causing the child harm, either in his or her 
current state or in the future.  These ideas bring up the principle of justice, as the communitarian 
interpretation of justice emphasizes the duties that the community has to the child, and vice versa 
once the child is old enough to do so, giving overall society impacts on the care of children.  
Children must have access to those therapies that promote their overall good and positive 
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outcomes.  The goal of the impacts of justice must be, like those from the principles of 
beneficence and non-maleficence, to promote the interests of the child and protect them from 
harm, while also doing what is many times, best for society.  Societal impacts shed light on 
another key goal of pediatrics, specifically that decisions must acknowledge not only the current 
interests of the child, but also the future interests.  The current and future interests of the child 
will be elaborated more in the following section as a critical goal of pediatrics that the new 
model must encompass and acknowledge in order for good decisions to be made in light of the 
tremendous advancements of genetics and neuroscience.  
Respect for autonomy, as the central principle of adult medicine also leads to goals 
within the field of pediatric medicine.37  When respect for autonomy is applied to children, it not 
only requires that parents weigh benefits and burdens to determine the best interests of the child, 
but more importantly that the child’s self-determination is acknowledged.  For adolescent 
children, it is crucial that their self-determination, decision making abilities, and overall future 
autonomy be acknowledged in order for them to appropriately develop into autonomous, capable 
adults.38  Adolescents, and all children, must be acknowledged as individuals and involved in 
decision making processes. Adolescents are challenging because they are closer to the 
development of autonomy, and should have more of a role and impact in decisions.  Despite this, 
even when the child patient is an adolescent, that does not mean that the wishes of the parents, as 
legal decision makers in most cases, should be ignored.  The final goal that is elaborated from 
the principle of respect for autonomy is that of the autonomy of the family.  McCullough argues 
that families as a unit have autonomy, which must be respected and held in balance with the 
future autonomy of the child.39   The balance of these two ideas and conceptions of autonomy 
respect and acknowledge the child as a person, facilitating their growth, and also give value to 
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the family unit. The goals of pediatrics include furthering the child’s best interests, protecting 
him or her from unjustified harms in regard to medical interventions, and showing respect for 
family autonomy.  These goals are central to the enhanced model of shared decision making that 
the later part of this chapter will describe and must be held as central components throughout 
pediatrics to ensure the best decisions are made for children, particularly in light of the new 
technologies provided and available to children.   
 
5.2.4 Promoting the Future and Current Interests of the Child 
One of the goals of pediatrics that deserves extra attention is the idea that the promotion 
and protection of the current and future interests of the child should be a central goal throughout 
pediatric medicine. New technologies pose unique issues to this goal due to the tremendous 
amount of uncertainty and inability to fully assess and understand future implications. More 
specifically,  these new developments and therapies make it extremely challenging to  really 
know what will happen with different interventions, that have unknown impacts on the child 
both at the time the decision is made, and those interventions that could possibly have effects 
that last the duration of the child’s life.  Respecting the current and future interests of the child 
emphasizes the importance of properly balancing the many influences on decision making 
processes, as many times different stakeholders have conflicting opinions or roles in the process.  
Within pediatric medicine, there are additional levels of the duty and responsibility of 
physicians, strongly connected to the goals of the field of medicine and pediatrics.  The 
professional goals of pediatrics are different for pediatricians as they must work with the parents, 
in many cases more than their actual patient, while upholding, balancing, and sometimes arguing 
for the child’s best interests.40  In pediatrics, pediatricians and parents both are crucial to the 
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selection of treatments for the child, as co-fiduciaries.41  Pediatricians have an obligation to 
protect and promote the health-related interests of the child and parents also have a fiduciary 
obligation to promote and protect the non-health-related interests of their child, who is the 
patient.42  The doctor-patient relationship is a focal point of medicine in general, however this 
becomes more challenging within pediatrics when the parents are added to the model, and both 
parents and physician are simultaneously working to do what is both right and best for the child, 
which does not always go together.43  The fact that there is some conflict in the roles makes is 
important that the goal of promoting the current and future interest of the child is a fundamental 
goal upheld by the enhanced model.  Children are in a unique position in that they are 
continuously developing and have tremendous potential and hopefully long lives ahead of them, 
which cannot be ignored or forgotten.  Decisions cannot be made for the child when he or she is 
a child that would undermine their future autonomy or interests, taking away decisions and 
choices that they should be able to make at a later date.  This will be reviewed further with the 
application of the enhanced model as it is a central component to the process and a goal that must 
be held highly in the process.  The enhanced model must respect the autonomy of the family, the 
future autonomy of the child, and the overall promotion of the current and future interests of the 
child, which are different than those of the parents or decision makers.44  Each of the goals 
derived from the principles of medicine will have an important role in the model because each 
must be met in order for the model to be acceptable and actually facilitate decision making with 
new technologies.  
 
5.3. Facilitated Shared Decision Making 
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 Shared decision making is the most common result of decision making processes 
throughout medicine.  In practice, decisions are typically reached through a shared process 
involving patients and physicians, both when the patient does and does not have the capacity 
necessary to make decisions.  Individuals do not often make decisions on their own and there are 
often many involved in the process.  Physicians work with patients, who frequently look to 
family or friends for guidance and assurance during the decision making process.  Despite being 
accepted, advocated for, and commonly utilized, there is not a standard, accepted definition of 
shared decision making other than it being a shared process to make medical decisions.  Shared 
decision making does not facilitate or guide the relevant stakeholders in the process or guide 
them to make the best decisions, it merely says that all relevant stakeholders should share in the 
process together to come to the best decision.  This is somewhat easier to apply to adult patients 
who are able to determine who the relevant stakeholders should be in a specific instance and 
involve them in a way that is meaningful to them.  It is however much more challenging with 
children as the model of shared decision making as it is currently elaborated does not apply in 
the same way nor does it accommodate the increasing complexity of the decisions that arise due 
to advancements in genetics, neuroscience, and pediatric research trials.45  In this section, the 
enhanced shared decision making model will be developed that accommodates all necessary 
roles and the challenging decisions of these growing fields.  This model, specifically a facilitated 
shared model, places an emphasis on the stewardship of the child and on a communitarian 
approach to parental decision making. 
 
5.3.1. Current Decision Making 
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 The current models of decision making utilized within pediatrics do not support parents 
in their role as decision maker nor does it guide the appropriate involvement of the physicians 
and child in the process, nor does it accommodate the challenging decisions of the rapidly 
growing fields of genetics, neuroscience, and pediatric research.  Shared decision making is the 
model that is most advocated for throughout the field in order to address the fact that there are 
several relevant and important stakeholders, however there is not a consistent understanding, 
definition, or interpretation of this model for pediatric medicine that accommodates all necessary 
roles or the great levels of uncertainty, privacy, and future implications of the technological 
advancements Before developing the enhancements proposed to the shared model, the current 
understandings of shared decision making will be elaborated, including the different 
interpretations of and challenges to shared decision making in practice.  It will then be reviewed 
how parents make decisions for their children, what they consider and find valuable during those 
decision making processes,  and some of the limitations and challenges that they face.  There are 
many barriers to decision making in pediatric medicine that must be addressed as enhancements 
and support tools will be elaborated at the end of this chapter.  It is additionally important to 
ensure that the new model incorporates the details and information that parents find important. 
Pediatric decision making is challenging necessitating a modified shared decision making model 
that is meaningful to all involved in the process.  
 
5.3.1.1 Shared Decision Making 
Shared decision making (SDM) is the most common decision making model utilized to 
make medical decisions in practice.46  SDM is advocated for instead of both the strict autonomy 
and paternalistic models by many European and Western countries as well as many medical 
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organizations including the American Medical Association, American College of Critical Care, 
the American Academy of Pediatrics, and the American College of Physicians.47  Despite this 
advocacy and widespread appeal, there is not a common definition of shared decision making 
and much confusion over what it means.48  Even research focusing on shared decision making 
lacks of a consistent definition, however much agreement exists that this is a problem for SDM 
in practice and some criticize it as nothing more than a name for the patient physician 
relationship.49 The lack of a definition leads to a different process, inconsistent application of the 
model, and different levels of satisfaction among both patients and physicians.  
The President’s Commission argues that it is the physicians’ role to help the patient 
understand the objective, medical situation and courses of action available, and the patient then 
conveys his or her wishes, adding the personal and subjective elements, both sharing in the 
process.50 Some of the major and primarily agreed upon characteristics of shared decision 
making include the fact that both the physician and patient are involved in the process, they share 
information with each other bi-directionally, they both take steps to participate in decision 
making processes by expressing preferences, and a decision is then made where they both agree 
on the proper course of action and next steps.51  In a shared decision-making model, information 
is shared in both directions rather than one sided, like paternalistic of patient driven models 
would be.  At a minimum, physicians must provide the patient with all information needed to 
make a decision, specifically information about proposed treatment options or interventions, the 
benefits and risks of each and potential risks or impacts to the patient's psychological and social 
health. The patient additionally has requirements in this process and must provide the physician 
with his or her preferences, beliefs, and knowledge of his or her illness ensuring that the patient’s 
preferences are taken into account and that he or she can make informed decisions.52 Ideally the 
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shared model is based on the medical facts, a basic understanding of the patient and his or her 
values, beliefs, and autonomous wishes (if the patient is not making his or her own decisions), 
and a general idea of what is best for the patient both personally and medically.53  Overall the 
shared process should be the mutual collaboration of patients and physicians that is different 
depending on the patients and decision to be made, however there is a need for some structure to 
guide this process and ensure that the patient is able to participate to the degree he or she wants 
to, and fully able to exercise autonomy and not subject to a paternalistic decision of the 
physician.54  Shared decision making can be thought of as a balance between paternalism and 
pure autonomy, described by A. Kon as a pendulum swinging back and forth between the two 
extreme models.55 
In addition to the balance of roles and sharing of information, the amount of information 
shared varies greatly between decision making models and specific scenarios. Typically the 
focus is on the minimum of information that must be shared, however there are additionally 
outside boundaries that should be mentioned, and bring into consideration issues of justice. 56  
The amount of information that is shared is almost infinite, in that the provider could always tell 
the patient more or teach him or her more. However in practice, there are outside constraints and 
restrictions such as time and money, both of which are not infinite. Shared processes, including 
more discussion and deliberation to come to a consensus, are likely to take more time than 
models that are more paternalistic or even patient driven. It is up to the physician to work with 
the patient to navigate and enable him or her to be a decision maker with the appropriate level of 
involvement with the correct amount of information.  This becomes challenging when the patient 
is a non-autonomous child, and parents are added to the relationship, there are additional 
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emotional barriers to comprehension, the patient is not always directly able to participate as he or 
she would in adult medicine, and time and money are just as limited.57  
Typically many treatment options exist, and many times there is not one option that is 
superior or clearly in the patients’ best interests, making shared decision making very 
beneficial.58  Treatment decisions should result in the most desirable outcomes for the patient, 
which requires active engagement from both the physician and patient so both parties understand 
what is valuable and desired.59  This process works well in adult medicine, where the patient can 
work with the physician to navigate care and participate as little or as much as they want to, 
however this is not possible with children in the same way.  Children are not and have never 
been autonomous with fully developed values and beliefs of their own distinct from their family.  
The shared model, as described, does not immediately allow for the child to be incorporated into 
the process because by adding a child, a non-autonomous agent, the roles of all involved are no 
longer clear.60  There are many challenges to shared decision making in practice, the biggest of 
which is that there is not a consistent definition or formulation of the model that establishes the 
appropriate boundaries and levels of involvement of all parties.  Additional barriers to shared 
decision making exist for all involved in the process – patients, parents, and physicians.  The 
child patient is not of the legal authority to make his or her own decisions, and parents have 
tremendous stress and emotions.  Physicians many times worry about time and do not know how 
to engage seemingly disinterested patients and convey complex information.61  All of these 
challenges lead to very different and inconsistent applications of the shared model throughout 
pediatrics.  
Shared decision making is considered the ideal model for pediatric decision making and 
advocated for by most groups and organizations, however without a consistent and clear process 
 187 
 
specific to children and the goals of pediatric medicine, it is impossible to be used in a 
meaningful way consistently yielding the best results for children.62  The quality of care heavily 
relies upon the decisions that are made as the outcomes of the decision making process, making 
these processes a crucial and central component of pediatric medicine.  Physicians must disclose 
to patients and parents enough detailed information about all options without bridging into 
territory where they are spending too much time with one patients.  Patients and parents in 
pediatrics must additionally cooperate and participate in the process, being honest about their 
opinions and beliefs, enabling them to be addressed and incorporated into decisions. There is a 
need for a well-defined shared decision making process specific to pediatric medicine that 
incorporates the child, parents, and physicians in an appropriate manner and accommodates the 
challenging ethical dimensions of the emerging technologies and developments of pediatric 
medicine.  
 
5.3.1.2 How Parents Make Decisions for Children 
Each day parents make treatment decisions for their children, many times without the 
involvement of the child.  This is not always a negative, as many times children are too young or 
incapable of being involved in the process, placing parents in challenging positons. Each person 
values and rates a given therapy in a unique way and has different outcomes that they view as 
acceptable or negative. This carries over into pediatric decision making in that all parents weigh 
impacts differently and think about unique elements when making challenging decisions.  The 
way in which parents make decisions currently in pediatric medicine is important to a new model 
because the things that they value and are impacted by shed light on areas that can be improved 
in the enhanced model.  Parents make decisions for their children in different ways as no two 
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people will weigh benefits or burdens in the same way nor will they understand information 
presented to them the same as another or even as the person presenting the information.63  When 
making decisions, it is extremely unlikely that parents make the decisions alone, without the 
involvement of others, leading to a shared model in almost  all instances.64  The specific 
enhancements to the shared decision making model will be elaborated in the following section, 
but first it must be understood what impacts parents’ decisions and the overall decision making 
process currently in pediatrics.  Parents take many things into consideration when making 
treatment decisions for their children such as their own personal experiences or beliefs, the 
situation and availability of options, and ideally the desires of the child, if relevant.65  Parents 
struggle to balance all of the influences and appropriately include their child in the decision 
making process.66 Challenging decisions are faced each day in pediatrics and parents must 
balance many influences in the decision making process with the complex information, treatment 
side effects, and the probability of benefit and burden.67  Parents work closely with physicians 
during this process in a bi-directional share of information, however, there are many outside 
impacts such as family, ranging from other children to extended family and including not only 
their opinions but also potential impacts that the decisions will have on them.68  Parents can 
additionally be impacted by their religion, the internet, social media sources, and support groups 
with parents in similar situations.69   
 In medicine, most medical problems can be treated in numerous ways, each with 
potential benefits and burdens, and many times no objective best treatment, leading to 
complicated decisions.70  These decisions can be very challenging for parents and despite their 
desire to be involved, they are not always included in a way that is meaningful to them or in a 
way that facilitates the best overall results for the child.71  Cox et al., found that parents felt ill 
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prepared to participate in decision making processes and noted high levels of stress and anxiety 
throughout the process, only suggesting therapies or interventions 9% of the time.72  Many times 
parents were involved in the decision making discussions with physicians but not necessarily 
meaningful deliberation processes.73  Passive participation is very common in pediatrics and in 
many instances parents rely on physicians heavily for guidance and even the selection of 
therapy.74  Parents routinely ask physicians what they would do if they were in the shoes of the 
parents, specifically what decisions they would make and why.  They often rely heavily on them 
for guidance and assistance throughout the decision making process.  Cox et al found that parents 
who were more involved in the processes were those with fewer outpatient visits in the past year 
compared to those who had more.75  On the contrary, it was found that on the inpatient side, 
parental participation increased with prior hospitalizations.76  The influence of prior hospital 
experiences may reflect parents’ growing understanding of their child’s illness, feeling 
comfortable with decision making processes, and with the overall medical setting. It may 
additionally emphasize that parents are involved in the basic care at a high level when it is not 
burdensome, specifically their child goes in for routine and regular visits, but once complexity 
increases, there is a point where knowledge barriers increase, and participation decreases.  It then 
picks back up with the increase of hospitalizations, emphasizing that parents have now become 
familiar with and accustomed to this complicated information and environment. This difference 
shows that parents want to be involved in decision making processes for their child’s care in a 
way that is meaningful to them and they are capable, but that there are barriers to work through. 
Physicians need to be able to work with parents in both settings from a diversity of backgrounds 
and prior experiences to elicit participation in the decision making process.  
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Beyond participation, there are many barriers in the decision making process for parents 
including the complex information, difficulties understanding all details, subjective elements of 
benefit and burden, uncertainty and unclear results or outcomes, language barriers, health 
literacy levels, education, stress, emotions.77  Physicians and parents influence each other 
throughout the decision making process, and these external factors not only impact the decisions 
that are made, but also how they are made and the entire decision making process.78 Decision 
making processes in pediatrics are based on the relationship between parents and physicians, and 
the child if possible.79 It is crucial that this relationship is formed to enable all to work together 
appropriately and share information openly and honestly. Many times parents are not 
comfortable asking questions and worry they may be seen as incapable of making a decision or 
taking care of their child, but there is a great knowledge gap between physicians and parents in 
almost all instances.80 Cox et al found that there was less deliberation between physicians and 
parents when the parents were college graduates and much more involvement when the parents 
were not of a college education.81  Despite this, emotional barriers many times impede education 
and even if parents are of the correct education level, there are still challenges to making 
decisions for one’s own child.  Some additional barriers that parents face include financial 
impacts and restrictions, access to a telephone, proximity to the healthcare facility, and the 
availability of the physician.82 These barriers will be more fully elaborated in later sections with 
suggestions to overcome them in the enhanced model.  Parents value many things, but overall 
they want to participate in decisions, and do what is best for their child, there just needs to be a 
way for this to occur83 There is a need for enhanced communication and education, different 
formats of informed consent documents, and physicians and parents to form a good relationship 
in order to work together in a productive, shared, and open way.84   
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5.3.2. Facilitated Decision Making and Proposed Roles 
 Concepts from adult medicine cannot be easily applied to pediatrics or the child-
physician-parent relationship triad, requiring a unique decision making model that 
accommodates the roles and relationships and is able to address the enhanced ethical issues 
associated with new technologies.85  There is a great need for an enhanced and defined shared 
decision making model that is specific to pediatric medicine that accommodates the complex 
decisions associated with emerging technologies within the fields of genetics and neuroscience 
that are available.  Shared decision making, as the common model executed in practice in 
pediatrics and model that in theory encompasses all the roles, is used as the foundation for the 
enhanced model.  It is crucial that the modified version of shared decision making addresses the 
goals of pediatric medicine and elaborates who should be involved in the decision making 
processes and how they should be involved.  This section will develop the specifics elements of 
the facilitated shared decision making model specifically the evaluation of the child, who is the 
patient, the review and classification of treatment options and decisions to be made, the proposed 
roles of physicians and parents in addition to that of the child, and the justified impacts of outside 
stakeholders, such as society.  
  
5.3.2.1 Evaluation of the Child 
The first step in the enhanced, shared model is to evaluate the child and identify how he 
or she can participate in decision making processes. It is important that the child participate since 
they are the patient and must be empowered as individuals, making it a crucial step that they are 
evaluated first and their role in the process is established and clarified to all in the process. The 
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child must be evaluated first and foremost in the decision making process in order to include him 
in a meaningful way.  Children do not have autonomy or the legal right to make their own 
decisions, but they are at a stage in life where they are developing the capacities needed for 
making medical decisions and including them has many benefits.  These benefits include better 
medical results, empowering the child as an individual, enabling him or her to learn to make 
decisions, help them feel responsible for own care, show them that they are valued in the 
process, and overall enable them to begin to take control of his or her life while approaching 
adulthood.86  Children will eventually, in most cases, be able to make their own decisions 
eventually, and incorporating children at a young age leads to not only better results when they 
are a child and with regard to a specific medical decision, but leads to more ideal outcomes later 
in life. The child’s involvement in the process should be based on an assessment of their 
developmental capacities, not merely age which is done in many places.  Buchanan and Brock 
discuss that there are general ages associated with specific capacities needed for decision 
making, but that they are merely estimates and there is a great deal of variation among children.87 
All children are different so it is important that each is evaluated by a clinician to determine how 
they can be involved.  
Different levels of capacity are needed for different situations and decisions.  Capacity is 
decision specific therefore physicians should evaluate a child’s capacity to give consent in light 
of the decision to be made.  It is essential that the person who will be evaluating the 
developmental capacities, typically the clinician but sometimes a psychologist or psychiatrist, 
understands the nature of the illness, proposed treatments and alternatives, and risks associated 
with all options including the refusal of treatment.88 He or she should begin the process with a 
discussion of the illness or disorder being treated to ensure a complete understanding and 
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additionally that it is taken into account with the evaluation.89  Developmental capacities that 
should be evaluated include the child’s ability to understand information, make other decisions, 
and overall act voluntarily and without the complete control or influence of their parents.90  
Understanding typically refers to the child’s ability to recall information that has been presented 
or explained to them, while making decisions refers to how this information is used to negotiate 
between available alternatives.91  It is important that the child not only understand the options but 
also that they are able to use this information in a meaningful way in relation to the options. 
Effective decision making involves identifying alternatives, weighing benefits and burdens, 
making a decision, and then evaluating the effectiveness of the decision.92  Additional qualities 
that should be taken into consideration during the evaluation include the ability to self-regulate 
and think about the future, their susceptibility to peers and family, and overall risk perception.  
Children should be able to understand not only the treatment, but the general concepts of benefit 
and risk.  By judging how the child perceives risk and what he or she understands it to be, 
specifically in relation to his or her future, a lot can be judged about his or her decision making 
abilities. Additionally, it is important that the child be able to make decisions for him or herself, 
without the persuasion of peers or family members.  This does not mean that the child must not 
interact with his or her parents, or ask their opinions; children gain much of their overall 
opinions and values from their parents, so it is not necessary that their goals be completely 
segregated, however the child must be able to make a decision without coercion.   
The most challenging group of children to assess is adolescents as they are in an 
undefined place and can likely play a much larger role than other age groups in decision making 
processes.  There is a great need to determine the developmentally appropriate involvement of 
adolescents as they approach adulthood and are in the process of gaining capacity rapidly.93  
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Young children may have limited decision-making abilities and not normally meaningfully 
participate, however adolescents have higher levels of decision making capacity and deserve 
greater levels of control and input into treatment decisions.  Adolescents need to be the stewards 
of their care in any way that they can; allowing them to participate in treatment decisions 
acknowledges their self-determination and helps enhance their developing capacities to make 
decisions, facilitating their growth into autonomous adults.94 Assessment of the child is not easy, 
which it why is does not happen in all cases currently.  There are many challenges to overcome 
when physicians assess and evaluate the capacities of a child, especially when trying to do it at a 
young age when they are continuously changing.  At a young age the capacities to respond, 
interact, or process information would not be present in a child that is developing at a normal 
pace, calling a need to give additional attention to those children who are not developing at that 
standard pace.95  Many times children have difficulties understanding what is being asked of 
them by the clinician, making it almost impossible to give a meaningful answer, inevitably 
leaving the physician in a difficult place attempting to assess the child on poor representations of 
true capacities.96  Assessment must take into account the full range of the child’s development, 
not only specific traits, including the child’s social and emotional capacities, cognitive abilities, 
language skills, social functioning, and environmental impacts including family, culture and 
beliefs.97  Capacity assessments cannot be based solely on the individual belonging to a specific 
group, such as being a child or age.  There should be a structured approach to assessments of 
capacity to yield more accurate and significant results.98  Despite challenges, it is crucial that the 
capacity of the child be gauged as the first step.  The child’s role may vary depending on the 
circumstances, such as potential risks and benefits, and the availability of alternatives, however 
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they, as the patient, must be included.99  Once the child’s capacities are determined, their 
involvement in care should then be identified to the highest degree that their capacities allow.  
 
5.3.2.2 Evaluation of Treatment Decision  
            The next step in the facilitated decision making model is the classification of the 
treatment decision to be made.  In order to appropriately structure the decision making model 
and proper involvement of stakeholders in addition to the child, the specific decision must be 
understood and then labeled.  Shared decision making is a powerful concept when applied 
appropriately and is especially valuable when there is more than one reasonable option.100 
Whitney et al classifies two basic types of decisions, (1) those with no reasonable medical 
alternatives, and (2) those with several reasonable options, emphasizing the need for shared 
decision making in the second type.  The second category of decisions deserves extra attention 
with regard to new technologies as the number of options continuously increase.  For this 
dissertation, the enhanced shared model will be utilized when more than one reasonable option 
exists primarily because decisions without alternatives are not as complicated or complex. The 
options do not necessarily need to be multiple therapies as the refusal of therapy is considered a 
valuable and reasonable option in many instances.  A major component of decision making is the 
elaboration of all possible options along with their possible outcomes.  When there are two or 
more reasonable choices, determined by evidence, the physician must encourage involvement of 
the patient with thoughtful and probing questions to help him or her work through uncertainty 
and reach a decision.101  When there is not apparent agreement, or alternatives have unclear 
benefits and burdens, or unrealized potential due to the new technological breakthroughs, a 
facilitated decision making process is required.  Depending on the specific case and situation, the 
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decision will fall somewhere on the continuum of shared decision making, described by A. 
Kon.102    This continuum ranges from completely patient driven to paternalistic, physician 
driven, connecting the level of involvement with the complexity of the decision. Shared decision 
making is described as a continuum from autonomy to paternalism, with models on the spectrum 
including patient or agent driven, physician recommendation, equal partners, informed non-
dissent, and physicians driven.  Patient and physician driven represent pure autonomy and 
paternalistic models and are not shared processes, led by either the patient or physician 
respectively, therefore no longer included in this analysis as SDM is the desired outcome for the 
pediatric scenarios elaborated.103  The other three options lead to the patient, or patient and 
parents when dealing with children, having more influence and control, an equal partnership 
where all work together, or the physician having more say and a larger role in the process.  These 
correlate directly with three possible outcomes of the decision making process that Whitney 
discusses, where the patient may (1) accept the clinician’s recommendation, leading to a 
clinician directed decision making model; (2) say no to the physician and the physician can 
reluctantly accept, leading to patient controlled decision making; or (3) the clinician may insist 
on his or her recommendation, leading to what Whitney refers to as the clinically controlled 
decision making model.104 Weir et al. also discusses models that parents use with neonatologists 
when making decisions about life saving measures and discusses 1) an expertise and 2) a 
negotiated decision making model.105  The expertise model is where the provider shares his or 
her “expert” opinion and then the parents are left to agree or disagree with this recommendation.  
In contrast, the negotiated model involves more collaboration where the parties work together to 
make decisions about treatment.  The combination of these concepts will be utilized to classify 
and review decisions and then determine the appropriate level of involvement of all stakeholders.  
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It is important to note that all decisions cannot easily be classified as decisions since all 
patients are different, and each scenario has different elements or important factors to consider, 
however the decisions can be classified when the patient, situation and alternatives are taken into 
consideration.106  Specifically, all decisions of whether or not to use a brain scan to determine if 
the child has ADHD cannot be made in the same way, using the same type of shared decision 
making, as the capacity of the child has not been taken into account, nor have the circumstances 
of the family or any outside impacts.  However, by focusing on the child patient and treatment 
options, it is possible to classify the decision to them determine roles and how they should be 
involved in decision making processes.  A good physician knows that they must explain things to 
the patient in ways meaningful to them.107 By identifying the type of decision to be made, 
specifically if there is more than one reasonable option, and understanding that there are 
different, yet specific types of decision making processes that can occur, it is possible for the 
roles of the physicians and parents to be added to the decision making model in addition to the 
already determined developmentally appropriate role of the child.    
 
5.3.2.3 Proposed Role of Parents and Physicians  
 The next component of the enhanced shared decision making model is the involvement of 
the parents and physicians.  After the level of involvement of the child has been determined 
based on his or her appropriate capacities and the options and decision to be made has been 
evaluated and placed along the spectrum of shared decision making, processes can begin with the 
appropriate level of involvement from parents or guardians and physicians, in addition to the 
already determined role of the child.  In order to ensure that good decisions are made for children 
and potential harms are avoided, parents and physicians must have a role in the decision making 
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process focused on the goals of pediatrics, including the furthering of the current and future 
interests of the child.108  Balancing the goals of pediatric medicine with the duties and 
obligations of both parents and physicians is challenging as many times their roles, 
responsibilities, or opinions may conflict, making it necessary that they work together in a 
structured way with the child held at the center. Some physicians tend to use only certain 
decision making approaches with parents for decisions, however it is crucial that it is not only 
based on the decision or physician’s common approach, but that it is also based on the family, 
child, and their preferences for involvement and overall values.109  The goal of these interactions 
and decision making processes must be for the patient, family, and caregivers to work together in 
an ongoing process of education and support enabling collaborative decision making, and ideally 
mutual influence to work through the evaluated decision and proposed options.110   
 Relationships between decision makers are crucial to the decision making process. 
Parents and physicians, as co-fiduciaries in the process, must work together and have a level of 
mutual respect and trust.  Additionally the relationship between parents and their children is 
central to the process as it can impact the way decisions are made, how empowered the child 
feels, the child’s views, and inevitably the decision that is made.  The parent-child relationship is 
an important aspect of pediatric decision making processes.  Collaborative decision making 
between parents and children provides a foundation for the child’s transition to become a 
decision maker for him or herself and gaining decision making independence, which is gained 
gradually.  Parental influences greatly impact treatment decisions of younger children, but also 
young adults and adolescents as parents are often sources of support and advice, even as children 
gain independence.111  Facilitating the parent child relationship is crucial, and enables parents 
and the child patient to work together in a meaningful way, identify decisions that are best for 
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them and their future, and additionally continue the development of the child’s autonomy.112  
Parents should not override the decision or opinions of their children but enable them to be 
individuals and develop into autonomous individuals.  This is why a central role for physicians 
should be to help parents determine when and how to include the child, bringing them into the 
process when it is appropriate.113  This determination is initially made during the evaluation of 
the child at the beginning of the process, however throughout the process physicians should 
ensure that the child is included and advocating for his or her opinion when necessary.   
Physicians have many important roles in the decision making process, requiring that they 
be open and honest with parents and child.114  There are instances where full honesty may not be 
optimal for care or outcomes, however it should be the goal both furthering the trust and 
relationships present and additionally empowering the decision makers to make decisions on 
accurate information.  Physicians must uphold the family unit and support the parents, while first 
and foremost serving the child’s best interests.115  Physicians not only have to make an accurate 
diagnosis and outline available treatment options, they also must communicate with the patient 
and their family, ensure understanding, and strive to empower parents and children to make 
decisions.116  Most decisions should be made within a shared process where the physician 
provides all medically relevant and applicable options and work with the patient to negotiate the 
options and make a choice.117  For value neutral decisions, physicians should be aware of patient 
preferences and beliefs and include them when possible and practical.118  Additionally they 
should be aware of their own opinions and potential biases that could be impacting decisions.  
Despite this, in some cases, it may be appropriate for the physician to bear more of the decision 
making burdens, however they still must be guided by the values of the child patient and parents 
and keep them involved in the process.119  Additionally, when parents ask physicians what he or 
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she would do, as they do in many cases, the physician must consider the patient’s perspective 
and ensure that he or she is neither intentionally or unintentionally coercive in the answer.120  
Finally, physicians can, and should, refuse parental requests for therapies that pose substantial 
harm to the child with minimal benefit.121  Parents, physicians, and children, when possible, must 
work through the potential burdens and benefits together and ideally select the therapy that is 
most beneficial with the least harm that promotes both the current and future interests of the 
child. Many times a clear option is not available, or benefits are minimal in all instances, making 
the expert opinion and role of the physicians crucial to the decision making process.122  
Balancing the roles of parents and physicians with the role of the child is challenging in 
practice, making it necessary that the processes are  focused on the specific decision that is to be 
made, on the unique elements and believes of the parents and child, and overall that the decision 
be fully evaluated.  All decisions of a certain type cannot be handled the same way as different 
parents want and need different levels of involvement.  Additionally, physicians cannot work 
with all parents in the same manner for all decisions that must be made as the child should be 
incorporated into the process based on the decision to be made and the child’s specific capacity, 
which must be evaluated on the basis of the decision.  For instance, all decisions about how and 
when to utilize whole genomic sequencing should not be physician led decision making 
processes, although it may be ideal model in some situations.  It is crucial that the options be 
elaborated first, in order for the parents and physicians to work with the child and overall 
promote the child’s current and future interests while maximizing benefits and avoiding potential 
harms.  Decisions must not only respect the child as a person but also the fact that they will one 
day be an autonomous adult and are part of a family that has autonomy. Decisions also should 
take place within the continuum of shared decision making, and not at either end of the spectrum 
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being led completely by either the parents of physician.  It is true that in some instances more of 
a role will be argued for with regard to one of the parties, however it is not a consistent 
recommendation nor should the decision even completely fall to one of them.  Overall parents 
and physicians have central roles to the decision making process in pediatrics, and by first 
looking at the capacities of the child and identifying an appropriate developmental role, then 
fully exploring all options in a collaborative process, all can work together, exercise their duties, 
and achieve the goals of pediatric decision making.  
 
5.3.2.4 Justified Impacts of Outside Stakeholders 
Beyond the parents or guardians, physicians, and child him or herself, there are 
additional, outside organizations or groups that have impacts on the decision making process 
within pediatric medicine and therefore must be addressed as part of the model.  These outside 
impacts are justified in many instances and further the goals of pediatric medicine, however in 
some instances, they do not provide benefit to the situation and potentially cause problems.  
Depending on the situation, there are many impacts on the decision making process, some of 
which directly parental decisions, such as extended family, the child’s school, other parents, 
community members, pediatric societies, and even society as a whole.123  These outside impacts 
must be held in balance with all of the relevant stakeholders in the process but can at times be 
challenging for parents to deal with and decipher as helpful or burdensome.  Parents are free to 
incorporate the views of extended family or friends, and reach out to online support or 
community groups, however those external sources do not have explicit roles in decision making 
processes other than when parents seek to consult them.  Pediatric societies or community groups 
have a right and many times duty to advocate for the interests of children overall, but their 
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actions do not directly impact specific decision making processes between parents, physicians, 
and children addressed here. They can however impact policies, such as leading to the expansion 
of screening panels.  Advocacy groups are largely responsible for the great variance in panels 
among states due to groups working to add a specific disorder in one place.  There are many 
impacts that these groups can have, many of which can be positive, however they must be 
evaluated by parents before incorporating their guidance into treatment decisions.   
In addition to academic or medical societies and advocacy groups, society as a whole has 
a stake in the care of children.  Children will eventually grow into adults, who contribute to the 
community and society at large, and may in some instances, impact or restrict individual decision 
making processes.  There are many legal dimensions to society’s role in medical care, and 
overall their intentions are not apparent due to somewhat contradictory regulations and rulings 
that exist throughout the country.  Society should work to further the goals of pediatrics, 
specifically prevent children from undue and excessive harms, while enabling parents to work 
with physicians and make treatment decisions that are in the child’s interests. However, not all 
measures that have been taken in the past or regulations that have been put in place accomplish 
that.  Many times the state takes too much control of situations, while in other instances not 
giving enough support or guidance, leaving the child vulnerable to harm and potential negative 
impacts from parents. It is true that when parents, as the legal decision makers, are unable or 
unwilling to make good choices for their children, the state can step in and many times even 
appoint another decision maker for the child, but this should not be a common occurrence and 
many times is not what happens even in cases many would argue it should.124  Courts are 
sometimes unduly intrusive into medical decisions, but many times they are justified to 
intervene, and even more so with children.  Depending on the situation they many times do not 
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step in soon enough, if at all, placing the child at risk. There is a very delicate balance that must 
be upheld to protect the child and also enable parents to be parents.  Parents know the child and 
are typically given a great amount of authority to raise their children in a way that is meaningful 
to them, and acknowledges their values, beliefs, and goals for their children.125  There is a line 
however, of things that parents are not allowed to do, which is in place to protect the child from 
harm.   
One specific instance of societal guidelines created for parental decision making are the  
Baby Doe Regulations.126 These regulations elaborate that the withholding of medically 
indicated treatment cannot be done unless (1) the infant is chronically and irreversibly comatose; 
(2) the treatment would merely prolong dying and not be effecting to correct the infant’s life 
threatening conditions; or (3) the treatment would be virtually futile in terms of the survival of 
the infant or the treatment itself would be inhumane under such circumstances.  The Baby Doe 
Regulations were created in order to protect young children and ensure that care is given to 
infants regardless of parental decisions, however it is not clear if these regulations are actually in 
the child’s interests.127  These regulations do not give enough leeway for physicians and parents 
to weigh options and potentially even legally make the best decision that is in the child’s 
interests.   On the other side of the spectrum, Baines discusses that many US states allow for 
parents to refuse vaccinations for their children, despite the proven and acknowledged medical 
evidence that it is in their best interests, emphasizing that parents have a right to raise their 
children as they see fit.128  The view on vaccinations seems to be contradictory to that of the 
Baby Doe regulations.  Both emphasize that society has an impact on the medical treatment 
decisions made for children, however there is a need for a more consistent approach, especially 
with the developing technologies of genetics and neuroscience, both of which potentially have 
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societal impacts and many ethical issues in the near future.  Overall there are outside stakes on 
parents as decision makers that cannot be avoided, so parents and physicians must be aware of 
them and ensure that they take them into account when necessary, but work to avoid those that 
may negatively impact the decision making process or inhibit the crucial triad of parents, child, 
and physician in working through treatment decisions and promoting the interests of the child.  
 
5.3.3. Enhancement 
 The basic process for decision making in the new enhanced shared decision making 
model has been outlined, beginning with the evaluation of the capacities of the child to determine 
his or her appropriate involvement, the assessment of the decision to be made, the determination 
of the roles of the parents and physicians in the shared decision making continuum and the 
potential for outside impacts.  This section will look at proposed enhancements that will enable 
decisions to be made in a manner that will properly involves all stakeholders and help facilitate 
the relationship between the child, physician, and parents or guardian.   These enhancements are 
consistent with the goals of pediatric medicine, furthering the current and future interests of the 
child, specifically with regard to new interventions of genetics and neuroscience.129  There are 
many challenges to shared decision making including limited parental health literacy, a lack of 
clinician training in the use and facilitation of shared decision making, and a lack of resources 
and decision aids for parents and children to use in the decision making processes 130 This section 
will look at the proposed enhancements including structured education for physicians, parents, 
and children, discussions of justice and access to resources, and the creation of tools to enhance 
communication between physicians and parents, and the overall understanding of parents.  The 
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utilization of tools to facilitate the decision making process are crucial to its overall success as 
this will be the way that this model can be placed into practice in the field..  
 
5.3.2.1 Education of Physicians, Parents, and the Child    
 Education is a very large part of an enhanced decision making model in order to ensure 
that physicians have the necessary skills to not only facilitate a shared decision making process 
but also enable parents and children to participate in the process and be validated as decision 
makers. The shared process is even more important in light of the new technologies that are not 
fully understood, come with greater levels of uncertainty, and need higher comprehension levels 
to make decisions and engage in the overall process.  Physicians, or  medical team members, as 
consistent and experienced members of the medical world, should bear the burden of facilitating 
the model and educating parents and children on their proper involvement because parents 
cannot be expected to know this.  There are many skills, such as communication, interviewing, 
the ability to focus on key concepts, and the ability to incorporate teach back into discussions 
with parents, that many physicians have that enable them to have strong relationships with 
parents and children that facilitates shared decision making. 131   These skills that are very 
beneficial to decision making processes are not present in all physicians.  These skills, currently 
not taught in depth to providers, should be taught to physicians to strategically place them in a 
position to succeed and inevitably work to engage parents to make the best decisions for children 
and promote the goals of pediatric medicine.132  Physicians need strong communication skills 
that can elicit the patient’s complete concerns and additionally strong listening skills to be 
partners with the parents and child and ensure they do not inappropriately take too much control 
in the situation.133  Additionally, providers need to be able to determine, after full evaluation of 
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all treatment options, where the decision falls on the shared decision continuum and the level of 
communication the patient and family feel most comfortable with.134  It is important that the 
provider be able to tailor the decision process to not only the decision but the parents and child, 
and additionally provide emotional support.135  Physicians need to know what method to use in 
different circumstances and be able to elicit details and communicate with families and the child 
patient.136A recent study found that only 28% of physicians elicited the patient’s complete 
agenda during decision making processes or overall courses of treatment.137  Physicians need to 
present the patient with balanced reviews and how he or she can clarify and apply their own 
preferences to the decisions to be made in a meaningful way.138  Specifically, medical 
practitioners cannot just present the options and medical details, they must ensure that the patient 
understands in a way that incorporates their opinions.  For example if a possible outcome is that 
the child would need a wheelchair forever and the family is a group of runners, that would need 
to be considered and discussed. It obviously should not entirely guide decisions, but a discussion 
should occur about what is in the child’s best interests in that situation, not all overall.  Although 
the majority of parents in our study preferred being offered choices in their child’s care, parents 
with low health literacy reported a preference for lower levels of participatory decision-
making.139  Patients and parents, must be enabled to seek information to ensure the interactions 
are appropriate and actually beneficial, making interviewing skills very beneficial.140 It is 
possible to teach physicians how to engage in behaviors that lead to the sharing of information 
and research suggests that this is true for patients and parents as well.141  In a study by Frosch 
and Kaplan, participants were educated during decision making processes and taught how to 
interview and participate in the decision making processes.142 Prior to meetings with physicians 
it was emphasized that they could ask questions and they were reminded of issues that could be 
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discussed or elaborated with the physician.  Additionally, they were taught basic negotiating 
skills to use during the interaction with the provider.  These aids and overall basic education led 
to a much more engaging decision making process for all involved, more questions asked, and 
the collection of more overall information, emphasizing the need for parental education.  Studies 
to date have additionally found that parents with low health literacy reported less participation in 
decision making processes and lower levels of empowerment.143  One in five parents reported 
that their child’s doctor did not help make them feel like a partner and more than half preferred 
to rely on the knowledge of the doctor.144  Health literacy is a big issue that becomes 
tremendously more important with the complex information and high levels of uncertainty 
associated with new technologies.145  In the new model, enhanced education of physicians to 
enable education of parents and the child to be decision makers is accomplished through a more 
structured decision making process that emphasizes the relationship between them as well as 
placing a burden on physicians to not only ensure understanding but to work with parents to 
make decisions. 
 
5.3.2.2 Justice and Access to Resources 
 Justice and access to healthcare and resources is an issue that is prevalent throughout the 
Unites States.  Regulations exist to provide healthcare to children when their parents cannot 
adequately provide medical attention for them, however there are still many barriers that come 
with the healthcare system in its current state.146  Many insurance plans place limitations on 
choices parents can make, providers patients can see, or the number of visits that they receive.  
Parents face many limitations when taking care of their children including financial limitations, 
low education levels, or location of their home.  Many times families do not live near a variety of 
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needed medical resources, making them extremely challenging to access.  Financial restrictions 
can also greatly impact care since many times insurance companies will not pay for new, or 
experimental therapies, making research look more appealing to parents since the cost is lower in 
most cases.  There are additional barriers outside of access to financial resources such as time 
and education levels.  Physician’s time must be thought of as a resource, as there is not an 
unlimited amount of it nor access to it for everyone.  Additionally the education level of parents 
plays a large role in the process.  The overall education level of parents as well as low health 
literacy are both major issues throughout pediatric medicine and have been the focus of much 
research in order to attempt to develop methods to overcome them and enable parents as decision 
makers.147  Almost half of parents studied were found either be unable to reach someone after 
hours or not know that they could, despite this access being ensured for the study.148  This study 
additionally found that parents of lower education were much more likely to be affected and not 
understand that they could call or reach someone after hours.  Parents need to have access to the 
provider, or a medical team, outside of office visits and physicians need to have lower patient 
volumes or enough staff to do this.149  There is a great need for the current healthcare system to 
accommodate the facilitated shared decision making model, specifically the interactions of 
parents, physicians, and the child.  Some of the ways that the current model restricts shared 
decision making, and could be fixed to accommodate it in the future, would be to ensure patients 
have access to providers of the correct type and location, and have enough time with the 
provider..   
 
5.3.2.3 Tools to Enhance Communication and Understanding 
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 There are many tools that can be utilized in practice to enhance the shared decision 
making process by building and supporting the relationship between parents, patients, and 
providers. This relationship is a central component to making good decisions and the partnership 
that must exist between all relevant stakeholders.150  A decision making tool can increase 
abilities of parents and children to participate in decision making, and improve overall levels of 
comprehension. The provider relationship with the parents and child in pediatrics is unique in 
that the patient is not the primary decision maker, nor a competent adult, but still must be 
incorporated into the decision making process in a meaningful way.  There is a need for 
communication with providers outside of office visits, furthering the patient-parent-provider 
relationship that is crucial to pediatric medicine and the enhanced shared decision making 
model.151  There are many tools that can be used to enhance the provider relationship with 
patients and their parents, the most beneficial of those being electronic communication and 
availability via the telephone, however with the growing number of technologies available, this 
list continues to grow.152  Electronic medical records standardly offer a patient portal for parents 
to work with their physicians on their care, send message back and forth, and take a more 
prominent role in their care. These portals are not available to everyone, nor do all populations 
have access to the devices needed to access them, but they offer tremendous enhancements to 
care and enable patients to be more involved and feel a greater sense of control.  The electronic 
medical record and patient portal becomes more complex with children since it is not clear what 
access parents should have for their children and what abilities they should have to speak on their 
behalf. The growth and tremendous development of patient portals however speaks to the 
growing desire of patients to be involved in their care and of parents to be involved for their 
children.  
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 In addition to basic involvement and interaction between stakeholders, there is a need for 
tools to enhance the overall comprehension levels of parents and children, and elaborate their 
specific roles in the decision making process.  Many times parents and children do not know how 
to participate in decision making processes , so it is important that the boundaries of this 
involvement  is part of the education process they go through before making decisions with the 
physician.  Parents and children must be provided with details about the treatments options 
including possible harms, benefits, and outcomes in their native language in a way that is 
meaningful to them.153  Physicians must use clear communication and work to reduce the 
complexity of information while providing tools to enhance the discussion and improve overall 
comprehension, such as printed pamphlets or supplemental materials available through a patient 
portal.154 Decision aids have been developed to help in decision making processes, however they 
are largely focused on adult conditions and processes.155  Future work should engage 
pediatricians to develop decision aids for the pediatric health setting because currently very few 
exist for children and their families and this would add a great benefit to the field.156  The use of 
decision aids is a recommended and proven approach as it works to enhance health literacy 
which is a difficult area for physicians to assess.  Physicians typically assume parents understand 
more than they do, which is additionally complicated by the fact that parents do not always asks 
questions when they do not understand, worried that they will be embarrassed.157  Electronic 
media and medical records should be leveraged in shared decision making, presenting 
information on treatment options and choices in a convenient way for parents and children.158  
Frosh and Kaplan emphasize that further research is needed to determine the best sequence for 
using aids in decision making processes as they have been very successful in the past and will 
continue to be a crucial component of decision making moving forward.159  There are currently 
 211 
 
holes in some of the research as there are not studies that look at the impacts of the Internet or 
took that into account, even though many parents use the Internet for decision making. There is a 
need for more research to determine how to best educate parents and children, however there is a 
definite need to do so through technology in a way that is accessible to parents, enabling them to 
have a relationship with the provider, be good decision makers and comprehend the medical 
information in a meaningful way to make good decisions for the child.160  
 
5.4. Conclusion  
The enhanced facilitated shared decision making model allows for parents, physician, and 
children to work together in a meaningful decision making process.  The steps outlined provide 
structure and guidance to all who should be involved in the processes and enable them to work 
through the challenging decisions of the expanding technologies of genetics and neuroscience.  
They additionally provide structure and assistance that can be applied to the currently 
complicated and somewhat contentious areas of pediatric research. The utilization of new 
technologies, especially when they are in experimental stages, is very complicated to rationalize 
and determine to be appropriate.  There are complicated issues and dimensions including 
uncertain outcomes, unclear benefits, heighten potential for harm or negative outcomes, and the 
status of the child, placing them in a vulnerable position.  It is necessary that the child is included 
in the decision making process, and involved to help determine which interventions he or she 
wants to participate in for a given situation.  The child, as the patient, should be the central focus 
of all decisions and involved in the discussions to determine interventions, which is why he or 
she is evaluated as the first step of the elaborated process.  Physicians must assess the 
developmental capacities of the child, looking further than their age, and determine the 
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appropriate level of involvement that the child should have in the process.  Not only must they 
determine and outline the appropriate involvement for the child, but the physician must also, in 
many cases, advocate for the role of the child and bring him or her into the process.  After the 
role of the child has been solidified in the decision making process, the decision itself must be 
fully understood so that the appropriate level of shared decision making between all relevant 
roles can be identified.  There are many stakeholders with large roles in the process and they 
must all work together in order to make the best decision for the child.  When the decision is 
classified, the role of the physician and parents will be placed along the spectrum of shared 
decision making, ranging from paternalistic, physician driven to pure autonomy, which would be 
parental or guardian driven with regard to pediatrics.  There are some instances where parents 
should be more in control, others where physicians should take more of the lead, and others 
where they truly are shared and equal decision makers.  A model where the child leads has not 
been discussed yet, however this will come into play in the next chapter when specific cases with 
adolescents are looked at.  After the decision has been evaluated, the physicians, parents, and 
child can all participate in decision making that acknowledges their duties and responsibilities 
and fully enables them as decision makers.  The final component of the enhanced model that was 
elaborated is that of outside impacts, discussing how society, among other potential outside 
impacts, has a stake in the decisions made for children in many instances.  The role of society is 
very important and must be engaged in many of the challenging decisions that arise within the 
fields of genetics and neuroscience.  There is a great need for regulation and oversight, and 
potentially for re-evaluation of current laws and legislation that exist to properly protect children 
and enable parents to be caregivers and make choices for them that they believe to be in the 
child’s best interests.   
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The final section of this chapter reviewed many of the changes that are needed to fully 
incorporate the enhanced model into practice. The enhancements discussed in the last few 
sections provide additional details for ways to improve decision making processes and fully 
enable children and parents to be decision makers, and ensure that physicians can properly 
coordinate the interactions and provide enough information.  There is a great need for 
enhancements to increase communication and overcome the educational barriers between 
physicians and their patients, specifically parents and the child in pediatrics.   Overall, this 
enhanced shared decision making model enables parents, children, and physicians to work 
together to make decisions in light of the tremendous uncertainty of the fields of genetics and 
neuroscience and the expanding number of research studies.  The new suggestions and 
enhancements address the goals of pediatric medicine, incorporate all relevant stakeholders, as 
well as accommodate the new technologies, which will be the topic of the next chapter.  
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Chapter 6 - Application of Enhanced Shared Decision Making to New Technologies  
6.1. Introduction 
 Shared decision making occurs throughout the field of medicine each day as physicians 
work with patients to make medical decisions about treatment and courses of care.  This process 
becomes challenging when the patient loses the ability to make a decision and someone else 
must step in to make decisions on his or her behalf.  When the patient is a child, he or she by 
definition does not have the ability to legally make medical decisions, therefore parents, or legal 
guardians, must be involved and make decisions for the child patient.  There is not a current 
model for parents to use to make decisions for their children that adequately incorporates all 
relevant stakeholders or supports the new and continuously emerging technologies present 
throughout pediatric medicine.  New therapies throughout the field of pediatrics are developing 
at an exponential rate, especially within the fields of genetics and neuroscience, including 
clinical research trials in both of those areas.  More options for diagnosis, treatment, and possibly 
even enhancement or prediction are available each day.  These therapies bring with them 
tremendous possibility and hope for improved futures for children, but also great levels of 
uncertainty and questions about what should and should not be done for children, specifically 
what parents can choose and what physicians should propose.  Over the course of the last 15-20 
years, these three areas have tremendously expanded, offering new therapies and diagnostic 
tools, but also much uncertainty and complex ethical issues, leading to difficult decisions that 
must be made and the poorly structured models of adult surrogate decision making or the ill 
defined model of shared decision making to support them.  The inability of current models to 
provide enough structure and support throughout decision making processes with regard to the 
utilization of new technologies led to the need for the enhanced shared model and overall a more 
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structured decision making process.  Advancements and new therapies within the fields of 
genetics, neuroscience, and pediatric research trials lead to a great number of decisions that must 
be made, which this chapter will address in more detail, and apply the previously discussed 
model.  
The enhanced shared decision making model elaborated in the previous chapter offers 
more support and guidance for all involved stakeholders while emphasizing the central role of 
the child, as the patient, where possible.  This chapter will apply the enhanced model to the areas 
of tremendous growth and expansion, specifically genetics, neuroscience, and pediatric research.  
This chapter will briefly elaborate the expansions of the fields of genetics, neuroscience, and 
pediatric research focusing on the elements that make them challenging for current decision 
making models to facilitate.  Although the ethical dimensions have been explained in an earlier 
chapter, the major issues that impact how decisions are made will be elaborated again to ensure 
they are directly addressed by the enhanced shared model in each of the case studies.  Within 
each section, the new model will be applied to two cases to show how the model would work in 
practice and call attention to the variance between young children and older children, 
emphasizing that all decisions that parents must make for their children with the utilization of 
new technologies are challenging, however these decisions are exponentially more complicated 
with adolescents who have varying abilities to make decisions and some levels of decision 
making capacity.  Decision making in pediatrics is very challenging, especially in light of the 
growth and enhanced ethical issues within the fields of genetics, neuroscience, and research, 
leading to the need for the enhanced shared decision making model that incorporates all relevant 
stake holders and offers more structure and support to the overall process, accommodating the 
many challenges and issues that arise.   
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6.2. Genetic Screening  
 The area of genetics has greatly expanded in the last few decades and will continue to 
grow at an exponential rate in coming years as technology progresses and becomes more 
accurate and accessible.  This section will look at the developments within the field of genetics, 
beginning with the emergence and expansion of newborn screening, tremendously impacted by 
the development and expansion of genomic sequencing.  There are many challenging ethical 
issues associated with genetic screening, including both newborn screening and whole genomic 
sequencing, all of which led to the need for the facilitated, enhanced shared decision making 
model for parents to work with physicians to make treatment decisions for their children, and 
incorporate the child when possible.1  Once the ethical issues of the field are reviewed, the 
enhanced shared decision making model described will be applied to two cases of genetic 
screening to emphasize how the model addresses the issues and facilitates the decision making 
process.  The first case involves parents requesting the genetic screening of their child with a 
strong family history of breast cancer.  The second involves an older child exhibiting symptoms 
of a developmental disorder that the physicians would like to diagnose with whole genomic 
sequencing, however before beginning the sequencing they must determine what should be part 
of the panel. The parents request information of genetic disorders that the child does not have a 
family medical history for nor are immediate therapies available.  The discussion and application 
of the model to these cases will emphasize the need for the enhanced shared decision making 
model to guide parents, children, and physicians to the best decision for the child.    
 
6.2.1 Expansion of Genetics  
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Growing knowledge of the human genome has greatly expanded as the number of 
disorders physicians can screen for in children as both the accuracy and efficacy of sequencing 
has increased.2  Genetic screening with children began with newborn screening in the 1960s with 
a genetic test for PKU, an easily identifiable and treatable disorder.3  Over time, new 
technologies emerged, including tandem mass spectrometry (MS/MS), leading to screening 
newborns for over thirty heritable disorders.  Currently, each state in the United States tests for 
different disorders on their standard panel with newborns, including some disorders that are not 
as easily remedied as PKU and many with unclear diagnosis or results.4  Over time, due to 
lobbyists, activist groups, parents, and the availability of more accurate tests, the newborn panel 
has expanded to include genetic conditions that are not treatable and additionally, the 
identification of the trait is not meaningful.5  Different organizations have argued for standards 
of the field and believe that children should only be tested for those disorders that are 
understood, can be accurately identified, and for which valuable treatments exist.6    Infants, and 
children in general, should not be tested for disorders that cannot be treated because there is not 
clear benefit or overall good that can come from the identification of the condition.7  As 
technology progresses, the lines between what can and cannot be treated however, will begin to 
blur as treatment may be available in some instances and not others.8 Making it necessary there 
is a model to facilitate each individual decision and case, and not rely on blanket statements.  
In addition to newborn screening, genetic testing is available for children as an important 
diagnostic tool that has become reliable and much more available throughout medicine.9  In the 
last decade whole genomic sequencing (WGS) has become more feasible due to decreasing 
prices, heightened accuracy, and the identification of a continuously growing number of 
disorders.10  WGS has made it possible to evaluate and many time identify disorders that were at 
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one time un-diagnosable and unknown.11  Additionally, many argue that it is probable that WGS 
could be added to the newborn panel, sequencing the genome of children when they are born, or 
in some cases, even in-utero.12  WGS is currently used as a diagnostic tool to identify 
neurological and developmental conditions, and has the potential to be used for personality or 
affective disorders, which only expand upon the previous issues of conditions that are not 
treatable or fully understood.13  The continuous development and focused research in genetics 
has led WGS and other screening techniques, such as exome sequencing, to be both a reliable 
diagnostic tool but also a way to develop effective therapies and gain an understanding of new 
disorders and areas of development.  These technologies have the ability to assess almost every 
gene in the human genome, providing a great amount of information 14  Current research 
addresses in-utero WGS and interventions, emphasizing the need for solid recommendations and 
guidance to move forward.15  The field of genetics continues to expand and with it societal and 
governmental regulations have appeared to help remedy the challenging ethical issues that arise 
and protect patients, both adult and children.  These new technologies and expansions of the field 
will be discussed with the application of the enhanced model after the specific challenging 
ethical issues that arise within the field are addressed.   
 
6.2.2 Ethical Issues and Dimensions  
There are many challenging ethical issues throughout the field of genetics, with both 
adults and children, due to the levels of uncertainty and rapidly expanding panels of disorders 
that can be identified.16  These expansions make interactions with children complex and 
challenging due to heightened issues, unclear decision making processes, and the future 
implications for the child associated with the nature of the screenings. Issues ranging from 
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parental authority and consent to the availability of therapies if a diagnosis is identified must be 
addressed on a regular basis.17  In the future there is likely to be a large array of DNA-based tests 
to diagnose single-gene disorders and identify predispositions to genetically influenced 
disorders.18  Testing and their results may offer medical or psychological benefits but 
additionally may harm the parent-child bonds or the child's understanding of self or even self-
esteem.  As identifiable disorders are found on a regular basis throughout the field of genetics, it 
becomes crucial to not only develop standards for what should be screened for, but a way for 
parents to work with physicians and the child, when possible, to determine what is best in 
specific instances.  The potential exists to screen for not only diseases and disorders but also 
skills or even intelligence levels, emphasizing the need for a facilitated shared model.  These 
issues of genetics are ethically troubling in themselves and when applying them to children the 
stakes are even higher.19   
 Currently in the United States, each state decides which disorders are part of newborn 
panels, leading to a great variance in testing.20  Depending on the state, newborns are screened 
for 29-54 different conditions.21  Additionally, since many individuals cross state lines to seek 
medical treatment and regularly travel throughout the country, it is difficult to know what a child 
has or has not been screened for at birth in the event that a physician needs to know for 
diagnostic purposes.  These issues become much more troubling with the potential addition of 
whole genomic sequencing at birth, expanding the list of disorders screened to include many 
with limited therapies, if any, and others that do not develop until adulthood, or have uncertain 
clinical significance.22  Some disorders that are screened for are not completely understood and 
lack effective treatments or options for the parents and child.23  There are arguably other benefits 
to screening other than treatment including for the family to know about the condition and 
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prepare themselves, or even for society at large for planning or budget purposes or to gain more 
knowledge of diseases and inevitably increase the ability to treat them.24  There are many 
benefits, however not all of those benefits are actual benefits of the child, making it difficult to 
determine if those benefits outweigh the possible harms posed to the child. Weighing benefits 
and burdens is additionally complicated by the actual results themselves.  It is difficult to 
determine the likelihood that a child will develop a certain illness and when they test high 
enough for a “positive” result that will develop into the condition.  Many tests give results that 
are not only positive or negative but give a probability that the child will develop the disease, 
making it challenging to decide what parents should be told and determine when the probability 
is meaningful.25  With WGS, the fact that a child has a specific gene does not guarantee that they 
will develop the disorder.  There are other factors, such as environment, that can be more of a 
marker for disorders, and combined with the genetic predisposition make the child more likely to 
develop a disorder, but still it is not guaranteed.  For example, many with the genes for breast 
cancer, suspected Alzheimer’s disease, and other conditions have never developed the diseases.26  
If a positive result has little bearing on whether the child will develop the disorder, there is not a 
strong argument for it to be part of screening panel, but arguments are made on the other side 
that if it has any bearing parents should be able to prepare for the chance that the child will 
develop the disorder.  The fact that lifestyle or environment in many instances can combine with 
a genetic predisposition make a decent argument for telling people what they have the genes for, 
however there are many other issues that arise with that and the potential for abuse or the misuse 
of information.  Determining if there is an actual benefit to the child when testing for untreatable 
illnesses, or when giving percentages with unclear meanings, is very challenging.27  An 
additional component of this is the duties of physicians in this, since it becomes their job to 
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counsel and provide information to the patient and his or her family.28  Primary care physicians 
are given the task of delivering the news of abnormal results and the outcome of these tests in 
general, seemingly being asked to predict the future, and discuss rare disorders that they may not 
have experience with, to parents who are scared and confused.  False positives or abnormal 
results lead to parental stresses, impacts on the parent-child relationship, and perceptions of the 
child’s health making it necessary that these results are followed up with, and in a meaningful 
way once the physician has interpreted the result.29  A recent study found that after counseling, 
many parents had inaccurate information about a disease from their PCP and those who received 
false positives had heightened stress levels over a year after the mistake.30  Another study found 
that both providers and genetic counselors, involved in many cases with genetic screening, were 
concerned that they were unable to give enough information to parents and that the patient may 
experience stress, anxiety, discrimination, or future impacts without access to the appropriate 
details.31  Issues of accuracy of test and diagnoses, the availability of meaningful therapies, and 
the potential benefits and burdens to the child all must be considered when determining what 
tests should be used with children.  
  Other major ethical issues impacting genetics include parental authority and informed 
consent.32  Parents are given a great deal of autonomy when making decisions for their children, 
but in order for parents to give valid informed consent, they must be able to not only understand 
the therapies and potential outcomes but weigh the benefits and burdens for their child in the 
specific case and situation.  Many parents want, and believe they have the right, to know 
everything they can about their child, while others do not want these details.  The ethical issue 
here is that the decision should not be what the parents want to know, but what the child would 
want to know since the parents are making the decision for the child. Consent is challenging for 
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many reasons but the major elements impacting and making consent challenging are a lack of 
parental understanding, information that may or may not be meaningful and beneficial to the 
child and family, and follow up on the results and information found with regard to access to 
providers, their time, and information that is meaningful and understood to them   When used 
therapeutically, many genetic studies currently in practice tell parents that they will only have 
access to the results that would impact their child’s current suspected illness.  For example, they 
would not tell parents the child has the BRCA gene when they are looking for a diagnosis for 
neurological problems.33  This becomes more complex when the family also has minimal history 
of breast cancer, leading to grey areas of both parental authority and their right to know. With 
current newborn screening, one of the major issues is a lack of information given to parents 
about the process, what they are screening for, and follow up and communication after the 
tests.34  Even in instances where details are given, due to how much the family is going through 
during the birth of a child, they do not comprehend everything that is going on, and a little prick 
is not likely to appear significant to parents.  In addition, after they leave the hospital unless the 
child receives a positive result they typically do not hear anything more.35  There are many 
lessons to be learned from newborn screening when looking to expand whole genomic 
sequencing and finding more information. 
 The final major issue of genetics reviewed is privacy and future implications of the 
results on the life of the child. Issues of privacy are prevalent throughout the field of genetics and 
will only become larger with the expansion of WGS.36  With newborn screening, issues range 
from the storage of the bloodspot and genetic information, to who has access to it and whether 
tests and research can be done on it without parental consent.37  These determinations are crucial 
because once the child is found to have something, it cannot end there, as this is a diagnosis the 
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child and his or her family will have to deal with the rest of their lives.38  There are also many 
burdens to knowing that a child has something, especially since these can go with the child for 
the rest of their lives and impact insurance, life decisions, employment opportunities, and the 
potential access to therapies and resources.  Privacy is a very large issue that will require 
governmental regulations and oversight in the future as genetics expands.39  When determining 
the spectrum of disorders tested for, there are advocates for testing everything to strictly 
regulating and only test for those with current affective therapies.40  The American Society of 
Clinical Oncology recommends that genetic testing be offered when the patient has a personal or 
family history, the test can be adequately interpreted, and the results are meaningful in that they 
will impact medical care or lifestyle decisions. 41 Overall, there are many ethical issues 
throughout the field of genetics and these become exponentially larger with the expansion and 
potential addition of WGS to screening panels and the increased use as a diagnostic tool.  The 
next section will look specifically at how the enhanced shared model facilitates decision making 
processes for parents, physicians, and the child to determine what should be screened for in 
different instances, as it cannot be the same across the board for each case and each child, 
however much guidance is needed.   
 
6.2.3 Application of the Model to facilitate the DM process 
Shared decision making is common in pediatrics however it is not evident that parents 
have enough support to be appropriately involved in a meaningful way balanced with the roles of 
the child and clinicians.  A decision making model does not exist to facilitate the discussions that 
will occur with the expansions of the field of genetics, specifically whole genomic sequencing.  
In this section, the enhanced shared model will be applied to two different cases considering the 
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utilization of WGS.  In the first case, the child’s family has a history of the illness that they 
would like to screen for, however there is not anything that could be immediately done with the 
information obtained.  The other case concerns a child with an unidentified disorder; the parents 
would like to use WGS for diagnostic purposes, however they  are requesting additional tests be 
part of the panel, specifically tests for a disorder that the child does not have a family history of.,  
For each case, the child will be evaluated and their appropriate level of involvement will be 
determined.  After this evaluation of the child, the decision to be made will be classified and the 
specific duties and obligations of all involved will be outlined.  Finally, the overall 
recommendations and proposed outcome will be developed, including policy suggestions and 
enhanced duties and tools will be discussed, and overall how the two cases should be handled 
differently.   
 
6.2.3.1 Cases and Enhanced Shared Decision Making  
 To fully demonstrate the utilization of the enhanced shared decision making model, two 
children will be evaluated for genetic testing using the enhanced model to determine whether or 
not they should be screened and if so, what should be included in the panel.  The child in the first 
case is an 11 year old female with a family history of breast cancer, among other cancers.  Her 
aunt and grandmother both had breast cancer and were diagnosed at ages 17 and 42 respectively.  
Her parents want to have her screened before she enters puberty to know if she carries the gene 
so they can be prepared and make a decision that is best for their family.  The second child is a 
14 year old female who does not have a history of breast cancer, however is being screening for 
a possible neurological disorder that physicians have not been able to diagnose and believe WGS 
will help with.  In this case, the parents have requested that she be screened for the BRCA gene 
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as they had a close family friend who recently died from breast cancer and they are worried 
about their daughter and would like to be able to prepare and take all prevention methods 
possible to avoid their daughter having to go through that.  In both instances the parents are 
requesting additional information and the screening of their daughter for the breast cancer gene.  
It is important to note that the identification of this gene does not necessarily mean that the child 
will develop the cancer, just that there is a heightened chance.  Breast cancer is treatable, not 
curable, however not until symptoms arise in most cases. Many argue that the knowledge could 
lead to earlier detection through the utilization of more regular exams, either by the child herself 
or a medical professional, however outside of that there are not clear next steps if the gene is 
identified. Additionally, it can be argued that if the only outcome would be preventative 
screenings, such as regular exams, that the child should do those regardless of having the 
information in order to protect the child from an incorrect diagnosis. 
 There are many ethical issues connected to both cases that will be worked through as the 
overall enhanced model is applied.  The first step in the process of facilitated shared decision 
making is the evaluation of the child by either the physician or other qualified medical 
professional.  This individual must look at the child’s ability to understand and comprehend, 
make decisions, weight benefit and burden, think about his or her future, their perception of risk, 
and overall susceptibility to peers or family.42 While assessing capacity, physicians must take 
into account their emotional status, cognitive abilities, language and communication skills, and 
social functioning.43  Similar to adult medicine, physicians must share as much or as little as the 
child needs to understand, and adjust how they share it based on the child and what he or she 
needs to know.  In these two cases, the children are approaching, if not already, adolescents as 
they approach adulthood.  The most challenging group of children to assess is adolescents as 
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they are in an undefined place, not clearly children but also not yet adults of 18, and can likely 
play a much larger role than other age groups.  Adolescents need to be the stewards of their care 
in any way that they can, and allowing them to participate in treatment decisions acknowledges 
their self-determination and helps enhance their developing capacities to make decisions, 
facilitating their growth into autonomous adults.44  There is a great need to determine the 
developmentally appropriate involvement of adolescents as they approach adulthood and are in 
the process of gaining capacity rapidly.45  In both of these cases as the children are older, they 
are both able to participate in the decision making processes, however the physician must work 
with the child to determine the exact level of involvement in correlation to where they fall on the 
spectrum of decision making capacities and their overall abilities to comprehend.  Just as adults 
and parents who make decisions for children, children making their own decisions must be able 
to understand the options, including the medical complexities, future implications that these 
screenings have, and overall the benefits and burdens associated.46  For the child with the strong 
family history, they must understand the potential negative impacts of not being screened now, if 
they physician thinks they exist, and the benefits of identifying a disposition to cancer early.  For 
the child without the family history it must be explained what would happen if they were 
identified to have the BRCA gene.   
 After the child has been evaluated, that understanding must be translated into a role for the 
child in the process.  Before it can be directly translated and applied to the cases though, the 
decision itself must be evaluated as capacity is decision specific.  In these two cases, physicians 
evaluate the two patients and work with them to determine if they understand the procedure, the 
information the sequencing can provide, and what can be done with that information.  In both 
cases, more than one option exists leading to a shared decision making model, however there is a 
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wide range of ways that a shared model can be executed with more or less involvement from the 
parties involved depending on the individuals and decision to be made.  In the first case, the 
decision is whether the child with history should be screened or wait until she is old enough to 
make her own decision and continue normal monitoring and prevention methods, such as annual 
exams, and in the second, it is not whether or not to screen, since they are already for another 
reason, but what information they should receive. Both cases bring up issues of parents authority 
and the ability of parents to request things for their children that they may believe they have a 
right to know. Discussions and details of the options for each scenario and outcome can be used 
to evaluate the expected benefits and burdens for the child, which must be taken into 
consideration before determining the involvement of the parents and physicians.  
 Once more than one option has been identified as appropriate or feasible, the decision 
needs to be classified along Kon’s continuum of shared decision making ranging from 
completely patient driven to paternalistic physician driven, where the level of involvement 
correlates to the complexity of the decision.  The roles of parents and physicians fluctuate based 
on the decision and overall the expected benefit and burden to the child, more so than that of the 
child which most strongly relies on their overall capacity and ability to be decision makers.  The 
first case with a family history is less complex than the decision to screen for additional 
conditions in the second with a more anticipated benefit, however both fall towards the side of 
heavy physician involvement due to the fact that there are many nuances to the BRCA gene, 
including what type of history should be looked for before making recommendations to screen or 
not.  Additionally both cases provide minimal initial impacts and burdens to the child due to the 
minimal impacts of the sequencing, but have the potential to have greater impacts to the child’s 
future.  Depending on the outcome, and future utilization, storage, or access to this information, 
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the potential exists that the child could be denied a job or medical insurance, or forced into 
higher insurance premiums due to the results of these test, rather than the diagnosis of the 
disorder. It additionally could impact the self-identification or self-esteem of the child as she 
grows into an adult.  The benefit and burden must be taken into consideration when determining 
where the decision falls on spectrum and expected decision making model utilized.   
  In the first case, Whitney’s discussed clinician directed or patient controlled decision 
making model would be the outcome, where the clinician’s recommendation is given and either 
accepted or refused and he or she accepts their decision because there is substantial medical 
evidence and societal recommendations, and both decisions are justifiable.  In relation to Weir’s 
expert and negotiated models, the first case would fall more into the expertise category where the 
physician should give all appropriate information and then work with the parents and child 
through the decision making process, leaving the final decision up to them.47  In this case, the 
benefits are moderate due to the increased susceptibility due to the established family history and 
the family has outlined what they would do if the result was positive.  The burdens are present 
and should be worked through, however they are not enough to allow for the physician to 
potentially override the parental rights or refuse the request.  
 In the second case, where there is not significant clinical evidence for screening of the 
child, the negotiated model will be the outcome with the physician being not only a facilitator 
but also key stake holder involved in the decision making process.  In the second scenario 
Whitney’s clinically controlled model may be the outcome as well because it may come down to 
the insistence of the physician depending on the clinical evidence.  This is the expected outcome 
due to the fact that there is not medical evidence to suggest benefits exist for the child.  Exposing 
the child to the potential burdens is not justified for a child who does not have a genetic history, 
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especially when no therapy exists until symptoms are present.48  Making this decision for the 
child undermines her future autonomy to either know or not know, and without a good reason, 
such as a strong family medical history, it should be left up to the child to decide once she is an 
adult.  In both cases, the physician must encourage and elicit the involvement of the child with 
thoughtful and probing questions to help them work through uncertainty and reach a decision.49  
Physicians have a very crucial role in this process and must provide all information that they can 
in ways that the parents and child will understand.  Parents have obligations to give accurate 
medical history to physicians and advocate for their child when necessary.  Additionally, parents 
legally have to give consent since the child is not an adult and it is not the legal decision of the 
physician. It is in the physician’s hands to evaluate the family history and advocate for the 
child’s interests, while leading the decision making processes.  Outside of the roles already 
mentioned, the overall process must be additionally guided by regulations about what can and 
cannot be tested for or divulged after the test is over, however due to the uncertainty surrounding 
the genetic sequencing for diagnostic purposes, the relevant stake holders together work through 
what they would or would not want to know from the test.  The ASCO recommends genetic 
testing when history suggests a genetic susceptibility and only in settings of pre- and post-test 
counseling which include discussions of prevention methods and possible risks and benefits of 
cancer early detection.50  Without meaningful treatment options or next steps if a positive result 
is found, there is not tremendous benefit to allowing for the test.  By classifying the decision in a 
clear way and relating that to the overall involvement of parents and physicians, in combination 
with that of the child, the physician is able to confidently know that he or she should be more 
heavily involved in the process or work to empower parents to take on a bigger role, leading to 
better decisions and courses of action for pediatric patients.51    
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6.2.4 Recommendations   
 Overall the model leads to proposed interactions between the child, physician, and parents 
to work through the proposed options and feel empowered in their roles.  Depending on the 
medical evidence and benefits and burdens of the available options, the involvement of the 
physician can be limited or increased, giving parents more or less control to work with their child 
and make a decision.  With the high level of scientific evidence and understanding needed there 
will unlikely be cases of genetic screening with minimal physician involvement, however when 
both options are valid, the parents and child, in a way determined to be meaningful to him or her, 
should be given the ability to make decisions.  In practice, it is likely that a genetic counselor 
will be involved with the physicians in the many complex discussion with the parents and 
child.52  When there is clinical evidence in one direction, or a lack of information, the physician, 
or other relevant medical professionals, must be more involved and in many instances either 
insist on or refuse genetic screening.  Additionally, governmental regulations and oversight will 
be needed as more conditions and disorders can be screened for to facilitate these situations.  
These decisions have a tremendous potential to impact the futures of many children and families, 
only to grow larger as time goes on, necessitating oversight.  There are strong recommendations 
from the ASCO and other cancer organizations about the screening of those with a family 
history, however as panels expand, there should be more governmental regulations and education 
available to the general public.   
 There are many challenging decisions to be made within the field of pediatric genetics 
and parents, physicians, and the child need a facilitated model in which to make decisions and 
overall decide on courses of treatment and what information they can request and inevitably 
 237 
 
learn about the child.  There are many unknown impacts that this information can have on the 
entire life of the child, and the decisions surrounding them cannot be made lightly.  The 
information that can be found impacts the child and parents in many ways including stress and 
anxiety, barriers to the parent-child relationship, and labeling the child for the future.  The 
enhanced model allows for the child to be involved to the highest level that they are capable with 
other relevant stake holders to the appropriate degree based on the decision to be made and the 
options that are available. Outside of the model, there is a need for education of all involved in 
decision making processes, including additional physician education to enable them to facilitate 
these processes.53  Before decisions are made, parents and the child should be separately 
educated on their roles in the process and empowered as decision makers.  Evidence has shown 
that being a good decision maker can be taught, and attempts should be made to teach these skills 
before decision making processes.54 Other areas that deserves additional research and attention is 
the development of  tools to enhance decision making processes and inevitably government 
oversight and regulations to ensure that the information that is collected of children is safe and 
cannot be used negatively to harm them in the future.    
 
6.3 Neurotechnologies 
Similar to the field of genetics, neuroscience has grown tremendously in recent years and 
has the potential to expand at a much faster rate in coming years.55 These expansions have led to 
much controversy and challenging issues that must be addressed within the field of medicine, 
specifically more challenging when applied to children.56  This section will first look at the 
history and expansion of neuroscience as well as the new therapies that are available.  There has 
been tremendous growth, with new processes identified on a regular basis that impact 
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understandings of the brain including emotions, cognition, and normal brain activity and function 
to use to diagnose conditions of the brain. Initially neuroscience will be examined with regard to 
children, addressing some of the unique issues that arise within pediatric medicine, specifically 
with the addition of neuroscience, and the immense possibility of diagnostic and therapeutic 
advancement. Following that, the developments and growth of the field will be elaborated in 
more detail followed by the emergence of the field of neuroethics as a specialty field of medical 
ethics.  After the overview and background sections, the ethical issues will be explained 
including privacy and safety, incidental findings, prediction, enhancement, and uncertainty, all 
leading to overall challenging best interests determinations and unclear roles of all involved in 
care decisions.  The final section will then apply the decision making model to two cases.  The 
first case is of a child with suspected autism and the other is of a family who would like to 
enhance the cognitive capacities of their child.  For each case, the decision will be evaluated, the 
proposed roles and responsibilities of each of the parties involved will be fully outlined, and the 
process of weighing benefit and burden will be explained within the new model, followed by 
recommendations and guideline suggestions.  
 
6.3.1 History and Expansion   
Advancements in the field of neuroscience have led to the creation of numerous therapies 
and diagnostic tools that have the potential to be utilized regularly throughout the field of 
medicine in coming years.57  Over the past few decades there has been tremendous growth in 
areas of functional neuroimaging, brain mapping, and psychopharmacology leading to 
opportunities for more accurate assessments, diagnoses, customized treatments, and even 
possible enhancements of capacities.  These interventions are surrounded by ethical issues and 
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heightened emotions due to the fact that many associate concepts of the self, free will, and even 
personhood with the brain.58  These interventions bridge many unknown areas and shed light on 
processes that many do not want to believe are actually genetic or hardwired into the brain.  New 
techniques for monitoring and manipulating brain functions are developing rapidly but it is not 
clear how these things should be used together.59  It is currently not known how all of the 
different systems of the brain interact, or what a particular brain abnormality can predict about an 
individual, and it is further unknown how intervening in these systems can affect the beliefs, 
desires, intentions and emotions that constitute the human mind.60  It is argued that doctors are 
able to use a brain scan to analyze the development of a child’s brain and track possible 
psychological or developmental disorders after a simple five-minute scan.61  This leads to 
questions of defining normality and then what is even able to be done with those results.62  These 
interventions and scans are thought to be especially helpful in the monitoring and treating of 
patients with psychiatric and developmental disorders.  A functional MRI also offers ways to 
analyze how different parts of the brain work together functionally.  By comparing data with 
standardized models of how the brain functions or how a specific disease develops a variety of 
new clinical insights becomes available and it can be seen how the child’s brain is out of sync 
with the normal developmental curve.  This approach could enable treatment before the onset of 
symptoms and help physicians track the results of clinical trials of new therapies.  Technological 
advancements of neuroscience, just as those of other fields of medicine, bring with them both 
new possibilities and new problems to address. The field of neuroethics looks specifically at 
resolving these issues so the positive outcomes of the technology can be utilized, with pediatric 
neuroethics focusing on the enhanced issues that arise with the addition of children.63  The 
development of a new field of ethics specifically for neuroscience highlights the fact that there 
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are many pressing and unique issues of the field, and recently a sub-specialty of that, pediatric 
neuroethics has emerged to deal with how these complex issues apply to children.64  
There are many challenging ethical issues within pediatrics and neuroscience 
individually, but when they overlap, even more are created with very high stakes and tremendous 
implications for the child and his or her family and future.  It is one thing to allow adults to take 
risks, participate in new treatments or therapies, and even to choose controversial therapies that 
many not have clear benefit, but a completely different thing for parents to make these decisions 
for their children.65  New technologies that can be utilized on children for both therapeutic and 
non-therapeutic benefits such as brain scans it is not clear if parents can make such a choice for 
their child, and if they can it is not clear how the decision should be made.66  Developments of 
neuroscience have great potential to diagnose and even treat disorders of the brain, many of 
which impact children tremendously.  A lack of effective therapies is a major problem but 
neuroscience has begun opening doors for these ranging from new techniques and methods for 
assessment and diagnosis, treatment, and potentially even fixing some of them, however it is still 
in the early stages.  There is a lack of evidence about what neurological interventions can do, and 
even less about what it should be doing, which leads to many ethical issues, which will be 
addressed in the following section.  
 
6.3.2 Ethical Issues and Dimensions  
 The utilization of neurotechnologies with pediatric patients is accompanied by the ethical 
dilemmas associated with their use in adult medicine, magnified exponentially, like other 
therapies of adult medicine applied to pediatrics.67  New technologies in the field of neuroscience 
have greatly increased the number of ethical issues as well as the magnitude of those that already 
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existed. The opportunities and implications of neurotechnologies greatly impact the roles of 
parents and physicians and emphasizes a need for a shared role.  Advancements in neuroscience 
have led to new possibilities and opportunities to diagnose or even predict, treat, and potentially 
enhance capacities.68  The major ethical component that will be elaborated here include the 
tremendous levels of uncertainty leading to challenges of the assessment and diagnosis by the 
physician, issues determining the best interests of the patient, and problems with informed 
consent and comprehension.69  Additional ethical dimensions that must be discussed that greatly 
impact decision making processes and are problematic include privacy of the information that is 
found and incidental findings that were not initially looked for.70  The final area of issues that 
will be addressed greatly impact the future of the child and include issues of prediction and 
enhancement potential of the new technologies.71  All issues relate to the overarching issue of 
uncertainty associated with these new interventions of neuroscience.   
The new neurotechnologies discussed, including brain scans, can be utilized with 
children for diagnostic, therapeutic, and other non-therapeutic reasons.  Brain scans specifically 
have great potential for the future including definitive assessment by correlating the scan with 
certain behaviors.72  However because brain scans are newer technology they are accompanied 
by great levels of uncertainty and providers are challenged with the task of assessment and 
evaluation of the child and his or her condition, leading to the overall diagnosis with and 
utilization of the scans.  Due to levels of uncertainty, providers and clinicians utilizing them are 
challenged with accurate assessment.  The uncertainty and unknown associated with them can 
lead to over-interpreting or reading too much out of results from a study or the possibility of 
finding something else that is not being looked for at that time.73  If it is not clear what the 
physician is looking for, it makes finding it and identifying it challenging, if not in many cases, 
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almost impossible. Additionally, since not all aspects of the brain are understood, in many cases 
they can only determine that the scan is normal or abnormal, not explicitly what that means.  If it 
is found that the child has an abnormal brain scan but the clinician cannot link the abnormality to 
a specific disease or disorder it is unclear what that means for the child or how this will impact 
his or her future.  Assessment with new technologies and interventions is very challenging for 
providers as they do not want to label the child or inaccurately diagnose them, but they also want 
to identify the problem and more than that find a way to treat or even cure it, which is 
accomplished by continuing research and utilization of the technology in practice.74  
Another challenge is how to deal with incidental findings when utilizing new these new 
neurotechnologies.75  If clinicians are looking to diagnose a possible developmental disorder and 
decide to use a brain scan, for instance, and then during the analysis a psychological disorder is 
found, it is not clear how that finding should be handled.  They were not looking for the second 
disorder, and regardless of whether or not the developmental disorder is found, the role of the 
physician in dealing with the incidental finding is not clear.  Additionally, due to this being new 
there is a great potential that what is found incidentally may or may not be fully understood. 
Since all children develop differently and at unique paces it is hard to define “normality” and 
develop standards to use to compare scans and define abnormalities.76  If there is not an accepted 
normal, there is the potential that physicians will begin to look for something that is wrong or 
make sense of the functions they view as outside of normal. These findings, either intentional or 
incidental in nature, carry with them a great deal of importance and weight as they can impact 
the child in many ways, including those that could be prevalent throughout the child’s life, 
impacting their future. These diagnoses have  the possibility to be attached to the child leading to 
them being labeled, treated differently, denied benefits (such as enrollment into competitive 
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schools or medical insurance for presumed pre-existing illness), and even subjected to low self-
esteem or additional stress.77  It is possible that the information from the scan will be used in 
negative ways that could lead to problems later in life such as negative treatment or labeling of 
the child if this information becomes a means of describing him or her in society, the family, or 
even to themselves.78 Disorders of the brain carry with them a lot of weight and implications that 
must be taken seriously and considered before utilizing the technology or specific intervention.  
Outside of diagnostic or therapeutic interventions, these neurotechnologies could also be 
utilized for possible enhancements.79  If it is found that a therapy can identify and treat a specific 
developmental disorder, it is possible that interventions could be used to enhance the capacities 
of those who are at or above the normal level, just as they could bring those below the level to a 
more normal capacity.  As technology progresses, these possibilities continue to grow and the 
opportunities for enhancement tremendously increase.   In the near future, parents will likely 
request enhancements for their children but with that come even more ethical dilemmas and 
issues ranging from justice to the rights of the child.  New technologies within the field of 
neuroscience have increased the burden on the physician of these patients both in obtaining 
informed consent, and potentially to refuse to provide treatment when inappropriately demanded 
or if it is of uncertain benefit.80  These neurological interventions make the basic components of 
decision making exponentially harder with the fact that they are new, changing, and filled with 
tremendous levels of uncertainty.  Physicians cannot fully outline what will happen or be found 
in each instance, challenging the processes of weighing and balancing benefits and burdens.  The 
impacts to the child are complex with therapies for the brain.  Additionally there are great 
barriers to comprehension and overall understanding of the child patient and the parents.81  
Inevitably, these issues come down to consent, specifically what parents should consent to, who 
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should be involved and have a voice in the process, and how they should all work together to 
make decisions. Consent is very challenging with gaps in knowledge, comprehension barriers, 
and high levels of disparity between clinicians and patients and their parents. It is unclear how 
knowing that a child has a significant chance of developing something that is untreatable and not 
preventable will impact the child, their family, or society in general, emphasizing the need for 
the enhanced shared decision making model which will be developed in the next sections.  
 
6.3.3 Application of the Model to Facilitate the Decision Making Process 
 There are many ethical issues that arise when making decisions to utilize new 
interventions of neuroscience.  These technologies are surrounded with great levels of 
uncertainty ranging from the evaluation or interpretation of results and the diagnostic 
intervention and likely outcomes of intervention.  The immediate impacts of the therapies 
themselves are not fully understood and it is unclear how to handle incidental findings that may 
arise while looking for something important or justified. Additionally there is great potential that 
the interventions will impact the entire life of the child due to carrying a label or diagnosis that 
may or may not be understood and has the potential to carry with it a social stigma that could 
hinder the child within society.82  Neurobehavioral disorders are relatively common and these 
therapies have a substantial impact on both the individuals who have them and those who 
interact with them, and improved treatment could have significant benefits for all involved.83  
Disorders of the brain in children can be extremely burdensome to not only the child but also to 
his or her parents and entire family, adding additional dimensions and ethical issues to 
consider.84  With interventions of the brain, the patient is often much more vulnerable than the 
typical child patient due to an abnormality, developmental delay or disorder, or an affective 
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disorder necessitating the intervention.  All of these things make the decisions made about the 
use of neurotechnologies challenging for parents.  This section will specifically look at the cases 
of a child with suspected autism, whose parents would like to have the physician screen for the 
disorders.  The second case concerns a child whose parents are requesting cognitive 
enhancements with a pharmacological drug.  For both cases, the facilitated shared decision 
making model will be applied offering recommendations at the end for potential policies, 
guidelines, and tools to enhance decision making processes.   
 
6.3.3.1 Cases and Enhanced Shared Decision Making 
 In order to demonstrate how the enhanced model alleviates many ethical issues associated 
with neurotechnological interventions with children and facilitates decision making processes 
with parents, physicians, and the child him or herself, this section will apply the model to two 
unique cases. The first case involves a 6 year old male patient with suspected autism who has 
had difficulty communicating properly and relating to others for several years, if not his whole 
life.85  His parents noted fine motor skill impairments at a young age but nothing ever came of 
the observations or comments they mentioned to their pediatrician.  In this case, the physicians 
are proposing the use of a brain scan to assess if the child has autism and if he does, attempt to 
identify the degree and severity.  Although treatments are most effective for cases of autism 
identified at a young age, there is still a great potential that things could be done for him, in 
addition to the parents overall just being able to understand and better take care of their son.86  
The second case is a 15 year old male previously diagnosed with childhood ADHD.  When he 
was diagnosed, the physician prescribed medication to increase his attention and he was on the 
medication for several years, but stopped before entering into high school.  He is able to perform 
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and concentrate in school, however not to the level of his two siblings who are at the top of their 
classes.87  This has led his parents to request the utilization of medicine to increase his 
concentration and overall enhance his performance since the medication was able to enhance his 
performance and focus in the past. 
 The first step of the enhanced, shared model is the evaluation of the child.  In the first case, 
the child is only 6 years old and has communication and social barriers.  Evaluation is 
challenging with neurological disorders as levels of uncertainty surrounding the brain, there is a 
great potential for misinterpretation or an inaccurate assessment of the child.  Developmental 
stages must be taken into consideration, including their emotional status, cognitive abilities, 
language and communication skills, and social functioning, all of which are limited in the case of 
the first child.88  The physician must still evaluate the child, however the young child will not be 
able to meaningfully participate in the decision making process.  This does not mean that the 
child should be excluded, however he should only be brought in to explain what is going on and 
the final decision once it is made.  With the second child, he is an adolescent and definitely 
should be involved in all decision making processes, acknowledging his self-determination and 
ability to be a steward of his own care.89  In both cases more than one reasonable option exists, 
leading to an instance of shared decision making.  Looking at the complexity of the decision and 
the medical evidence we can apply Kon’s continuum of shared decision making to both of the 
cases and then determine the involvement of all stakeholders.   
 In the first, because there is not strong clinical support for the use of brain scans, the 
physician needs to be highly involved in the decision making processes.  On the other hand, 
since there is not tremendous evidence that a diagnosis for autism can be found this way, and 
additionally, that there are therapies that exist if a diagnosis is achieved, the parents must be 
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involved and their opinions weighed as heavily as the physician. Due to the young age of the 
child in the first case, the parents and physicians must work together to make the decision of 
whether or not to scan the child, talking through all benefits, burdens, and potential outcomes 
including uncertainty of results and what to do if incidental yet unrelated things are identified 
during the scan.  The benefits and burdens are not easily accessed due to the impacts that the 
results could have on the future of the child, and unforeseen burdens that could come with those 
results. Parents, as the legal decision makers for the child, must work with physicians to make a 
decision that not only upholds the autonomy of their family, but the future autonomy of the child, 
making benefit burden analysis crucial, as well as discussions of options and paths to take for 
each potential outcome.  Without a clear path if a positive result is found, it is not clear that 
intervention is justified, emphasizing the role of the physician to not only understand what could 
happen if varying degrees of positive or negative results are found, but accurately explain that to 
the parents to fully understand what they would or would not want to do in both cases.  In this 
case the rights of the parents must be held in balance with those of the child, where the physician 
must be an advocate for the current and future interests of the young child who cannot 
adequately represent them. Parents attempt to represent their children and do what is best for 
them, however they are in a very challenging place and will not be able to accurately and 
adequately do this in all cases, making the more neutral role of the physician so crucial with 
young children.  
 In the second case, the decision is not as complex resulting in a much more balanced, 
shared process, with a strong role of the adolescent child.  Although it is not as complex, the 
physician still has a large task and must not only present all medical options, benefits, burdens 
and possible harms, but also work to ensure that the medications utilized would be medically 
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necessary for the child and that the decision that is made is guided by legal regulations and in the 
medical best interests of the child.  The physician, parents, and child must all work together to 
outline the options and what actions they would take depending on the results.  In cases of 
enhancement and drugs with children, depending on the legal context, there are different 
regulations in place guiding the decisions that can and cannot be made.  There are interventions 
that can be done with children at a young age that have the great potential to not only impact 
their whole lives but possibly change outcomes, limit or increase the number of jobs or insurance 
the child can receive, and be used as a means of describing the child. Children do not fully 
understand the implications or impacts that decisions they may make or want to do not have on 
their entire lives, making the role of adults crucial in the process, but it is also very important that 
the adolescent child be heard and have a large role in the overall decision making process. 
Privacy and uncertainty of the interventions, both of which have unknown future impacts, are 
two of the major issues impacting decision making processes.  Neurotechnologies are an area 
where it is likely that government regulations will expand.  As more enhancements are 
developed and possible, normally aimed at those in need or who are below average, there are 
more and more possibilities that the enhancements will be used to enhance the abilities of those 
who do not necessarily need them, leading to the need for physician guidance and government 
regulations and oversight.  This model helps facilitate decision making processes around the use 
of these new interventions, defining the appropriate roles of all involved based on the levels of 
uncertainty and options for the child, but legal regulations provide additional context and 
guidance that may eventually limit the authority of parents in more ways.  Parents must give 
valid consent in order for their children to participate in a therapy, but without full understanding 
that is not possible, emphasizing the involvement of the physician and need for a more structured 
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model that ensures comprehension, understanding, and overall the appropriate involvement of all 
parties.90 
 Overall, the utilization of Weir and Whitney’s models, guiding the enhanced shared 
decision making model, parents, physicians and children can work to make good decisions about 
the utilization of neurotechnological interventions.91 In the first case, Whitney’s discussed 
clinician directed or patient controlled decision making model should be the outcome, where the 
clinician’s recommendation is given and either accepted or refused.  At this point the parents 
make the decision and the physician will accept the parent’s decision because there is substantial 
medical evidence and societal recommendations, making both decisions justifiable and 
reasonable options.  In relation to Weir’s expert and negotiated models, the first case would fall 
into the expertise category where the physician should give all appropriate information, 
including all scientific evidence and expected outcomes, and work with the parents through the 
decision making process, leaving the final decision up to them.92  In this case if they decided to 
use the brain scan there would be additional considerations to review, however these 
considerations would be after the initial decision had been made and could use the same 
negotiated models.  For the second case, because there is not tremendous immediate evidence 
that the medication is medically necessary, the physician must guide the discussions in more of 
an expert model, and potentially fall into the area of Kon’s continuum where the physician must 
insist on something that they know is best.  In this case, they must include the child and work 
with both parents and the child, but inevitably, the physician will have more of the needed 
scientific knowledge.  The enhanced shared decision making model helps address issues of 
uncertainty, unclear benefit and burden, the lack of therapies, and potential future implications 
for the child while respecting the rights and authority of parents, the role and obligations of the 
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physician or other clinicians, and the central and important role of the child in his or her own 
care and decisions.  
 
6.3.4 Recommendations   
 Neurotechnologies bring with them the possibility to enhance and help the lives of many 
patients, offering diagnoses or treatment for situations previously unable to treat, but also create 
challenging decisions that must be made with caution and extra attention must be paid to 
potential burdens on the patient, outcomes, and long term impacts that these decisions have on 
the child.  Similar to the genetics cases, when there is strong clinical information, the physician 
must be involved to supply the data and evidence, however the parents and child can be more in 
control of the decisions.  When there is limited evidence, or the request has questionable 
benefits, the physician must be more involved and inevitably more in control than the parents or 
child.  Physicians must also be transparent in what is and is not known about the particular 
intervention, which is difficult with new neurotechnologies and interventions that have very high 
levels of unknown and uncertainty.  There is great potential for these technologies, both 
therapeutic and diagnostic, however they are not completely proven at this time, meaning the 
physicians must not only be highly involved, but they also must be honest, work hard to ensure 
comprehension of all involved, and advocate for the child.  In cases of neurological issues the 
child may be even more vulnerable than in other cases due to decreased capacity or the effects of 
the neurological or developmental disorders, necessitating increased attention to not exploit the 
child.  
 The specific scenarios discussed with neurotechnologies are hypothetical, as a brain scan is 
not a definitive way to diagnose autism nor are there pharmacological drugs guaranteed to 
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enhance cognitive capacities and brain function, however such products exist on the market for 
both of these cases, necessitating regulation and oversight, and emphasizing the fact that the field 
is constantly changing and in need of a decision making model that is flexible.  Therapies or 
diagnostic tools should not be available to the general public until they have undergone extensive 
testing and research, which will be looked at in the following section specifically with regard to 
research with neurotechnologies, but even then, there will be a need for oversight and control to 
a degree. Additionally, this field has seen a great number of consumer products that fall outside 
of the scope of medical practice, which physicians must be aware of as many patients will use 
them or want to.93   The enhanced shared decision making model elaborated enables parents to 
work with physicians depending on the decision to be made, options available, and the levels of 
uncertainty involved.  These are all components that vary from situation to situation, but 
additionally can be assessed in all situations, leading to appropriate decision making.  With this 
model, stakeholders are involved in a way that makes the most sense for the decision to be made 
and incorporates the child in a meaningful way, acknowledging their future autonomy, enabling 
them to grow into successful adults who are involved in their medical care.   
 
6.4 Clinical Research 
Research is a controversial area of medicine that has led to the development and 
refinement of therapies for many diseases and disorders.94  It has also led to refined 
understanding of the human body and health.  Physicians have come a long way and it was not 
an easy road to get here as we did not always know what we do now and conditions previously 
thought of as incurable or a death sentence are becoming manageable if not curable.95  The 
growth of the past however is not without its ethical missteps as progress was not always made 
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in the best ways.96  Research is especially challenging with children as researchers and clinicians 
must work with emotional parents and non-autonomous children to serve the overall good of 
medicine.  This section will outline the emergence of research with children highlighting the 
expansion and development of research within the fields of genetics and neurosciences.  Then 
the regulations that impact research including governmental oversight, review boards, and issues 
of consent and assent will be discussed since they greatly impact decision making processes and 
outline what can and cannot be done. Regulations also appeared in light of the troubling start 
research had in the past, and an emphasis has been made on protecting the child, as it has in other 
areas of society.97 Following the development of the expansion of the field and the overarching 
issues, the specific ethical issues that make decision making challenging in the current model 
will be elaborated.  Following this, the enhanced decision making model will be applied to two 
research cases, one of an infant and genetic research and the other at an adolescent with a 
possible, unidentifiable neurological disorder.  Overall it will be argued that the new model 
facilitates smoother decision making and enables all stakeholders to work together to come to the 
best decisions, while enhancing the understanding of all involved. 
 
6.4.1 Expansion of Research with Children 
 Research has been a central component in the developments and advancements of and 
successes within the fields of genetics and neuroscience.98  Research is an area full of new 
technologies, both for therapeutic and diagnostic purposes.  Clinical research has many ethical 
issues, especially when it involves human subjects, needed before the general public can utilize 
therapies.  Research with children is possibly the most troubling area of development for the 
current decision making models as it encompasses the issues of both genetics and neuroscience, 
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highlights the vulnerable status of children, makes it possible that they will be exploited, and 
makes issues of therapeutic and non-therapeutic interventions immediately more troubling.  
There are many legal and ethical issues associated with vulnerable populations such as children, 
especially those with genetic, neurological, or developmental abnormalities making conducting 
pediatric research challenging.99  Children cannot be isolated from research, as they then would 
not have protections and good medical care available to them, however they are vulnerable and 
not of legal consenting age so there are many additional considerations that must be taken.100  
 Historically, clinical research has exploited vulnerable and underserved populations, which 
has led to increasing regulation and oversight, and initially, the exclusion of children.101  Over 
time they were included in research but just as all other areas of medicine, when children are 
involved there are additional ethical issues to consider, heightened stakes, and the need for 
enhanced models of consent and decision making.  As the care of children developed into its 
own field a need for research and the development of therapies and drugs specifically for 
children emerged.  Children are both vulnerable subjects who need protection from research risks 
and “therapeutic orphans” who have been denied access to the benefits of research.102  The long 
term tradition of protecting children, extending to not include medical research was recently 
shifted when the US created mandates promoting the inclusion of children in clinical research.103  
The development of lifesaving cures for terminal childhood diseases depends on the 
advancement of pediatric research even though children are vulnerable.104  Translating 
knowledge gained from scientific advances in biology, genetics, and neuroscience into 
treatments for children is possible only through research.105  Children cannot be ignored from 
research, as they have been before, because they themselves need treatments, therapies, and 
inevitably drugs but because they are children more issues must be considered.  If new advances 
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are not tested or studied with or on children, then they will be blindly used on them without 
knowing exactly how it will work in a child.106  Children are developing and changing at a much 
more complex rate than adults, and things that would not be issues for adults may be for 
children, and –on the other side, things that may not be issues for children are with adults; adults 
and children cannot be lumped together and treated the same necessitating research to flush out 
those differences and fully understand how they must each be treated 
 Research exists in all fields of medicine ranging from the use of ibuprofen with infants to 
identify what it can treat to trials to determine the correct dose for different weights.107  Currently 
more than 1900 clinical trials are approved for children with more each day as technologies are 
developed.  Many advancements have been made in the areas of genetics and neuroscience that 
have great ethical issues in and of themselves, placing parents in very difficult positions.  
Research in these areas is necessary in order to be able to utilize the developments and 
advancements of these areas throughout society and impact the general population, but to get to 
that stage research must be done with these technologies with high levels of uncertainty and 
many complicated and unknown elements.  Within the field of genetics, whole genomic 
sequencing is becoming much more prevalent and researchers have identified many new 
disorders that can be or can possible be identified through WGS.108  WGS has immense potential 
to be used as a diagnostic and potential screening tool, however there are many concerns and 
ethical issues associated with this utilization.  Whole genomic and exome sequencing have the 
potential to change the field of medicine with diagnostic potential, leading to the hope that 
disorders that were untreatable or diagnosed in the past will one day be understood and even 
treatable.109  With this potential however comes a large burden on parents and physicians to 
together determine what should and should not be tested for, and how to handle additional results 
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that are found.  Additionally, the complex nature of genetics leads to a large responsibility placed 
on physicians, or other involved clinicians such as geneticist to educate parents before the child 
is sequenced and then review the results and counsel them once they are identified,110   
 Within the field of neuroscience there are therapies and technologies that are currently 
being researched and this number is only going to grow in the near future as advancements are 
being made and more processes of the brain are being understood.  Some of the most promising 
and controversial developments of neuroscience with ongoing research studies include functional 
neuroimaging, brain mapping, psychopharmacology, and enhancement opportunities with the 
potential to impact behavior, personality, and consciousness.111  Many researchers have 
identified brain processes that are related to experiences and concepts such as free will, agency, 
moral judgment, self and personality, while others are utilizing brain scans to diagnose pediatric 
disorders such as autism or ADHD.112  New techniques for monitoring and manipulating brain 
functions are developing rapidly but it is not clear how all of the different systems of the brain 
interact, or what a particular brain abnormality can predict about an individual, and it is further 
unknown how intervening in these systems can affect the beliefs, desires, intentions and 
emotions that constitute the human mind  This approach could enable treatment before any onset 
of symptoms and help physicians track the results of clinical trials of new therapies.  Pediatric 
brain scans are not currently being used throughout medicine, but this is potentially where things 
are going with care for children, along with genetic screening, which are the two areas of focus 
for the cases at the end of this section.  Much research and effort is being spent in these two areas 
to develop tools that will accurately identify and treat childhood illnesses and inevitably improve 
the lives of children and their families.113  As science and technology progress, more research 
trials will be necessary to appropriately include and treat childhood illnesses and disorders, 
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making an enhanced shared model necessary for parents to utilize with the physicians and child, 
when possible, to do what is best but not automatically exclude them from all research.  This 
necessity to include them additionally leads to another need for guidelines and regulation for 
research from legal entities. Because this is such an expanding area of medicine that has 
tremendous levels of uncertainty, regulations are needed in addition to an enhanced model.   
 
6.4.2 Guidelines for Research with Children 
There is a great deal of regulation and oversight that exists within the fields of genetic 
research with children.114  Research in general is subjected to a lot of regulation from review 
boards, however even more so when the research subjects are children. Children are not just 
“little adults” as they were once thought and they cannot be treated as such.  In addition, because 
of their exceptional vulnerability, the structure of research methods are crucial because children 
must not be exploited or abused.  During the Nazi regime children were used as guinea pigs for 
research leading to the Nuremberg code which appears to suggest an absolute prohibition of 
pediatric research stating “the voluntary consent of the human subject is absolutely essential.  
This means that the person involved should have the legal capacity to give consent.”115  In the 
1970s, the United States developed regulations that allow advances and the participation of 
children in research while protecting them from unnecessary and uncompensated risks and 
discomfort.116  Current US regulations are there to provide additional protections for children 
participating in research, however there will always be risks.117  Children require additional 
safety measures due to their limited capacity to give informed consent and vulnerable status, but 
well-designed and well-regulated research with children is needed to improve children’s health, 
and pediatric ethics can work with doctors and researchers to help ensure that this happens.  
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Children are in a unique position in that they must be protected while also advocated for so they 
are appropriately and meaningfully included in not just research, but also the decision process to 
select to enter into the study so they are not exploited or taken advantage of.   
Children have been exploited for research in the past, but this cannot be held as a reason 
not to continue and pursue more research with children, it merely argues that extra precautions 
must be taken into consideration to adequately protect them.118  Society is obligated to protect 
children from excessive risk to foster their development and grow into competent, autonomous 
adults, but also need to allow for enough research for the best interests of children as a 
population, and not prevent parents from being parents and making decisions for their 
children.119  The United Nations and the US have both commented on pediatric research through 
addresses and legislation, offering some ways to potentially enhance the process so it is more 
ethical and not as burdensome to children.  The UN Convention on the Rights of the Child 
adopted in 1989 articulated several considerations that pediatric research must follow to improve 
results and limit the exploitation of children.120  The Convention stated that children’s views 
should be given and taken into consideration in medicine, including with new treatments and 
therapies.  However, it did acknowledge that research with children raises additional ethical 
questions.  Children and parents must be given details about the purpose and nature of the 
research, the methods and timing, in addition to the possible harms, benefits, and outcomes.121  
Beyond the basics, doctors must also work with patients and their families to explain the 
concepts, such as consent, and give as much information as possible.122  Children should be 
given a leaflet to explain the research in their native language as well as talk directly to the 
researcher and encourage the child to ask questions because the children themselves must be 
informed.  In the last 15-20 years, there has been tremendous growth in research with children, 
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the reporting of children’s own views and experiences, formal pediatric research ethics 
committees and ethics training for pediatric research.123  There is a need for change and 
continued development in the current system, and the UN Convention gives some good starting 
points.  It is argued that the current research model does not adequately protect children from 
harmful and useless research nor promote their participation and interests overall, but that does 
not mean it should be stopped.  Additional regulations from the Department of Health and 
Human Services, the Food and Drug Administration, the Children’s Health Act of 2000, and 
pediatric review boards give additional regulations and protections for children emphasizing the 
importance of adequately protecting children in research.124  All research studies should be 
subject to evaluation by research ethics committees and review boards to minimize risks and 
ensure that ethical guidelines are followed.125 Additionally there must be a focus on the interests 
and unique elements of children.  Despite these regulations and attempts to protect children and 
their best interests, many ethical issues and problems still exist, which will be looked at in the 
following sections.  
 
6.4.3 Ethical Issues  
Ethical issues are prevalent throughout medical research, and become more complex with 
children, leading to tremendous oversight and regulation within the field.  There is a need for 
balance between protecting children and reducing harms while respecting and involving them in 
necessary research.126  There are many ethical issues of pediatric research, some new and unique 
to research and others that are present throughout pediatrics but become more challenging 
research including consent, autonomy, comprehension of the child, vulnerability, and possible 
exploitation  The issues that will be highlighted here and directly addressed by the enhanced 
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shared decision making model in the following section are issues assessing and determining the 
developmental capacity of the child, which makes the already challenging elements of consent, 
assent, and refusals of children extremely difficult.  Other issues prevalent in research with 
genetics and neurotechnologies, include the comprehension of parents, burden on physicians to 
explain to parents and the child, and the therapeutic misconception, which all make it 
challenging to assess benefit and burden for the child.127 The issues discussed in relation to both 
genetics and neuroscience are present here, heightened by the fact that they are part of clinical 
research placing the child and his or her parents in a vulnerable place.  Research in and of itself 
complicates aspects of the decision making process specifically informed consent, including the 
assent or dissent of the child and comprehension levels to fully understand and give informed 
consent.  Additionally the unclear outcomes and potential for the research subject to not even 
receive the therapy, benefits and burdens are challenging to weigh.  
A central issue to research is the ability to give and receive accurate informed consent.128  
Consent processes are extremely important throughout clinical research, adult and pediatric, due 
to the fact that the participant must understand what he or she is participating in and all potential 
outcomes.129  Research, unlike therapeutic interventions, do not guarantee results, effectiveness, 
or even that the participant will receive the treatment being tested.  In order to participate, 
consent, or assent in the case of a child, must be given after the physician explains the potential 
outcomes, side effects, and burdens in addition to the general research processes themselves, 
which most are not familiar with.  This is challenging for children because in order to give assent 
or possible dissent, physicians must assess their capacity to make decisions, which is challenging 
because with genetics or neurotechnologies, these children many times have developmental or 
other severe disorders.130  Since children cannot give formal consent, regulations require that 
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both parental permission and the assent of the potential child subject before they are enrolled in a 
research trial to protect the child from unreasonable risk but also recognize the child as a 
person.131  In order for research to be valid, the trials themselves and consent processes must 
follow strict ethical guidelines and valid consent must be obtained and present for all 
participants.132  Research subjects must understand what they are signing up for and all of the 
possible outcomes, however the research studies in this area are complicated and there are many 
barriers to comprehension and a large burden on the physician and researcher to explain all 
options.  
 Parental comprehension of the proposed therapy impacts consent processes within 
pediatric research, and research processes in general, and the potential outcomes.  This impacts 
consent, as in order for consent to be valid, parents and the child must fully understand the 
options, benefits and burdens, and inevitably what he or she is consenting to.  With research, the 
benefit cannot always be best interests because sometimes the child does not stand much of a 
chance of receiving a benefit but other children do, and other factors that come into play are 
altruism, compensation to parents or child, the maintenance of hope, or even confusion coming 
from the therapeutic misconception that anything offered will be of benefit.133 In order for assent 
to be meaningful, the child must understand the intervention of the research study, voluntarily 
choose to undergo the procedure, and communicate this choice to the researcher.134   In a study of 
200 IRBs, by A. Whittle et al, 2004, only half of the IRBs required investigators to determine if 
children were capable of assent, and when they were it was primarily based on an age rather than 
capacity assessment.135  Refusals of children are additionally troubling and many argue that 
children who have been deemed to be competent should be able to refuse therapies, potentially 
even those that are in his or her best interests, however if interventions will protect the child from 
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harms, there are arguments to be made to override this, however with clinical research since 
nothing is certain, these cases are rare.136  Even in these instances, efforts should be made to 
persuade them rather than immediately just overriding their decision to respect them as persons.   
 Research poses additional complexity for parental consent and comprehension due to the 
therapeutic misconception.  The therapeutic misconception refers to the problem created when 
providers offer therapy to patients, that may or may not have benefit to them, and the patient 
perceives such a benefit based solely on the fact that the provider offered them the 
intervention.137   In research, in addition to the complex treatment options and unique terms to 
research, such as randomization of placebo, many times parents assume that there is therapeutic 
benefit to be gained from the study.138  Despite these recommendations, 58% of the surveyed 
IRBs would enroll a child who was incapable of assent in a non-beneficial study even if the 
children who are capable could be enrolled instead.139  Additionally, when asked about the 
payment of children, 46% believe that it sometimes or always acceptable to offer incentive 
payments to children, and more than one third thought it was acceptable to offer payment to the 
parents.  There are regulations in place to help protect children however none of them are 
tremendously specific because it depends on the child, the study itself and what the intervention 
is, and the overall circumstances.  The enhanced facilitated shared decision making model 
addresses these issues and elaborates how to include the child based on the specific decision and 
attempts to further open lines of communication to help the other issues.  The following section 
will apply the enhanced shared decision making model to two pediatric research cases and look 
at how this model enhances the process and facilitates the involvement of all necessary 
individuals and allows for the best decisions to be made for children. 
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6.4.4. Application of the Model to Facilitate the DM Process 
There are challenging ethical issues to overcome within the area of research, especially 
when it comes to interventions within the fields of neuroscience and genetics utilized with 
children.   Research is a key component of medicine that leads to the development and utilization 
of new therapies and interventions, however research with children in areas of new technologies 
with great levels of uncertainty, unknown outcomes, and future implications must be considered 
carefully.  Before developments of these fields can be used by the general public they must 
undergo extensive research to prove their efficacy and safety.  This section will apply the 
facilitated shared decision making model to cases of research in the areas of neurotechnologies 
and genetics to demonstrate how this model alleviates many of the challenging ethical issues and 
outlines the roles of all involved in the process.   In each of the following cases, the enhanced 
shared model will be applied to guide and structure decisions, help decision makers determine 
what information should be revealed, and when, including relevant aspects that should be taken 
into account and those that should not. The first case is of a male infant with parents requesting 
that he be part of a genetic research study to sequence the child’s genome.  In this case the child 
is not sick nor does he have an illness.  In the second case, the child is an adolescent with an 
unidentified neuro-affective disorder.  His parents would like to enroll him in a research study to 
try to identify the disorder but this brings up issues of other information that is available with the 
sequencing.  All steps of the process will be elaborated in both cases to show that the model 
facilitates decision making processes and addresses the many ethical issues.   
 
6.4.4.1 Cases and Enhanced Shared Decision Making 
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 The enhanced shared decision making model facilitates decisions surrounding the 
enrollment of children into research trials and will be specifically analyzed with the application 
of the model to two cases, one within the field of neuroscience and the other in genetics. This 
application will show that the enhanced model is needed to overcome the many ethical issues 
parents must overcome and work through when making decisions to enroll their children in 
clinical research studies. The first case that will be analyzed involves an infant boy whose 
parents are requesting that he be part of a genetic research study where the researchers want to 
sequence the infant’s genome.  Whole genomic sequencing does not involve a complicated 
medical procedure and is very straightforward for the actual sequencing, however the unknowns 
here involve the accuracy of the genetic disorders or traits currently identifiable and what the 
researcher will or will not tell parents, and further what parents have a right to know or request to 
know about their child.  Benefits and burden analysis is not easy because it is unclear what the 
sequencing will identify and what actions could be taken on the findings. The second case is of a 
12 year old male with a neuro-affective disorder whose parents want to enroll him in a research 
study to see if it is a genetic condition.  In this case, the child has a disorder that they want to use 
sequencing to identify to better treat the child, but while performing the basic sequencing the 
parents and researchers will have access to an abundance of information about the child, leading 
again to issues of what can and will be done with the results that are found.  In both cases there 
are multiple options available, leading to situations of shared decision making involving the 
parents, physician, and in the second, the child.  
 To work through many of the ethical issues and complex roles of the decision makers, the 
enhanced shared decision making model will be applied to each case to outline the proposed 
roles and the inevitable recommended outcome.  The first element of the enhanced shared 
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decision making process is to assess the child, who is in this case both the patient and potential 
research subject.  Determining competence for research is similar to competence for other areas 
of medicine and decision making; the child must show that he or she can understand the 
information given to them including the proposed therapy, treatment, and details of their own 
condition or illness, so they can give assent or dissent.140  The first child is a newborn so there is 
not anything to assess as he is not of capacity to be involved in decisions.  This does not mean 
that his interests should be excluded, but that the child cannot be involved in the process.  The 
second child has a neuro-affective disorder so he is likely not able to meaningfully participate, 
however the physician must still evaluate him and determine if there is a way to include him or 
pieces that he may be able to comprehend.  The physician must be sure to evaluate the important 
elements of capacity that are relevant to the specific decision at hand since capacity should be 
decision specific, not absolute.  Beyond the evaluation of the capacity of the child, competency 
and understanding are crucial to parental consent.  Parents must fully understand what they are 
agreeing to for their child, therapeutic or not, which is very difficult in cases of new technologies 
surrounded by great levels of uncertainty. This comprehension barrier and the assessment of 
compromised children places a large burden on the physician. The model however, by forcing 
the physician to first analyze the child, keeps the focus on the child as the central component of 
the decision.  
 After the assessment of the child, the boundaries and roles of the physician and parents is 
then defined based on the options available, evidence for the outcomes, and the level of 
uncertainty.  Both of these treatment decisions are complex, however in the second case, there is 
more of a medical reason for the intervention, although both are questionable since the amount of 
therapeutic interventions that could come from them are unknown.  The complexity of both 
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decisions would lead them to fall on the physician led side of Kon’s continuum of shared 
decision making.  Additionally, Weird and Whitney’s models can be utilized to guide the 
decision making by classifying them as both clinician directed and expertise. In these cases, the 
physician should give his or her recommendations and work with another physician and within 
the legal parameters to guide parents to make decisions and include children in research that will 
not only respect the rights of the parents but also the current and future interests of the child.  
In cases of research it is crucial that an outside physician be involved to lead as the principal 
researcher is not always the ideal advocate for the child and the parents do not always have the 
ability to understand or know what questions to ask.   The child in the first case is very young so 
it will likely only be the parents working with the physician(s), and researchers to make a 
decision in a clinician directed, expertise model.  In these cases it is possible that parents will 
look to other family members for support or even turn to advocacy or parental support groups for 
guidance or advice, but those sources do not have a legal say and can only impact decision 
making processes in ways that parents allow them to. The same should be the outcome in the 
second situation, however in this case the child may have more of a role depending on the 
severity of its impairment and the outcomes of the clinical competency assessment.  Regardless 
of ability to comprehend and give consent or assent, in the second case, the patient must be 
included, even if his opinion does not carry much weight.  Overall with research, especially in 
the areas of neurotechnologies and genetic interventions, the role of the outside, non-research 
related physicians is crucial as they will be the ones who have the knowledge and medical 
background to fully explain the case to the parents and child, and work them through the process 
with the involvement of the researcher.  The enhanced model allows for the classification of the 
 266 
 
decision in a streamlined way based on the number of options and complexity, allowing all to 
know their roles in the process and be empowered to participate.  
 
6.4.5 Recommendations  
 There are many legal and ethical issues associated with vulnerable populations such as 
children, especially those with suspected neurological or genetic disorders, making conducting 
pediatric research problematic.141  By following the enhanced shared decision making model, 
parents and physicians are able to work in a meaningful way together and incorporate the child 
into the process to enable them to be in control of their medical care and inevitably lives.  
Children must be empowered to be stewards of their healthcare, and this model helps facilitate 
this growth and ensure that they are include and their voice is heard before they are entered into a 
study.142  Additionally, it is recommended that in cases of research, the patient’s PCP or other 
primary physician, not involved in the research study, be around to support the family and 
overall guide them through the decision making process.  Review boards exist to ensure that 
research follows ethical guidelines, standards, and does not exploit patient or their families, 
however in current practice there are many things that occur on a regular basis that are not 
considered ideal, such as payments to parents of children and only considering the age of the 
child when determining if they can give assent or refuse enrollment, making it not only necessary 
that a decision making process be streamlined, but that a physician not involved in the research 
study be involved in these processes and work with the child and parents to make decisions.  By 
involving a physician who is not part of the study, the parents and child are able to get a better 
full picture of the research study so they can make the best decision and weight the benefits and 
burdens in a meaningful way.  
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 Additionally, research is a very good candidate for the utilization of enhancement tools to 
facilitate the decision making process and overall communication processes.143  A great deal of 
research has been devoted to learning about how parents and children learn and best comprehend 
information, which can then be developed into communication tools.  These tools need to 
facilitate the growth of the relationship between the child, physician, and parents, but also work 
to ensure comprehension.  Comprehension and complexity of information are important issues 
throughout all areas discussed in this chapter, more complicated by research since the technology 
used is not well understood and there are components of research in and of itself that parents or 
decision makers do not routinely comprehend, such as the concept of a placebo.  It has been 
found that many parents do not know what they are consenting to and that they assume there is a 
benefit to their child, regardless of the fact that the forms they signed outlined that this was not 
the case.  The therapeutic misconception is prevalent throughout research and parents, or patients 
in general, believe that there is a benefit due to the fact that a medical professional, with the goal 
of helping patient and making them better, is proposing the intervention. There is a great need for 
new ways of communicating and bridging the educational gaps present between researcher and 
clinician and patients, including the child and his or her parents. Overall there is a great need for 
enhancements within the field of pediatric research, but the enhanced shared model is a good 
starting point to help parents, physicians, and children identify their roles in the process and 
inevitably determine which trials they should or should not be part of.   
 
6.5 Conclusion  
Over the past few decades there has been tremendous growth in the areas of genetics and 
neuroscience, including and led by clinical research trials in both of those areas.  With these 
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advancements come great levels of uncertainty and many complicated decisions that parents, as 
the legal decision makers, must make for their children. There is a need for the enhanced model 
to facilitate decisions and enable the best decisions to be made for children with the utilization of 
new technologies.  Tremendous expansion in the fields of neuroscience and genetics, both with 
growing numbers of new technologies and interventions available makes it crucial that 
physicians have a structured way to work with parents and incorporate the child into the process 
at a level that is appropriate, and advocate for the involvement if necessary.  It is crucial that the 
child, parents, and physicians work together in a meaningful way to make decisions about the 
utilization of these new and expanding technologies.  Additionally, the cases reviewed within 
each area of medicine emphasize that the most complex and controversial cases are those with 
older children, as determining their level of involvement is one of the central pieces to the 
decision making process, enabling them to be involved in the current decision and further 
enabling them to become and grow into good decision makers in the future.  Many mature 
minors have more capacity than adults with diminished capacity allowed to make decisions, 
making it not only important that they are involved, but relevant and optimal.  It is important to 
note that all decisions cannot easily be classified as decisions since all patients are different, 
however they can be when the patient and situation are taken into consideration.144  For instance, 
all decisions of whether or not to use a brain scan to determine if the child has ADHD cannot be 
made in the same way, using the same type of shared decision making, as the capacity of the 
child has not been taken into account, nor have the circumstances of the family or any outside 
impacts.  A good physician knows that they must explain things to the patient in ways 
meaningful to them in order to enable them to be good decision makers.145  By identifying the 
type of decision to be made, specifically if there is more than one reasonable option, and 
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understanding that there are different, yet specific types of decision making that can occur, it is 
possible for the roles of the physicians and parents to be added to the decision making model in 
addition to the already determined developmentally appropriate role of the child and ideally, the 
selection of the best course of action for the child.  
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Chapter 7 – Conclusion  
Shared decision making occurs throughout the field of medicine each day as physicians 
work with patients to make medical decisions about treatment and courses of care.  This process 
becomes challenging when the patient loses the ability to make a decision and someone else 
must step in to do so on his or her behalf.  When the patient is a child, he or she by definition 
does not have the ability to make medical decisions, and therefore the parents, or legal guardians, 
must be involved and make the decisions for the child patient.  There is not a current model for 
parents to use to make decisions for their children that adequately incorporates all relevant 
stakeholders or supports the new and continuously emerging technologies present throughout 
pediatric medicine.  The objective of this dissertation is to present a new model that better 
facilitates decision making processes for decisions in pediatric medicine. The enhanced shared 
decision making model offers more support and guidance for all involved while emphasizing the 
central role of the child, as the patient, where possible.   
Chapter 2 reviewed the relevant background, including the history and development of 
pediatric medicine.  It was argued that pediatric medicine developed out of adult medicine, 
creating problems for pediatric patients since they were not initially treated different than adults. 
Pediatric medicine was not always a medical specialty due to the fact that children were not 
always seen as children, but rather as miniature adults. However, over the past few centuries, an 
increased focus has been placed on the period of childhood and ideas of childhood.1  Over time, 
children were acknowledged as different from adults, and as a central piece of the family, 
vulnerable and innocent, and in need of protections.2  These ideas led to the UN Convention for 
the Rights of a Child, giving children a legal voice, as well as child labor laws and other societal 
mechanisms.3  As it was realized that children were different from adults in numerous ways it 
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became evident that they were in need of specialized medical care.4 In the initial phases of 
pediatric medicine, children were treated the same way as adults, and many of the regulations, 
practices, and delivery methods from adult healthcare were directly applied, such as limited 
visiting hours of parents.5 New regulations, practices, and understandings were needed 
specifically for the medical care of children. One area where there is a need for new 
understandings is with regard to the goals of pediatric medicine as they are in fact different than 
those of adult medicine.6  Additionally, the ethical issues with children and their families are 
different from those in adult medicine and cannot be handled in the same manner. In pediatrics, 
respect for the patient, rather than autonomy is more significant, involving both protection of the 
vulnerable child and respectful listening to the voices of the key stake-holders, specifically the 
child and parents or guardian(s).7 The professional goals of physicians are also different as 
pediatricians must not only work with their patients to select both the right and good course of 
action, but instead primarily with their patient’s parents.8 Within pediatrics, the child patient 
relies completely on adults, specifically parents and doctors, to define what is right and good for 
them.9  Goals of pediatrics are complex and include protecting the child and furthering his or her 
best interests, protecting the child from unjustified harms in regard to medical interventions, and 
showing respect for family autonomy.10  Pediatric medicine has many unique issues and 
problems such as heightened emotions, decisions with potentially higher stakes and longer 
impacts, and making decisions for someone else, specifically one’s own child. In response to 
these unique challenges, considerations, and goals, a special area of ethics was developed. 
Pediatric ethics emerged out of the realization that issues within pediatric medicine are not only 
different but must be handled in way that is not similar to adult medicine.  Pediatric medicine 
emerged as they were given a place in society, however there is still a great need for 
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developments in the field, not only of science, but also of ethics and inevitably a decision making 
model.  The medicine, ethics, or decision making processes of adult medicine cannot be used as 
a model for those within pediatrics, and it is crucial that pediatric medicine has its own standards 
and models in order for the roles of the family, child, and society to be balanced while providing 
the best care for the child.  
Chapter 3 developed the dimensions of medical decision making and the complicated 
area of surrogate decision making.  There are models that guide surrogate decision making, 
substituted judgment and best interests, however neither apply to pediatrics.  In most cases of 
adult medicine patients make their own treatment decisions based on respect for autonomy.11  In 
the past, physicians made treatment decisions for patients, however over time, this paternalistic 
approach changed to the patient centered, personal autonomy based model of today, allowing the 
patient to make decisions for him or herself through a process of informed consent.12  Informed 
consent enables patients to make decisions based on their own values and goals, ranking options 
according to personal standards rather than those of the physician.  Decisions made by others are 
more challenging in that the person making the decision cannot know for certain the decision the 
patient would make, leading to the creation of ethical standards to guide surrogate decision 
makers, substituted judgment and best interest, both of which are patient-centered.13  Substituted 
judgment focuses on executing the wishes of the patient, while best interests asks the surrogate to 
select the course of action that will most benefit the patient overall.  The substituted judgment 
model, as the ideal model, asks surrogates to make the decision or choice that would mirror that 
of the patient if he or she would be able to make decisions, specifically to act as a “substitute” for 
the patient.14 This model requires a lot of knowledge of the patient and this model is used in 
combination with the best interests model, asking the surrogate decision maker to weight the 
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potential benefits and burdens of each available option and determine the “best” course of 
action.15   
There are many problems with the substituted judgment and best interests models in 
practice, including giving too much power to or placing too much of a burden on families, who 
may or may not be reliable sources of information about the patient.16  Additionally both are 
seemingly impossible to execute as defined in practice, and regardless of the decision-making 
model utilized, decisions will typically be made in a shared effort.  Shared decision making 
(SDM) involves an exchange of information between the medical team and the patient or 
surrogate where they each work together, share knowledge, and express preferences and 
negotiate the treatment plan, ideally reaching an option most consistent with the patient’s 
personal wishes.17 Decision making is complex in adult medicine, especially when a surrogate is 
involved, and it becomes even more so when the patient is a child, an individual who has never 
had decision making capacity, making the application of adult decision  making models 
challenging if not impossible.18   
Dimensions of autonomy, decision making capacity, and informed consent make the 
decision making process with children more challenging since these concepts do not directly 
apply to children in the same way that they do in adult medicine. In pediatrics, parents or 
guardians are typically given the legal authority to make decisions for their child, however the 
child must be involved in the process in a way that they are capable. Capacities necessary for 
decision-making include communication, the ability to understand information, reasoning and 
deliberation, and the ability to have and apply a set of values or conception of the good, all of 
which are challenging to assess in children.19  Despite the fact that it is challenging to assess, it is 
crucial that they are included to the level they are able to be decision makers, and additionally 
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apply concepts of assent or possibly consent when available.20   The child, as the patient, should 
be the center of the decision making process, however there are many individuals with large 
responsibilities in pediatric decision making, specifically the parents or guardians, physicians, 
and even society.  Parents, as the legal decision makers and those thought to know the child 
better than others, will be looked at next.21  Physicians also have obligations to the child as his or 
her doctor, and additionally to the family.22 Within pediatrics, parents and physicians are many 
times thought of as co-fiduciaries, both having strong obligations to the child patient.23  Finally, 
society has a role in ensuring that the child’s well-being is protected.24  There are many 
stakeholders in pediatric medicine and the opinions and conceptions of all parties must be 
balanced.  Although the parents legally have the final say and authority to make the child’s 
medical decisions, ethically this is not sufficient for the best decision to be made and there is a 
need for a model that incorporates and acknowledges all parties. 
The model of adult medicine, substituted judgment and best interests were argued to be 
insufficient for pediatric medicine for many reasons, primarily that they do not address the 
unique or different dimension of pediatric medicine. Substituted judgment is not typically 
relevant with children because they have never had the capacity for decisions, or fully developed 
personal beliefs and values, which is the basis of this model.25  The best interest standard, on the 
other hand, requires that parents select the best treatment for their child after weighting potential 
benefits and burdens of each option, selecting the therapy with the maximum benefits and 
minimum burden.26  Some of the issues and problems with this standard include that it is 
subjective, places a large burden on parents already in a difficult position, does not ensure 
understanding, or does not give the child or physician a clear role. Neither the best interests nor 
the substituted judgment models are sufficient for pediatric decision making, however elements 
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of these standards are incorporated into the enhanced model since the inevitable goal is to make 
the best decision for the child patient in a given setting.  
Chapter 4 focused on the scientific developments and advancements in areas of genetic 
screening, neurotechnologies, and clinical research.  All three fields have experienced 
tremendous growth in the last 10-15 years, leading to the creation of numerous challenging and 
complicated ethical issues. Genetic screening with children began initially with newborn 
screening for the easily identifiable and remedied PKU. Over time, the panel has steadily 
increased to include anywhere from 20-54 conditions, some of which have no therapies.27  The 
American Society of Human Genetics and The American Academy of Pediatrics believe that 
testing for disorders without therapies should be limited, however, there are arguable benefits 
other than therapy, such as planning for the future or identifying subjects for research, making it 
unclear if it is in the child’s interests to be screened or not.28  Deciding what should and should 
not be screened for becomes a much bigger issue with the decreasing costs of whole genomic 
sequencing (WGS), and the possible detection of a multitude of diseases, and can be utilized at 
birth or later in life.29  Genetic testing is becoming an important diagnostic tool in medicine, 
making discussions of determining benefit and burden crucial.30  The next area of advancements 
addressed is neurotechnologies, examining the emergence and utilization of interventions within 
neuroscience such as functional neuroimaging, brain mapping, psychopharmacology, and 
potential enhancement opportunities with the potential to impact behavior, personality, and 
consciousness.31 In the last decade tremendous technological advancements have been made, 
leading to new possibilities and opportunities to diagnose or even predict, treat, and potentially 
enhance capacities.32 Many physicians believe that they can analyze the development of a child’s 
brain and track possible psychological or developmental disorders after a simple five-minute 
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brain scan or functional MRI (fMRI), to identify and treat psychiatric and developmental 
disorders, possibly even before the onset of symptoms.33 Neuroimaging with children is 
accompanied by all the ethical dilemmas associated with neuroimaging adults, enhanced due to 
their status as children.34  It is not clear what therapies physicians should offer parents, or how 
parents are to make decisions for their children.35  The final area of growth is pediatric research, 
and was specifically addressed with the growing number of research trials for genetic screening 
and the use of neurotechnologies with children. New technologies create the possibility for 
parents to enroll their children in trials both with and without therapeutic benefits, but it is not 
clear if they can make such a choice for their child, and if they can, it is not understood how they 
should decide.36  
 Many ethical issues that accompany the new technologies render decision making 
challenging and inevitably the models of adult medicine insufficient.  The new technologies 
make the ethical issues prevalent throughout all areas of pediatrics more complicated and 
additionally add unique dimensions. Some of these basic yet more complicated dimensions 
include barriers to comprehension, emotional distress of the family, assumed benefit because 
therapy is offered (specifically the therapeutic misconception), overall impacting parental 
consent. Consent is troubling with regard to pediatric research because it is not clear if the 
consent of the family carries the same weight as in other areas of pediatric medicine and if 
parents can consent to risky research. Other issues are caused when disorders are identified that 
cannot be treated because with whole genomic sequencing (WGS) it will be possible to screen 
for specific diseases, but also identify risk factors for multi-genetic diseases, carrier status for 
many autosomal recessive conditions, adult-onset conditions, or those with uncertain clinical 
significance.37 Other challenging issues include uncertainty, privacy, and future implications of 
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findings in children. There is a lack of evidence of what neurological interventions can do or 
exactly what the identification of a mutation means, and even less about what it should be 
doing.38  Additionally these expanding technologies bring with them concerns of privacy and 
possible future implications of information discovered with the technological interventions and 
impacts on the child and family.39   There is a very real possibility that the information from the 
scan will become a means of “describing” the child, which makes the issue of privacy of the 
information tremendously crucial and problematic and additionally emphasize the need that 
decisions to treat and utilize these interventions be considered in light of both current and future 
outcomes.40  Overall, decision making in the light of the new technologies is extremely difficult 
and here is a need for a new model that accommodates the enhanced ethical issues and all of the 
stakeholders appropriately. 
In chapter 5 the enhanced shared decision making model is developed specifically for 
children to address the issues of the expanding technologies of genetics, neuroscience, and 
pediatric research.  Ideally, a shared model should be based on the medical facts, some 
understanding of the patient and his or her values, beliefs, and autonomous wishes (if the patient 
is not making his or her own decisions), and a general idea of what is “best” for the patient both 
personally and medically.41  This works well in adult medicine, however this is not possible with 
children because they are not and have never been autonomous with fully developed values and 
beliefs of their own, necessitating an enhanced model.  The enhanced model presented 
incorporates the goals of pediatric medicine, facilitates the numerous roles of stakeholders in 
decisions made in the treatment of children, and additionally places the child, as the patient, at 
the center of the model, with regard to participation and current and future interests that are 
weighed. The goals incorporated were (1) beneficence and non-maleficence, (2) respect for 
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family autonomy, (3) respect for the future autonomy of the child, and (4) promoting the current 
and future interests of the child.42 The stakeholders include parents, as legal decision makers in 
most instances, the physician, with professional and legal duties to uphold, the child, who is the 
patient, and even society.  All are trying to overcome barriers of the new technologies, including 
uncertainty and unclear benefit and burden to the child, to overall advocate for and do what is 
best for the child patient. Each of the appropriate stakeholders and goals have an important role 
in the enhanced model because each must be met in order for the model to be acceptable and 
actually facilitate decision making with new technologies.  
 The enhanced model begins with the evaluation of the child patient as the central 
component. Children are at a stage in life where they are developing the capacities needed for 
making medical decisions and including them has many benefits, making it crucial that the child 
be involved in any way possible, for both the end resulting medical treatment and the future of 
the child as an autonomous individual.  During the initial step of the process, the capacities of the 
child are evaluated, including their developmental stage, comprehension, and communication 
abilities. Following the assessment of the child, the medical decision to be made is evaluated and 
classified utilizing the medical scenarios outlined by Whitney et al, 2008 and Kon’s continuum 
of shared decision making.  Whitney et al, 2008 discuss situations where (1) there are no medical 
alternatives, and patient preferences are irrelevant, so no shared process occurs and (2) those 
where there are several options and potential disagreement arises, where shared decision making 
occurs. Whitney and colleagues classify the second group as when agreement is not met, yet 
even in instances where agreement is realized, this category deserves extra attention with regard 
to new technologies. This is where pieces from the negotiated and expertise models of Weir et al, 
2011 and Kon, 2010’s continuum of shared decision making ranging from completely patient 
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driven to paternalistic will be elaborated, connecting the level of involvement with the 
complexity of the decision. After the level of involvement of the child has been determined and 
the decision has been classified, decision making can begin at the appropriate level of 
involvement from all stakeholders. The overall goal is for the patient, family, and caregivers to 
work together in a process of education and support enabling collaborative decision making, and 
ideally mutual influence while taking into account both current and future interests of the child 
as well as communitarian claims such as the protection of others from harm or the preservation 
of public goods, which may override those of parents.43   
Overall, the enhanced facilitated shared decision making model allows for parents, 
physician, and children to work together in a meaningful decision making process.  It is 
necessary that the child is included in the decision making process, which is why he or she is 
evaluated as the first step of the process.  Physicians must assess the developmental capacities of 
the child, looking further than their age, and determine the appropriate level of involvement that 
the child should have in the process.  After that, the decision itself must be fully understood so 
that the appropriate level of shared decision making can be identified and all decision makers can 
participate in the process in a meaningful way that acknowledges their duties and 
responsibilities, fully enabling them as decision makers.  The enhancements discussed in the last 
few sections provide additional details for ways to improve decision making processes and fully 
enable children and parents to be decision makers, and ensure that physicians can properly 
coordinate the interactions.  Structured education, discussions of justice and access to resources, 
and the creation of tools to enhance communication between physicians and parents, and the 
overall understanding of parents can greatly add to the decision making process.  There is a great 
need for continued development in these areas to put the facilitated model to use and overall 
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enhance communication. In the proposed model, enhanced education of both parents and 
physicians is accomplished through a more structured decision making process that emphasizes 
the relationship between them as well as placing a burden on physicians to not only ensure 
understanding but to work with parents to make decisions.44  The final component of the 
enhanced model is the justified outside impacts, discussing how society, among other potential 
outside impacts, has a stake in the decisions made for children in many instances.  This enhanced 
model enables parents, children, and physicians to work together to make decisions in light of 
the tremendous uncertainty of the fields of genetics and neuroscience and the expanding number 
of research studies.  The new suggestions and enhancements address the goals of pediatric 
medicine, incorporate all relevant stakeholders, as well as accommodate the new technologies.  
Chapter 6 then applied the enhanced shared model to scenarios of the expanding 
technologies of genetics, neuroscience, and pediatric research. The first section presented the 
background and history of genetics as it applies to children, developing from newborn screening 
panels to the increasing use and accessibility of whole genomic sequencing.  As the field has 
expanded, recommendations have attempted to keep up, establishing guidelines and suggestions 
to protect the needs and interest of the child, however there are still tremendous ethical issues 
and challenging decisions to be made.  The ethical issues of genetics that necessitate an enhanced 
shared model include the spectrum of disorders screened for, consent models, privacy, and 
different policies and procedures in each state and the problems created by those differences. 
When determining the spectrum of disorders tested for  
There is not clear guidance to identify what should and should not be tested for, as many 
advocate for the testing of all that is possible or requested while others believe it should be 
strictly regulated and only test for those disorders with current therapies available to the child.45 
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This determination is crucial as once the child is found to have a mutation, it cannot end there 
since this is a diagnosis the child and his or her family will have to deal with the rest of their 
lives. Many parents want to know everything they can about their child, while others do not, but 
the bigger ethical issue is whether or not they get to make that decision for their child. These 
issues become much more troubling with the potential addition of whole genomic sequencing at 
birth, by expanding the list of disorders that can be tested for, many of which have limited 
therapies available, if any, do not develop until adulthood, or have uncertain clinical 
significance.46  Beyond these issues of privacy, there are issues with the storage of the bloodspot 
and genetic information, who has access to it, and whether test and research can be done on it 
without parental consent.47  Currently in the United States, each state decides each of the 
previous issues, leading to more problems because many people cross state lines to see 
physicians or move, leading to problems such as knowing what the child was or was not tested 
for.48  The enhanced model was then applied to two cases of genetic testing, specifically where 
the decision was about the utilization of whole genomic sequencing and if so, what should be 
included in the panel.  Case one was of a child with a family history of breast cancer and the 
second is of a child without such history, however both sets of parents are requesting the 
sequencing of their child’s genome.  For each case, the child was evaluated first and their role in 
the process was established.  Following this, the decision to be made was discussed and 
classified along Kon’s continuum of shared decision making to identify the necessary 
involvement of the parents and physician.  Kon’s continuum ranges from completely patient 
driven to paternalistic physician driven, where the level of involvement correlates to the 
complexity of the decision in light of the ethical issues, medical facts, and levels of uncertainty 
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to determine the appropriate balance of the physician and parents for the overall facilitation of 
the decision.  
 The decision making framework was next applied to cases of neurotechnology.  There has 
been tremendous growth in the field of neuroscience, developing new interventions and therapies 
for children which brought with them many ethical issues and dimensions, including privacy and 
safety, incidental findings, prediction, enhancement, and uncertainty, all leading to overall 
challenging best interests determinations and unclear roles of all involved in care decisions, 
creating difficult decisions that must be made.49 Neuroscience is unique in that there is a field of 
ethics that has developed specifically for the field, neuroethics, however even within that there 
are not accommodations made for children, necessitating the enhanced model.  The enhanced 
model was then applied to two pediatric cases about the utilization of neurotechnologies and the 
decision of what to do. Neurotechnologies bring with them the possibility to enhance and help 
the lives of many patients but decisions must be made with caution and extra attention must be 
paid to potential burdens on the patient, outcomes, and long term impacts that these decisions 
have on the child.  The first case involves a 6 year old male with suspected autism who has 
difficulty communicating properly and relating to others and physicians are proposing the use of 
a brain scan to assess if the child has autism and if he does, attempt to identify the degree and 
severity.  The second case is a 15 year old male previously diagnosed with ADHD and treated 
with medication, however now that he is older the doctor has taken him off of the medication.   
His parents are requesting the utilization of medicine to increase his concentration and overall 
enhance his performance.  The first step in the application of the enhanced model is the 
evaluation of the child. This is exponentially more challenging in cases where neurotechnologies 
are proposed as they are typically suggested for children, and patients in general, with disorders 
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or conditions of the brain, many of which have diminished levels of capacity or overall 
development and comprehension.  After the evaluation of the child, the decision to be made itself 
is classified with the review of the medical facts, uncertainty, and potential benefits and risks. 
Once the decision was classified, it was then related to Whitney’s models to elaborate the 
appropriate involvement of the physician and parents, in addition to the pre-determined level of 
involvement of the child.  
 The final technology is pediatric research and the two cases looked at were for research 
specifically with current research of brain scans and whole genomic sequencing.  Clinical 
research, similarly to the field of medicine in general, started as a field focused on adults.  As it 
was applied to children new regulations and processes were put into place, but many ethical 
issues are still present including issues of consent/assent, the comprehension of parents, and the 
therapeutic misconception will be analyzed, emphasizing the difficulty in assessing the actual 
benefit and burden within pediatric research.50  The enhanced model was then applied to two 
cases. The first case that has been analyzed involves an infant boy whose parents are requesting 
that he be part of a genetic research study where the researchers want to sequence the infant’s 
genome.  The second case is of a 12 year old male with a neuro-affective disorder whose parents 
want to enroll him in a research study to see if it is a genetic condition.  In this case, the child has 
a disorder that they want to use sequencing to identify to better treat the child, but while 
performing the basic sequencing the parents and researchers will have access to an abundance of 
information about the child, leading again to issues of what can and will be done with the results 
that are found. In each of these cases the enhanced model was applied to show how parents and 
physicians should be working together to ensure understanding, weigh benefit and burden, and 
ultimately make a decision about a specific intervention. The model guided and structured the 
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decisions, shed light on what information should be revealed, and when, including relevant 
aspects that should be taken into account and those that should not.  
There is a need for the enhanced model to facilitate decisions and enable the best 
decisions to be made for children with the utilization of new technologies.  Tremendous 
expansion in the fields of neuroscience and genetics, both with growing numbers of new 
technologies and interventions available makes it crucial that physicians have a structured way to 
work with parents and incorporate the child into the process at a level that is appropriate, and 
advocate for the involvement if necessary. It has been noted by many researchers that there is a 
great need for future research and studies to be done with physicians and parents making medical 
decisions, specifically regarding cases of new technologies to accurately create and implement a 
model for shared decision making, however this enhanced model is an example of a way for this 
to begin. The new model facilitates smoother decision making and enables all stakeholders to 
work together to come to the best decisions, while enhancing the understanding of all involved.  
Depending on the medical evidence and benefits and burdens of the available options, the 
involvement of the physician can be limited or increased, giving parents more or less control to 
work with their child and make a decision.  With the high level of scientific evidence and 
understanding needed there will unlikely be cases of genetic screening with minimal physician 
involvement, however when both options are valid, the parents and child, in a way determined to 
be meaningful to him or her, should be given the ability to make decisions.  When there is 
clinical evidence in one direction, or a lack of information, the physician must be more involved 
and in many instances either insist on or refuse genetic screening.  Additionally, governmental 
regulations and oversight will be needed as more conditions and disorders can be screened for to 
facilitate these situations.  There is a need for more research additionally to look at the steps of 
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the current decision making processes of parents, to properly integrate the enhancements and 
decision aids.  Decision aids are crucial to facilitating the new decision model, and have been 
found very valuable by many researchers, and are a component of this enhanced model. Despite 
the need for more research to fully integrate this model, and increased costs associated, it will 
best facilitate the decisions that surround the enhanced ethical issues of new technologies.  
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